<html lang="en" class="pb-page js" data-request-id="94d64c3dc210a517-SJC"><head data-pb-dropzone="head"><style type="text/css" nonce="94d64c3dc210a517-SJC">@font-face {font-family: "Source Sans Pro";src: url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.ttf) format("truetype"),url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.woff) format("woff"),url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.otf) format("opentype"),url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.eot) format("embedded-opentype");}.truste_cursor_pointer {cursor: pointer;}.truste_border_none {border: none;}.truste_accessible_link {font-family: "Source Sans Pro", sans-serif;color: #1D4ED8;font-size: 14px;font-weight: 600;text-decoration: underline;}.truste_accessible_link:hover {color: #1D4ED8;text-decoration: none !important;}.truste_accessible_link:focus-visible {outline: none;border-radius: 4px;box-shadow: 0 0 0 1px #FFFFFF, 0 0 0 4px #3699F1;}</style><script src="https://ssl-cdn.janraincapture.com/widget_data/flow.js:7h8bznq6j7bvyvzqcrwvyp8dfb:en-US:20240514181256512029:standard" type="text/javascript"></script><script src="https://cssjs.nejm.org/akamai/capture:login" type="text/javascript"></script><script src="https://ssl-widget-cdn.rpxnow.com/translations/login/en-US" type="text/javascript"></script><script type="text/javascript" id="janrainAuthWidget" src="https://cssjs.nejm.org/akamai/mms-prod.js"></script><script type="text/javascript" src="https://www.nejm.org/qGlcdtDjuTdn9ZxQVGSFx_d5LLW_jhVEI56bECcvKCSkp2_JQRtkDkYb9YqdvPVnpxjIZrSvcCuXzGvn_K3OMA=="></script>
            

<meta charset="UTF-8">






    
        
            
        
    
        
            
        
    
        
            
        
    
        
            
        
    
        
    
        
    
        
            
                
                
<title>Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC | New England Journal of Medicine</title>





                
            
        
    







    
        
            
        
    
        
            
        
    
        
            
                
                



                
            
        
    
        
            
        
    
        
    
        
    
        
            
        
    











    








    

    
    

    
    
    
    
        
            
                <link rel="stylesheet" type="text/css" href="/wro/1125813~article-metrics.css">
            
            
            
        
    

    
    
        
            <link rel="icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_nejm_1-994b0160d1eb33dc79517ef0295aab1b.ico" type="image/x-icon">
        
        
            <link rel="icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_16-4aa032aa775940f725817b7ff42f0e2c.png" type="image/png" sizes="16x16">
        
        
            <link rel="icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_32-0a94fa44823476ffa0bb15bdb320fb34.png" type="image/png" sizes="32x32">
        
        
            <link rel="apple-touch-icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_152-d6c3522864a8e483996b7e9c132c901a.png" sizes="152x152">
        
        
            <link rel="apple-touch-icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_180-f2538afc53a365d4cd3f10ab73c56aad.png" sizes="180x180">
        
        
            <link rel="apple-touch-icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_167-8e888012bbdd31a00c3e54bc5b8ca5b6.png" sizes="167x167">
        
    

    
    
            <link rel="stylesheet" href="/products/mms-nextgen/mms/releasedAssets/css/build-5b89b331018866a4a965.css" media="all">
        <link rel="stylesheet" href="/products/mms-nextgen/mms/releasedAssets/css/print-5b89b331018866a4a965.css" media="print">
           <link rel="stylesheet" href="/products/mms-nextgen/mms/releasedAssets/css/build-article-5b89b331018866a4a965.css" media="all" id="article-style-sheet">
    
        <script nonce="94d64c3dc210a517-SJC">
        try {
            document.documentElement.classList.add('js');
        } catch (e) {
        }
    </script>
     
    

















    
        
            
                
                
                
                    
                    <!-- TrustArc Scripts -->
<script async="async" src="https://consent.trustarc.com/notice?domain=nejm.com&amp;c=teconsent&amp;js=nj&amp;noticeType=bb&amp;gtm=1&amp;text=true&amp;pcookie" crossorigin="" id="truste_0.6948229579850445"></script>
<script src="https://consent.trustarc.com/autoblockasset/core.min.js?domain=nejm.com"></script>
<script src="https://consent.trustarc.com/autoblockoptout?domain=nejm.com"></script>
<!-- /TrustArc Scripts -->
<!-- BlueConic Scripts -->
<script src="https://bc.nejm.org/script.js"></script>
    <!-- /BlueConic Scripts -->
<!-- Printing Meta Tags -->
    <meta name="Specialties" content="Hematology/Oncology">
<meta name="articleType" content="Original Article">
<meta name="articleCategory" content="Research">
<meta name="topics" content="Treatments in Oncology|Lung Cancer"><script type="text/javascript">var mmsData = {"access":{"isFreeCountry":"n"},"ad":{"category":"article"},"imageChallenge":{"id":null},"article":{"doi":"10.1056/NEJMoa1917346","title":"Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC","category":"Research","type":"Original Article","topics":"Treatments in Oncology|Lung Cancer","specialties":"Hematology/Oncology","seriesTitle":"","viewType":"Full","age":"2Years-1990","issueDate":"2020-10-01T00:00Z","isFree":"y","broadTopics":"","perspectiveTopics":"","granularTopics":"","methodologicalArea":"","isOnlineFirst":"n","isCurrentIssue":"n","metaTags":"\u003cmeta name\u003d\"Specialties\" content\u003d\"Hematology/Oncology\"/\u003e\n\u003cmeta name\u003d\"articleType\" content\u003d\"Original Article\"/\u003e\n\u003cmeta name\u003d\"articleCategory\" content\u003d\"Research\"/\u003e\n\u003cmeta name\u003d\"topics\" content\u003d\"Treatments in Oncology|Lung Cancer\"/\u003e"},"page":{"activity":"showFullText","url":"www.nejm.org/doi/full/10.1056/NEJMoa1917346","viewType":"desktop","journal":"NEJM"},"user":{"ucid":null,"audienceSegment":null,"specialtyGroupCode":null,"meterCountRemaining":null,"totalMeterCount":null},"object":[]};</script>
    <script type="text/javascript">var mmsDataAdd = {"user":{"customerType":"null","accessInstitutionID":"null"}};</script>
    <!-- Prehiding snippet for Adobe Target with asynchronous Launch deployment -->
    <!-- placeholder id=null, description=Adobe-Target-Prehiding-Snippet --><!--
  Adobe Target - Prehiding Snippet
  v2.0.0
-->
<script nonce="94d64c3dc210a517-SJC">
function tgtNoFlicker(e,n,t,o,i,c,l,r){function d(){return n.getElementsByTagName("head")[0]}function a(e,t){if(e){var o=n.getElementById(t);o&&e.removeChild(o)}}function f(e,o){!function(e,t,o){if(e){var i=n.createElement("style");i.id=t,i.innerHTML=o,e.appendChild(i)}}(d(),t,e),setTimeout(function(){a(d(),t)},o)}var m;n.location.href.indexOf(c)>-1?f(l,r):f(o,i),n.location.href.indexOf("mboxDisable")>-1?(a(d(),t),console.log("[TARGET] - Disabled, removing prehiding style")):(m=function(e){e&&(a(d(),t),console.log("[TARGET] - Blocked, removing prehiding style"))},fetch("//cdn.tt.omtrdc.net/cdn/target-vec.js",{method:"HEAD",mode:"no-cors"}).then(e=>m(!1)).catch(e=>m(!0)))}

tgtNoFlicker(window, document, 'at-body-style', 'div[data-location-name="Anonymous Module"], div[data-location-name="Anonymous Banner"], main > div.page-body > div > div > div > div.col-md-2-3.o-col.o-col--primary > div[class*="u-hide"], main > div.page-body > div > div > div > div.col-md-1-3.o-col.o-col--secondary > aside, header > h1#mainContent, a.m-article__link[href*="/10.1056/NEJMoa2116747"] > span.m-article__blurb > p, li.g-nejm-group__user-tool-secondary {opacity: 0 !important}', 3000);

tgtNoFlicker(window, document, 'at-mbox-style', '.N-ad-global-top-right, #N-ad-myNEJM-contextual-top, .N-ad-recentArticles, #N-ad-article-rightRail-1, #N-ad-siteWide-rightRail-1, #N-ad-imageChallenge-rightRail-2 {opacity: 0 !important}', 3000);
</script><!-- /Prehiding snippet for Adobe Target with asynchronous Launch deployment -->
    <!-- Launch Header Embed Code -->
    <script src="//assets.adobedtm.com/launch-ENcd6450fae3ae4870becbe6a2b01ab2e1.min.js" async="" type="ta-blocked" data-ta-blocked="1"></script>
    <!-- /Launch Header Embed Code -->

                    
                
            
        
    
        
            
                
                
                
                    
                    <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/"><meta name="citation_journal_title" content="New England Journal of Medicine"><meta name="dc.Title" content="Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC"><meta name="dc.Creator" content="Roy S. Herbst"><meta name="dc.Creator" content="Giuseppe Giaccone"><meta name="dc.Creator" content="Filippo de Marinis"><meta name="dc.Creator" content="Niels Reinmuth"><meta name="dc.Creator" content="Alain Vergnenegre"><meta name="dc.Creator" content="Carlos H. Barrios"><meta name="dc.Creator" content="Masahiro Morise"><meta name="dc.Creator" content="Enriqueta Felip"><meta name="dc.Creator" content="Zoran Andric"><meta name="dc.Creator" content="Sarayut Geater"><meta name="dc.Creator" content="Mustafa Özgüroğlu"><meta name="dc.Creator" content="Wei Zou"><meta name="dc.Creator" content="Alan Sandler"><meta name="dc.Creator" content="Ida Enquist"><meta name="dc.Creator" content="Kimberly Komatsubara"><meta name="dc.Creator" content="Yu Deng"><meta name="dc.Creator" content="Hiroshi Kuriki"><meta name="dc.Creator" content="Xiaohui Wen"><meta name="dc.Creator" content="Mark McCleland"><meta name="dc.Creator" content="Simonetta Mocci"><meta name="dc.Creator" content="Jacek Jassem"><meta name="dc.Creator" content="David R. Spigel"><meta name="dc.Description" content="The efficacy and safety of the anti–programmed death ligand 1 (PD-L1) monoclonal antibody atezolizumab, as compared with those of platinum-based chemotherapy, as first-line treatment for patients w..."><meta name="Description" content="The efficacy and safety of the anti–programmed death ligand 1 (PD-L1) monoclonal antibody atezolizumab, as compared with those of platinum-based chemotherapy, as first-line treatment for patients w..."><meta name="dc.Publisher" content="Massachusetts Medical Society"><meta name="dc.Date" scheme="WTN8601" content="2020-10-01"><meta name="dc.Type" content="research-article"><meta name="dc.Format" content="text/HTML"><meta name="dc.Identifier" scheme="doi" content="10.1056/NEJMoa1917346"><meta name="dc.Identifier" scheme="publisher-id" content="NJ202010013831408"><meta name="dc.Language" content="EN"><meta name="dc.Relation" content="YXQYoa1917346"><meta name="dc.Coverage" content="world"><meta name="dc.Rights" content="Copyright © 2020 Massachusetts Medical Society. All rights reserved.">




<link rel="meta" type="application/atom+xml" href="https://doi.org/10.1056%2FNEJMoa1917346">
<link rel="meta" type="application/rdf+json" href="https://doi.org/10.1056%2FNEJMoa1917346">
<link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1056%2FNEJMoa1917346">


                    
                
            
        
    
        
            
                
                
                
                
                
            
        
    
        
            
                
                
                
                    
                    





<meta name="robots" content="noarchive">





    





    
    
        
        <meta name="twitter:title" content="Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC | NEJM">
        <meta property="og:title" content="Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC | NEJM">
    


    <meta property="og:type" content="article">


    
    
        <meta property="og:url" content="https://www.nejm.org/doi/full/10.1056/NEJMoa1917346">
    
    


    
    
        <meta property="og:image" content="https://www.nejm.org/cms/asset/4ab0fe9d-3f41-4880-900c-a2685477da75/nejmoa1917346_f1.jpg">
        <meta name="twitter:image" content="https://www.nejm.org/cms/asset/4ab0fe9d-3f41-4880-900c-a2685477da75/nejmoa1917346_f1.jpg">
    



    <meta property="og:site_name" content="The New England Journal of Medicine">


    
    
        
        <meta property="og:description" content="The efficacy and safety of the anti–programmed death ligand 1 (PD-L1) monoclonal antibody
atezolizumab, as compared with those of platinum-based chemotherapy, as first-line
treatment for patients w...">
        <meta name="twitter:description" content="The efficacy and safety of the anti–programmed death ligand 1 (PD-L1) monoclonal antibody
atezolizumab, as compared with those of platinum-based chemotherapy, as first-line
treatment for patients w...">
    


    
    
        <meta property="og:image:width" content="2640">
    


    
    
        <meta property="og:image:height" content="3281">
    


    <meta name="twitter:card" content="summary">


    <meta name="twitter:site" content="@NEJM">


<meta name="viewport" content="width=device-width,initial-scale=1"><meta name="publication_doi" content="10.1056/NEJMoa1917346">


    















                    
                
            
        
    
        
    
        
    
        
            
                
                
                
                
                
            
        
    




<meta name="format-detection" content="telephone=no">

<meta http-equiv="X-UA-Compatible" content="IE=edge">
    




    
        
        
        <link rel="canonical" href="https://www.nejm.org/doi/full/10.1056/NEJMoa1917346">
    
    







<meta name="pbContext" content=";requestedJournal:journal:nejm;page:string:Article/Chapter View;issue:issue:doi\:10.1056/nejm_2020.383.issue-14;ctype:string:Journal Content;article:article:doi\:10.1056/NEJMoa1917346;wgroup:string:MMS NextGen Website Group;pageGroup:string:Publication Pages;subPage:string:Full Text;website:website:mms-site;journal:journal:nejms">
        <link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-933-8e181dff8b36ea01dc4c.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-34-6ea546d794fb7a1cea52.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-743-ddd329e1530654ec0846.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-305-9eee37798fdfe5196307.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-388-bb098c62445f518c0b46.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-556-8e58ca05fb5497e541ef.css"><script charset="utf-8" src="https://www.nejm.org/products/mms-nextgen/mms/releasedAssets/js/0-dfd243c732a07d3608f6.js"></script><script charset="utf-8" src="https://www.nejm.org/products/mms-nextgen/mms/releasedAssets/js/7-10d355ba95f7ec1fddf2.js"></script><script charset="utf-8" src="https://www.nejm.org/products/mms-nextgen/mms/releasedAssets/js/11-04bf2a0da30146b4a5d0.js"></script><script id="altmetric-embed-js" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/altmetric_badges-288192a491f0ad9cc434f05ea175659426f5ab0cfd6befb3f3592f96bb90b0d1.js"></script><script src="https://static.addtoany.com/menu/modules/core.pt5ow5lr.js" type="module"></script><link rel="preconnect" href="https://use.typekit.net"><meta http-equiv="P3P" content="CP=&quot;NOI DSP ADM OUR IND OTC&quot;"><link rel="stylesheet" href="https://quilt-cdn.janrain.com/HEAD/providers.css" type="text/css"><link id="altmetric-embed-css" rel="stylesheet" type="text/css" href="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed-59614f5c46b49b21eeef3bb28c4fb38d1e7069e8d014752fcb66e84942556802.css"><style type="text/css">.a2a_hide{display:none}.a2a_logo_color{background-color:#0166ff}.a2a_menu,.a2a_menu *{-moz-box-sizing:content-box;-webkit-box-sizing:content-box;box-sizing:content-box;float:none;margin:0;padding:0;position:static;height:auto;width:auto}.a2a_menu{border-radius:6px;display:none;direction:ltr;background:#FFF;font:16px sans-serif-light,HelveticaNeue-Light,"Helvetica Neue Light","Helvetica Neue",Arial,Helvetica,"Liberation Sans",sans-serif;color:#000;line-height:12px;border:1px solid #CCC;vertical-align:baseline;overflow:hidden}.a2a_mini{min-width:200px;position:absolute;width:300px;z-index:9999997}.a2a_overlay{display:none;background:#616c7deb;backdrop-filter:blur(4px);-webkit-backdrop-filter:blur(4px);position:fixed;top:0;right:0;left:0;bottom:0;z-index:9999998;-webkit-tap-highlight-color:transparent;transition:opacity .14s,backdrop-filter .14s}.a2a_full{background:#FFF;border:1px solid #FFF;box-shadow:#2a2a2a1a 0 0 20px 10px;height:auto;height:calc(320px);top:15%;left:50%;margin-left:-320px;position:fixed;text-align:center;width:640px;z-index:9999999;transition:transform .14s,opacity .14s}.a2a_full_footer,.a2a_full_header,.a2a_full_services{border:0;margin:0;padding:12px;box-sizing:border-box}.a2a_full_header{padding-bottom:8px}.a2a_full_services{height:280px;overflow-y:scroll;padding:0 12px;-webkit-overflow-scrolling:touch}.a2a_full_services .a2a_i{display:inline-block;float:none;width:181px;width:calc(33.334% - 18px)}div.a2a_full_footer{font-size:12px;text-align:center;padding:8px 14px}div.a2a_full_footer a,div.a2a_full_footer a:visited{display:inline;font-size:12px;line-height:14px;padding:8px 14px}div.a2a_full_footer a:focus,div.a2a_full_footer a:hover{background:0 0;border:0;color:#0166FF}div.a2a_full_footer a span.a2a_s_a2a,div.a2a_full_footer a span.a2a_w_a2a{background-size:14px;border-radius:3px;display:inline-block;height:14px;line-height:14px;margin:0 3px 0 0;vertical-align:top;width:14px}.a2a_modal{height:0;left:50%;margin-left:-320px;position:fixed;text-align:center;top:15%;width:640px;z-index:9999999;transition:transform .14s,opacity .14s;-webkit-tap-highlight-color:transparent}.a2a_modal_body{background:0 0;border:0;font:24px sans-serif-light,HelveticaNeue-Light,"Helvetica Neue Light","Helvetica Neue",Arial,Helvetica,"Liberation Sans",sans-serif;position:relative;height:auto;width:auto}.a2a_thanks{color:#fff;height:auto;margin-top:20px;width:auto}.a2a_thanks>div:first-child{margin:0 0 40px 0}.a2a_thanks div *{height:inherit}#a2a_copy_link{background:#FFF;border:1px solid #FFF;cursor:pointer;margin-top:15%}label.a2a_s_link#a2a_copy_link_icon,label.a2a_w_link#a2a_copy_link_icon{background-size:48px;border-radius:0;display:inline-block;height:48px;left:0;line-height:48px;margin:0 3px 0 0;position:absolute;vertical-align:top;width:48px}#a2a_modal input#a2a_copy_link_text{background-color:transparent;border:0;color:#2A2A2A;cursor:pointer;font:inherit;height:48px;left:62px;max-width:initial;min-height:auto;padding:0;position:relative;width:564px;width:calc(100% - 76px)}#a2a_copy_link_copied{background-color:#0166ff;color:#fff;display:none;font:inherit;font-size:16px;margin-top:1px;padding:3px 8px}@media (forced-colors:active){.a2a_color_buttons a,.a2a_svg{forced-color-adjust:none}}@media (prefers-color-scheme:dark){.a2a_menu a,.a2a_menu a.a2a_i,.a2a_menu a.a2a_i:visited,.a2a_menu a.a2a_more,i.a2a_i{border-color:#2a2a2a!important;color:#fff!important}.a2a_menu a.a2a_i:active,.a2a_menu a.a2a_i:focus,.a2a_menu a.a2a_i:hover,.a2a_menu a.a2a_more:active,.a2a_menu a.a2a_more:focus,.a2a_menu a.a2a_more:hover,.a2a_menu_find_container{border-color:#444!important;background-color:#444!important}.a2a_menu:not(.a2a_thanks){background-color:#2a2a2a;border-color:#2a2a2a}.a2a_menu_find{color:#fff!important}.a2a_menu label.a2a_s_find svg{background-color:transparent!important}.a2a_menu label.a2a_s_find svg path{fill:#fff!important}.a2a_full{box-shadow:#00000066 0 0 20px 10px}.a2a_overlay{background-color:#373737eb}}@media print{.a2a_floating_style,.a2a_menu,.a2a_overlay{visibility:hidden}}@keyframes a2aFadeIn{from{opacity:0}to{opacity:1}}.a2a_starting{opacity:0}.a2a_starting.a2a_full,.a2a_starting.a2a_modal{transform:scale(.8)}@media (max-width:639px){.a2a_full{border-radius:0;top:15%;left:0;margin-left:auto;width:100%}.a2a_modal{left:0;margin-left:10px;width:calc(100% - 20px)}}@media (min-width:318px) and (max-width:437px){.a2a_full .a2a_full_services .a2a_i{width:calc(50% - 18px)}}@media (max-width:317px){.a2a_full .a2a_full_services .a2a_i{width:calc(100% - 18px)}}@media (max-height:436px){.a2a_full{bottom:40px;height:auto;top:40px}}@media (max-height:550px){.a2a_modal{top:30px}}@media (max-height:360px){.a2a_modal{top:20px}.a2a_thanks>div:first-child{margin-bottom:20px}}.a2a_menu a{color:#0166FF;text-decoration:none;font:16px sans-serif-light,HelveticaNeue-Light,"Helvetica Neue Light","Helvetica Neue",Arial,Helvetica,"Liberation Sans",sans-serif;line-height:14px;height:auto;width:auto;outline:0}.a2a_menu a.a2a_i:visited,.a2a_menu a.a2a_more{color:#0166FF}.a2a_menu a.a2a_i:active,.a2a_menu a.a2a_i:focus,.a2a_menu a.a2a_i:hover,.a2a_menu a.a2a_more:active,.a2a_menu a.a2a_more:focus,.a2a_menu a.a2a_more:hover{color:#2A2A2A;border-color:#EEE;border-style:solid;background-color:#EEE;text-decoration:none}.a2a_menu label.a2a_s_find{background-size:24px;height:24px;left:8px;pointer-events:auto;position:absolute;top:7px;width:24px}.a2a_menu label.a2a_s_find svg{background-color:#FFF}.a2a_menu label.a2a_s_find svg path{fill:#CCC}#a2a_menu_container{display:inline-block}.a2a_menu_find_container{border:1px solid #CCC;border-radius:6px;padding:2px 24px 2px 0;position:relative;text-align:left}.a2a_cols_container .a2a_col1{overflow-x:hidden;overflow-y:auto;-webkit-overflow-scrolling:touch}#a2a_modal input,#a2a_modal input[type=text],.a2a_menu input,.a2a_menu input[type=text]{display:block;background-image:none;box-shadow:none;line-height:100%;margin:0;outline:0;overflow:hidden;padding:0;-moz-box-shadow:none;-webkit-box-shadow:none;-webkit-appearance:none}#a2afeed_find_container input,#a2afeed_find_container input[type=text],#a2apage_find_container input,#a2apage_find_container input[type=text]{background-color:transparent;border:0;box-sizing:content-box;color:#2A2A2A;float:none;font:inherit;font-size:16px;height:28px;line-height:20px;left:38px;outline:0;margin:0;max-width:initial;min-height:initial;padding:2px 0;position:relative;width:99%}.a2a_clear{clear:both}.a2a_svg{background-repeat:no-repeat;display:block;overflow:hidden;height:32px;line-height:32px;padding:0;pointer-events:none;width:32px}.a2a_svg svg{background-repeat:no-repeat;background-position:50% 50%;border:none;display:block;left:0;margin:0 auto;overflow:hidden;padding:0;position:relative;top:0;width:auto;height:auto}a.a2a_i,i.a2a_i{display:block;float:left;border:1px solid #FFF;line-height:24px;padding:6px 8px;text-align:left;white-space:nowrap;overflow:hidden;text-overflow:ellipsis;width:132px}a.a2a_i span,a.a2a_more span{display:inline-block;overflow:hidden;vertical-align:top}a.a2a_i .a2a_svg{margin:0 6px 0 0}a.a2a_i .a2a_svg,a.a2a_more .a2a_svg{background-size:24px;height:24px;line-height:24px;width:24px}a.a2a_sss:hover{border-left:1px solid #CCC}a.a2a_more{border-bottom:1px solid #FFF;border-left:0;border-right:0;line-height:24px;margin:6px 0 0;padding:6px;-webkit-touch-callout:none}a.a2a_more span{height:24px;margin:0 6px 0 0}.a2a_kit .a2a_svg{background-repeat:repeat}.a2a_default_style a:empty,.a2a_flex_style a:empty,.a2a_floating_style a:empty,.a2a_overlay_style a:empty{display:none}.a2a_color_buttons a,.a2a_floating_style a{text-decoration:none}.a2a_default_style:not(.a2a_flex_style) a{float:left;line-height:16px;padding:0 2px}.a2a_default_style a:hover .a2a_svg,.a2a_floating_style a:hover .a2a_svg,.a2a_overlay_style a:hover .a2a_svg svg{opacity:.7}.a2a_overlay_style.a2a_default_style a:hover .a2a_svg{opacity:1}.a2a_default_style .a2a_count,.a2a_default_style .a2a_svg,.a2a_floating_style .a2a_svg,.a2a_menu .a2a_svg,.a2a_vertical_style .a2a_count,.a2a_vertical_style .a2a_svg{border-radius:4px}.a2a_default_style .a2a_counter img,.a2a_default_style .a2a_dd,.a2a_default_style .a2a_svg{float:left}.a2a_default_style .a2a_img_text{margin-right:4px}.a2a_default_style .a2a_divider{border-left:1px solid #000;display:inline;float:left;height:16px;line-height:16px;margin:0 5px}.a2a_kit a{cursor:pointer;transition:none}.a2a_floating_style{background-color:#fff;border-radius:6px;position:fixed;z-index:9999995}.a2a_overlay_style{z-index:2147483647}.a2a_floating_style,.a2a_overlay_style{animation:a2aFadeIn .2s ease-in;padding:4px}.a2a_vertical_style:not(.a2a_flex_style) a{clear:left;display:block;overflow:hidden;padding:4px}.a2a_floating_style.a2a_default_style{bottom:0}.a2a_floating_style.a2a_default_style a,.a2a_overlay_style.a2a_default_style a{padding:4px}.a2a_count{background-color:#fff;border:1px solid #ccc;box-sizing:border-box;color:#2a2a2a;display:block;float:left;font:12px Arial,Helvetica,sans-serif;height:16px;margin-left:4px;position:relative;text-align:center;width:50px}.a2a_count:after,.a2a_count:before{border:solid transparent;border-width:4px 4px 4px 0;content:"";height:0;left:0;line-height:0;margin:-4px 0 0 -4px;position:absolute;top:50%;width:0}.a2a_count:before{border-right-color:#ccc}.a2a_count:after{border-right-color:#fff;margin-left:-3px}.a2a_count span{animation:a2aFadeIn .14s ease-in}.a2a_vertical_style .a2a_counter img{display:block}.a2a_vertical_style .a2a_count{float:none;margin-left:0;margin-top:6px}.a2a_vertical_style .a2a_count:after,.a2a_vertical_style .a2a_count:before{border:solid transparent;border-width:0 4px 4px 4px;content:"";height:0;left:50%;line-height:0;margin:-4px 0 0 -4px;position:absolute;top:0;width:0}.a2a_vertical_style .a2a_count:before{border-bottom-color:#ccc}.a2a_vertical_style .a2a_count:after{border-bottom-color:#fff;margin-top:-3px}.a2a_color_buttons .a2a_count,.a2a_color_buttons .a2a_count:after,.a2a_color_buttons .a2a_count:before,.a2a_color_buttons.a2a_vertical_style .a2a_count:after,.a2a_color_buttons.a2a_vertical_style .a2a_count:before{background-color:transparent;border:none;color:#fff;float:none;width:auto}.a2a_color_buttons.a2a_vertical_style .a2a_count{margin-top:0}.a2a_flex_style{display:flex;align-items:flex-start;gap:0}.a2a_default_style.a2a_flex_style{left:0;right:0;width:100%}.a2a_vertical_style.a2a_flex_style{flex-direction:column;top:0;bottom:0}.a2a_flex_style a{display:flex;justify-content:center;flex:1;padding:4px}.a2a_flex_style.a2a_vertical_style a{flex-direction:column}.a2a_floating_style.a2a_color_buttons,.a2a_floating_style.a2a_flex_style{border-radius:0;padding:0}.a2a_floating_style.a2a_default_style.a2a_flex_style{bottom:0}.a2a_kit.a2a_flex_style .a2a_counter img,.a2a_kit.a2a_flex_style .a2a_dd,.a2a_kit.a2a_flex_style .a2a_svg{float:none}.a2a_nowrap{white-space:nowrap}.a2a_note{margin:0 auto;padding:9px;font-size:12px;text-align:center}.a2a_note .a2a_note_note{margin:0;color:#2A2A2A}.a2a_wide a{display:block;margin-top:3px;border-top:1px solid #EEE;text-align:center}.a2a_label{position:absolute!important;clip-path:polygon(0px 0px,0px 0px,0px 0px);-webkit-clip-path:polygon(0px 0px,0px 0px,0px 0px);overflow:hidden;height:1px;width:1px}.a2a_kit,.a2a_menu,.a2a_modal,.a2a_overlay{-ms-touch-action:manipulation;touch-action:manipulation;outline:0}.a2a_dd{-webkit-user-drag:none}.a2a_dd img{border:0}.a2a_button_facebook_like iframe{max-width:none}</style></head>
    

    



    
        
        
        
            <body class="pb-ui website-mms-site loaded">
            






    
    
        





    
    
        
        
    
    
    







<input type="hidden" id="isRoMode" name="isRoMode" value="false">

        <div id="pb-page-content" data-ng-non-bindable="">
                
            <div data-pb-dropzone="main" data-pb-dropzone-name="Main">
                
                    
                        



        
        <header data-sticky="false" class="ng-header js_stickyAd"><a href="#mainContent" class="ng-skipToMainContent">Skip to main content</a><div class="ng-header_topAd"><div class="ng-header_topAd-content d-flex justify-content-center align-items-center">



        
        <div id="DTM_Position_Topbanner" class="ad">
 <!--emptycomment-->
</div>
</div></div><div class="ng-header_journal-navbar"><div class="ng-header_journal-navbar-content"><div class="container-fluid"><div class="row"><div class="ng-header_journal-navbar_left col-lg-8 col-sm-12 pr-lg-0 d-flex align-items-center"><div data-location="nejm_group_product_nav" class="ng-header_journalNavMenu">



        
        <nav data-location="nejm_group_product_nav" role="navigation" class="ng-journalNavMenu">
<ul class="ng-journalNavMenu_list">
<li class="ng-journalNavMenu_list-item"><a href="/" class="ng-journalNavMenu_mainLink active" aria-current="page" aria-label="The New England Journal of Medicine selected item"><span class="ng-journalNavMenu_mainLink-text d-lg-block d-none">The New England Journal of Medicine</span><span class="ng-journalNavMenu_mainLink-text d-lg-none d-block">NEJM</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://evidence.nejm.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> Evidence</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://ai.nejm.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> AI</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://catalyst.nejm.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> Catalyst</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://www.jwatch.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> Journal Watch</span></a></li>
</ul>
</nav>

</div></div><div class="ng-header_journal-navbar_right col-lg-4 pl-lg-0 d-none d-xl-flex align-items-center justify-content-end"><div class="ng-header_loginBar d-xl-flex align-items-lg-center">



        
        <div data-location="authstring_nav" class="ng-header_loginBar-menu"><span class="ng-simple-menu_mainLink-icon signIn newIcon-2"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#user2"></use></svg></span></span><span class="ng-header_loginBar-signIn"><a href="/sign-in?uri=/doi/full/10.1056/NEJMoa1917346" class="ng-header_loginBar-signIn-link">Sign In</a></span><span class="ng-header_loginBar-separator">|</span><span class="ng-header_loginBar-createAcc"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC1" class="ng-header_loginBar-createAcc-link ro-mode_disabled">Create Account</a></span></div><div data-location="authstring_nav" class="ng-header_loginBar-subscribe pl-xl-16"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS1" class="ng-header_loginBar-subscribe-btn ng-btn_primary ro-mode_disabled">Subscribe</a></div>
</div></div></div></div></div></div><div class="ng-header_instBanner d-none d-lg-block"></div><div class="ng-header_logoBar"><div class="container-fluid"><div class="row"><div data-location="logo" class="ng-header_logoBar_left col-lg-4 col-6 d-flex align-items-center justify-content-start"><a href="/" title="The New England Journal of Medicine homepage" class="ng-header_logo-link"><img src="/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/nejm-logo-166667e91992a5212bc723b03e45d39f.svg" alt="The New England Journal of Medicine homepage" width="366" height="58" class="ng-header_logo-image"></a></div><div class="ng-header_logoBar_right ng-header_navBar col-lg-8 col-sm-12 p-lg-0 align-items-center justify-content-end"><div class="ng-header_navBar-content"><div class="container-fluid"><div class="row"><div class="ng-header_instBanner-md col-12 d-block d-lg-none"></div><div class="ng-header_loginBar-md col-12 d-block d-xl-none">



        
        <div data-location="authstring_nav" class="ng-header_loginBar-menu"><span class="ng-simple-menu_mainLink-icon signIn newIcon-2"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#user2"></use></svg></span></span><span class="ng-header_loginBar-signIn"><a href="/sign-in?uri=/doi/full/10.1056/NEJMoa1917346" class="ng-header_loginBar-signIn-link">Sign In</a></span><span class="ng-header_loginBar-separator">|</span><span class="ng-header_loginBar-createAcc"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC1" class="ng-header_loginBar-createAcc-link ro-mode_disabled">Create Account</a></span></div><div data-location="authstring_nav" class="ng-header_loginBar-subscribe pl-xl-16"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS1" class="ng-header_loginBar-subscribe-btn ng-btn_primary ro-mode_disabled">Subscribe</a></div>
</div><div class="ng-header_navBar_left col-lg-8 col-sm-12 d-flex align-items-center"><div class="ng-header_stickyLogo mr-32"><a href="/" title="The New England Journal of Medicine homepage" class="ng-header_stickyLogo-link"><img src="/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/nejm-small-logo-070df7a3f4d8cfa2e71c3c45bb4b172f.svg" alt="The New England Journal of Medicine homepage" class="ng-header_stickyLogo-image"></a></div><div class="ng-header_mainMenu">









    
    
        <div data-widget-def="menuWidget" data-widget-id="97fb3983-db63-4b0b-97dd-d9bb7929fce1" data-location="main_nav">
        



        
        <nav class="ng-menu"><ul class="ng-menu_list ng-simple-menu"><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/toc/nejm/current" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">current issue</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/toc/nejm/current" class="ng-simple-menu_list-link">VIEW CURRENT ISSUE</a></li><li class="ng-simple-menu_list-item"><a href="/toc/nejm/recently-published" class="ng-simple-menu_list-link">BROWSE RECENTLY PUBLISHED</a></li><li class="ng-simple-menu_list-item"><a href="/loi/nejm" class="ng-simple-menu_list-link">BROWSE ALL ISSUES</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/medical-specialties" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">SPECIALTIES</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/browse/specialty/cardiology" class="ng-simple-menu_list-link">Cardiology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/clinical-medicine" class="ng-simple-menu_list-link">Clinical Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/endocrinology" class="ng-simple-menu_list-link">Endocrinology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/gastroenterology" class="ng-simple-menu_list-link">Gastroenterology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/hematology-oncology" class="ng-simple-menu_list-link">Hematology/Oncology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/infectious-disease" class="ng-simple-menu_list-link">Infectious Disease</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/nephrology" class="ng-simple-menu_list-link">Nephrology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/neurology-neurosurgery" class="ng-simple-menu_list-link">Neurology/Neurosurgery</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/obstetrics-gynecology" class="ng-simple-menu_list-link">Obstetrics/Gynecology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/pediatrics" class="ng-simple-menu_list-link">Pediatrics</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/pulmonary-critical-care" class="ng-simple-menu_list-link">Pulmonary/Critical Care</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/surgery" class="ng-simple-menu_list-link">Surgery</a></li><li class="ng-simple-menu_list-item"><a href="/medical-specialties" class="ng-simple-menu_list-link">View All Specialties</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/topics" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">TOPICS</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/ai-in-medicine" class="ng-simple-menu_list-link">AI in Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/climate-change" class="ng-simple-menu_list-link">Climate Change</a></li><li class="ng-simple-menu_list-item"><a href="/coronavirus" class="ng-simple-menu_list-link">Coronavirus</a></li><li class="ng-simple-menu_list-item"><a href="/equity" class="ng-simple-menu_list-link">Efforts toward Equity</a></li><li class="ng-simple-menu_list-item"><a href="/firearm-injury-prevention" class="ng-simple-menu_list-link">Firearm Injury Prevention</a></li><li class="ng-simple-menu_list-item"><a href="/nam" class="ng-simple-menu_list-link">From the National Academy of Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/fundamentals-of-medical-ethics" class="ng-simple-menu_list-link">Fundamentals of Medical Ethics</a></li><li class="ng-simple-menu_list-item"><a href="/gray-matters" class="ng-simple-menu_list-link">Gray Matters</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/health-policy" class="ng-simple-menu_list-link">Health Policy</a></li><li class="ng-simple-menu_list-item"><a href="/medicine-and-society" class="ng-simple-menu_list-link">Medicine and Society</a></li><li class="ng-simple-menu_list-item"><a href="/nutrition-in-medicine" class="ng-simple-menu_list-link">Nutrition in Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/outbreaks" class="ng-simple-menu_list-link">Outbreaks Center</a></li><li class="ng-simple-menu_list-item"><a href="/race-and-medicine" class="ng-simple-menu_list-link">Race and Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/recognizing-historical-injustices" class="ng-simple-menu_list-link">Recognizing Historical Injustices and the Journal</a></li><li class="ng-simple-menu_list-item"><a href="/tobacco-use-reduction" class="ng-simple-menu_list-link">Tobacco Use Reduction</a></li><li class="ng-simple-menu_list-item"><a href="/topics" class="ng-simple-menu_list-link">View All Topics</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/multimedia" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">MULTIMEDIA</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/rss-feed" class="ng-simple-menu_list-link">Podcasts</a></li><li class="ng-simple-menu_list-item"><a href="/double-take" class="ng-simple-menu_list-link">Double Takes</a></li><li class="ng-simple-menu_list-item"><a href="https://illustrated-glossary.nejm.org/" class="ng-simple-menu_list-link">Illustrated Glossary</a></li><li class="ng-simple-menu_list-item"><a href="/image-challenge" class="ng-simple-menu_list-link">Image Challenge</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/images-in-clinical-medicine" class="ng-simple-menu_list-link">Images in Clinical Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/interactive-medical-case" class="ng-simple-menu_list-link">Interactive Medical Cases</a></li><li class="ng-simple-menu_list-item"><a href="/plain-language-research-summaries" class="ng-simple-menu_list-link">Plain Language/Research Summaries</a></li><li class="ng-simple-menu_list-item"><a href="/multimedia/quick-take-video" class="ng-simple-menu_list-link">Quick Takes</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/videos-in-clinical-medicine" class="ng-simple-menu_list-link">Videos in Clinical Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/multimedia" class="ng-simple-menu_list-link">View All Multimedia</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/learning" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">LEARNING/CME</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/continuing-medical-education" class="ng-simple-menu_list-link">Weekly CME</a></li><li class="ng-simple-menu_list-item"><a href="/cme-ce/obesity" class="ng-simple-menu_list-link">Obesity CME/CE</a></li><li class="ng-simple-menu_list-item"><a href="/learning" class="ng-simple-menu_list-link">VIEW ALL LEARNING/CME</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item"><a href="/author-center/home" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">AUTHOR CENTER</span></a></li></ul></nav>

        </div>
    

</div><button aria-label="Search" class="ng-header_searchBtn searchBtnNav d-block ml-24"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#search"></use></svg></span></button></div><div class="ng-header_loginBar ng-header_loginBar-sticky col-4">



        
        <div data-location="authstring_nav" class="ng-header_loginBar-menu"><span class="ng-simple-menu_mainLink-icon signIn newIcon-2"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#user2"></use></svg></span></span><span class="ng-header_loginBar-signIn"><a href="/sign-in?uri=/doi/full/10.1056/NEJMoa1917346" class="ng-header_loginBar-signIn-link">Sign In</a></span><span class="ng-header_loginBar-separator">|</span><span class="ng-header_loginBar-createAcc"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC1" class="ng-header_loginBar-createAcc-link ro-mode_disabled">Create Account</a></span></div><div data-location="authstring_nav" class="ng-header_loginBar-subscribe pl-xl-16"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS1" class="ng-header_loginBar-subscribe-btn ng-btn_primary ro-mode_disabled">Subscribe</a></div>
</div></div></div></div></div><div class="ng-header_logoBar_right-lg col-lg-8 col-6 d-flex align-items-center justify-content-end d-xl-none"><button aria-label="Search" class="ng-header_searchBtn d-flex justify-content-end"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#search"></use></svg></span></button><div class="ng-header_openCloseBtns d-flex align-items-center justify-content-end"><button aria-label="Open" class="ng-header_openBtn"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#burger"></use></svg></span></button><button aria-label="Close" class="ng-header_closeBtn"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></button></div></div><div class="ng-header_quickSearch col-12"><div class="ng-header_quickSearch-content">



        
        <div class="ng-quick-search js-ng-quick-search"><form action="/search" method="get" class="ng-quick-search_form js-form"><div class="ng-quick-search_inputArea js-inputArea"><input type="search" name="q" placeholder="Enter keyword, author, title or citation" autocomplete="off" value="" required="required" class="ng-quick-search_allField ng-large-text-input js-allField js-allField-def-tmpl ui-autocomplete-input"><button type="submit" aria-label="Search Button" class="ng-quick-search_iconBtn d-xl-none d-block js-submitBtn"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#search"></use></svg></span></button><ul id="ui-id-1" tabindex="0" class="ui-menu ui-widget ui-widget-content ui-autocomplete ui-front" style="display: none;"></ul></div><div class="ng-quick-search_btnsArea d-none d-xl-flex align-items-center justify-content-end"><a href="/search/advanced" class="ng-quick-search_advSearchLink ng-btn_link js-advancedSearchLink">Advanced Search</a><button type="submit" class="ng-quick-search_textBtn ng-btn_secondary ng-btn_iconRight js-submitBtn"><span class="ng-btn_text">SEARCH</span><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-right"></use></svg></span></button></div></form></div>
</div></div></div></div></div></header><div class="ng-header_overlay"></div><div class="ng-header_after">









    
    
        <div data-widget-def="literatumAd" data-widget-id="4931ddbd-d46e-4597-b4fd-92549e9847ca" id="ad-global-banner-FULLx64-1">
        



        
        



    

    

    
        
    



        </div>
    

</div>

                    
                        



        
        <div>









    
    
        <main data-widget-def="axelPublicationContent" data-widget-id="fcdb5261-d6a2-4a9c-81d5-3a3e2304e9c1" id="mainContent">
        



        
        <div class="article-tools__savePopup"><div class="ng-save"><input type="hidden" value="/action/getSavedTags" class="getKeywordsServiceUrl"><input type="hidden" value="/action/mmsSaveItemsService?itemType=article" class="saveServiceUrl"><input type="hidden" value="article" class="saveType"><input type="hidden" value="10.1056/NEJMoa1917346" class="inputDoi"><input type="hidden" value="R.S. Herbst and Others" class="inputAuthor"><input type="hidden" value="N Engl J Med 2020;383:1328-1339" class="inputCitation"><input type="hidden" value="09-30-2020" class="inputEPubDate"><input type="hidden" value="October 2020" class="inputCoverDate"><input type="hidden" value="Original Article" class="inputContentType"><input type="hidden" value="Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC" class="inputArticleTitle"><input type="hidden" value="/browse/nejm-article-type/original-article" class="inputContentTypeUrl"><button type="button" id="saveArticleShowPopupBtn" aria-hidden="true" tabindex="-1" class="ng-save-btn ng-btn_secondary isLoggedOut">Save</button></div></div><div class="article-tools__articleAlertPopup"><div id="articleAlertModal" tabindex="-1" role="dialog" aria-labelledby="exampleModalCenterTitle" aria-hidden="true" class="ng-modal modal"><div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered"><div class="ng-modal_content modal-content"><div class="ng-modal_header modal-header"><h5 id="articleAlertModalTitle" class="ng-modal_title modal-title">Create an E-mail Alert for This Article</h5><button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></span></button></div><div class="ng-modal_body modal-body"></div></div></div></div></div><div class="ng-do-media_popup"><div id="doPopup" tabindex="-1" role="dialog" aria-labelledby="exampleModalCenterTitle" aria-hidden="true" class="ng-modal modal"><div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered"><div class="ng-modal_content modal-content"><div class="ng-modal_header modal-header"><button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></span></button></div><div class="ng-modal_body modal-body"></div></div></div></div></div><link id="build-style-article" rel="stylesheet" type="text/css" href="/products/mms-nextgen/mms/releasedAssets/css/build-article-5b89b331018866a4a965.css"><article xmlns="http://www.w3.org/1999/xhtml" data-design="pill" data-has="right-rail" data-type="research-article" vocab="http://schema.org/" typeof="ScholarlyArticle" lang="en" dir="ltr"><header data-extent="frontmatter" data-location="header_article"><div class="core-container"><div data-article-access="free" data-article-access-type="free" class="meta-panel"><div class="meta-panel__left-content"><div class="meta-panel__type"><a href="/browse/nejm-article-type/original-article">Original Article</a></div></div><div class="meta-panel__right-content"><div class="meta-panel__share">









    
    
        <div data-widget-def="UX3share" data-widget-id="eee5f139-16f2-48f8-97ea-1b114367da16" data-location="share_tools_article">
        



        
        <!-- Go to https://www.addtoany.com/buttons/customize/ to customize your tools --><script type="text/javascript" defer="defer" src="https://static.addtoany.com/menu/page.js" nonce="94d64c3dc210a517-SJC"></script><div class="share"><div class="share__block share__inline-links"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="d-flex list-unstyled a2a a2a_kit a2a_default_style mb-0 a2a_kit_size_32" style="line-height: 32px;"><li class="a2a_listitem_custom"><a role="link" title="Facebook" data-interactiontype="social" class="share__link a2a_button_facebook" target="_blank" rel="nofollow noopener" href="/#facebook"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-facebook"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="X (formerly Twitter)" data-interactiontype="social" class="share__link a2a_button_twitter" target="_blank" rel="nofollow noopener" href="/#twitter"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-twitter"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="Linked In" data-interactiontype="social" class="share__link a2a_button_linkedin" target="_blank" rel="nofollow noopener" href="/#linkedin"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-linkedin"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="Email" data-interactiontype="content_email_click" class="share__link a2a_button_email" target="_blank" rel="nofollow noopener" href="/#email"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-email"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="Bluesky" data-interactiontype="social" class="share__link a2a_button_bluesky" target="_blank" rel="nofollow noopener" href="/#bluesky"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-bluesky"></use></svg></span></a></li><div style="clear: both;"></div></ul></div></div>

        </div>
    

</div></div></div><h1 property="name">Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC</h1><div class="core-relations my-3"></div><div class="contributors"><span class="authors"><span class="heading">Authors</span>: <span role="list"><span property="author" typeof="Person" role="listitem"><span property="givenName">Roy S.</span> <span property="familyName">Herbst</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Giuseppe</span> <span property="familyName">Giaccone</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Filippo</span> <span property="familyName">de Marinis</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Niels</span> <span property="familyName">Reinmuth</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Alain</span> <span property="familyName">Vergnenegre</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Carlos H.</span> <span property="familyName">Barrios</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Masahiro</span> <span property="familyName">Morise</span>, <span property="honorificSuffix">M.D.</span></span><span data-displayed-on="all">, <span data-action="reveal" tabindex="0" role="listitem">+14</span> </span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Enriqueta</span> <span property="familyName">Felip</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Zoran</span> <span property="familyName">Andric</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Sarayut</span> <span property="familyName">Geater</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Mustafa</span> <span property="familyName">Özgüroğlu</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Wei</span> <span property="familyName">Zou</span>, <span property="honorificSuffix">Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Alan</span> <span property="familyName">Sandler</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Ida</span> <span property="familyName">Enquist</span>, <span property="honorificSuffix">Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Kimberly</span> <span property="familyName">Komatsubara</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Yu</span> <span property="familyName">Deng</span>, <span property="honorificSuffix">Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Hiroshi</span> <span property="familyName">Kuriki</span>, <span property="honorificSuffix">M.Sc.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Xiaohui</span> <span property="familyName">Wen</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Mark</span> <span property="familyName">McCleland</span>, <span property="honorificSuffix">Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Simonetta</span> <span property="familyName">Mocci</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Jacek</span> <span property="familyName">Jassem</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span></span>, and <span property="author" typeof="Person" role="listitem"><span property="givenName">David R.</span> <span property="familyName">Spigel</span>, <span property="honorificSuffix">M.D.</span></span><span data-displayed-on="none" data-on-display="all" aria-hidden="true"> <span data-action="hide" tabindex="0" role="listitem">-14</span></span></span></span><a href="#tab-contributors" class="to-authors-affiliations" data-id="article-authors-viewall">Author Info &amp; Affiliations</a></div><div class="core-self-citation"><div class="core-date-published">Published <span property="datePublished">September 30, 2020</span></div><div property="isPartOf" typeof="Periodical"><span property="name">N Engl J Med</span> 2020<span property="isPartOf" typeof="PublicationVolume">;<span property="volumeNumber">383</span></span>:<span property="pageStart">1328</span>-<span property="pageEnd">1339</span></div><div class="doi">DOI: 10.1056/NEJMoa1917346</div><div class="core-enumeration"><a href="/toc/nejm/383/14"><span property="isPartOf" typeof="PublicationVolume">VOL. <span property="volumeNumber">383</span></span> <span property="isPartOf" typeof="PublicationIssue">NO. <span property="issueNumber">14</span></span></a></div><div><a href="#tab-information">Copyright © 2020</a></div></div><div class="info-panel"><div class="info-panel__left-content"><div class="info-panel__metrics info-panel__item"></div></div><div data-location="tools_article" class="info-panel__right-content"><div class="info-panel__article_tools info-panel__item">



        
        <div data-permission="/servlet/linkout?type=rightslink&amp;url=publisherName%3Dmassmed%26author%3DRoy%2BS.%2BHerbst%252C%2BGiuseppe%2BGiaccone%252C%2BFilippo%2Bde%2BMarinis%252C%2Bet%2Bal%26publication%3Dnejm%26orderBeanReset%3Dtrue%26volumeNum%3D383%26issueNum%3D14%26contentID%3D10.1056%252FNEJMoa1917346%26title%3DAtezolizumab%2Bfor%2BFirst-Line%2BTreatment%2Bof%2BPD-L1%25E2%2580%2593Selected%2BPatients%2Bwith%2BNSCLC%26publicationDate%3D10%252F01%252F2020" class="article-tools"><button id="articleToolsAlertBtn" data-url="/action/addCitationAlert?doi=10.1056%2FNEJMoa1917346" data-toggle="" data-target="#articleAlertModal" aria-label="Sign in or create account to add an article alert" data-interactiontype="article_alert" class="article-tools__citation btn btn--slim isLoggedOut"><span title="" data-toggle="tooltip" class="d-inline-block" data-original-title="Sign in or create account to add an article alert"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#alerts"></use></svg></span></span></button><button id="articleToolsSaveBtn" data-toggle="modal" data-target="#saveArticle" aria-label="Sign in or create account to save this article" data-interactiontype="article_tools_save_click" class="article-tools__favorite btn btn--slim isLoggedOut"><span title="" data-toggle="tooltip" class="d-inline-block" data-original-title="Sign in or create account to save this article"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#bookmarkFilled"></use></svg></span></span></button><a href="/servlet/linkout?type=rightslink&amp;url=publisherName%3Dmassmed%26author%3DRoy%2BS.%2BHerbst%252C%2BGiuseppe%2BGiaccone%252C%2BFilippo%2Bde%2BMarinis%252C%2Bet%2Bal%26publication%3Dnejm%26orderBeanReset%3Dtrue%26volumeNum%3D383%26issueNum%3D14%26contentID%3D10.1056%252FNEJMoa1917346%26title%3DAtezolizumab%2Bfor%2BFirst-Line%2BTreatment%2Bof%2BPD-L1%25E2%2580%2593Selected%2BPatients%2Bwith%2BNSCLC%26publicationDate%3D10%252F01%252F2020" target="_blank" title="" data-toggle="tooltip" aria-label="Permissions" data-interactiontype="article_tools_permissions_click" class="article-tools__permissions btn btn--slim" data-original-title="Permissions"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#permissions"></use></svg></span></a><a href="/about-nejm/reprints" title="" data-toggle="tooltip" aria-label="Reprints" data-interactiontype="article_tools_reprints_click" class="article-tools__reprints btn btn--slim" data-original-title="Reprints"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#reprints"></use></svg></span></a><a href="/cms/asset/4bff200c-7b16-4073-8bae-d1254cc7f601/nejmoa1917346.pptx" target="_blank" title="" data-toggle="tooltip" aria-label="Download Slides" data-interactiontype="article_tools_slide_set_download" data-multimedia-type="Article Slideset" data-multimedia-filename="nejmoa1917346.pptx" class="article-tools__downloadSlides btn btn--slim" data-original-title="Download Slides"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#download"></use></svg></span></a><div class="article-tools__permissionsPopup"><div id="permissionsModal" tabindex="-1" role="dialog" aria-labelledby="exampleModalCenterTitle" aria-hidden="true" class="ng-modal modal"><div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered"><div class="ng-modal_content modal-content"><div class="ng-modal_header modal-header"><h5 id="permissionsModalTitle" class="ng-modal_title modal-title">Permissions</h5><button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></span></button></div><div class="ng-modal_body modal-body">For permission requests, please contact NEJM Reprints at <a href="mailto:reprints@nejm.org">reprints@nejm.org</a></div></div></div></div></div></div>
</div><div class="info-panel__citations info-panel__item"><a href="#tab-citations" class="btn btn--slim" aria-label="View Citations" data-toggle="tooltip" data-original-title="View Citations" data-interactiontype="article_tools_citation_download" data-multimedia-type="Citation"><i aria-hidden="true" class="icon-format_quote"></i></a></div><div class="info-panel__formats info-panel__item"><a href="https://www.nejm.org/doi/pdf/10.1056/NEJMoa1917346" class="btn btn--pdf btn--slim" aria-label="View PDF" data-toggle="tooltip" data-original-title="View PDF" data-behavior="trackDownloadEvent" data-doi="10.1056/NEJMoa1917346" data-interactiontype="article_tools_download_pdf" data-multimedia-type="Article PDF" data-multimedia-filename="nejmoa1917346.pdf"><i aria-hidden="true" class="icon-PDF"></i></a></div></div></div></div></header><div data-core-nav="header" data-extent="frontmatter"><div class="core-nav-wrapper core-container" aria-label="Article navigation"><div class="core-sections-menu"><button data-id="article-toolbar-showhide" aria-controls="article_sections_menu" aria-expanded="false" aria-label="Toggle section navigation menu" style="margin-top: 0px;"><i class="icon-list" aria-hidden="true"></i><span>Contents</span></button><nav id="article_sections_menu" aria-label="Contents" data-core-nav="article" style="margin-top: 0px;"><ul><li><a href="#summary-abstract" aria-current="true">Abstract</a></li><li><a href="#sec-1" aria-current="false">Methods</a></li><li><a href="#sec-2" aria-current="false">Results</a></li><li><a href="#sec-3" aria-current="false">Discussion</a></li><li class="bordered"><a href="#backnotes" aria-current="false">Notes</a></li><li><a href="#supplementary-materials" aria-current="false">Supplementary Material</a></li><li><a href="#bibliography" aria-current="false">References</a></li></ul></nav></div><nav id="article_collateral_menu"><ul data-core-nav="collateral" class="collateral-pill" style="margin-top: 0px;"><li><a href="#core-collateral-info" data-id="article-nav-menubar-info" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Information &amp; Authors"><i aria-hidden="true" class="icon-info"></i><span class="sr-only">Information &amp; Authors</span></a></li><li><a href="#core-collateral-metrics" data-id="article-nav-menubar-metrics" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Metrics &amp; Citations"><i aria-hidden="true" class="icon-timeline"></i><span class="sr-only">Metrics &amp; Citations</span></a></li><li><a href="#core-collateral-fulltext-options" data-id="article-nav-menubar-metrics" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="View Options"><i aria-hidden="true" class="icon-eye"></i><span class="sr-only">View Options</span></a></li><li><a href="#core-collateral-references" data-id="article-nav-menubar-references" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="References"><i aria-hidden="true" class="icon-references"></i><span class="sr-only">References</span></a></li><li><a href="#core-collateral-media" data-id="article-nav-menubar-media" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Media"><i aria-hidden="true" class="icon-photo"></i><span class="sr-only">Media</span></a></li><li><a href="#core-collateral-tables" data-id="article-nav-menubar-tables" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Tables"><i aria-hidden="true" class="icon-tables"></i><span class="sr-only">Tables</span></a></li><li><a href="#core-collateral-share" data-id="article-nav-menubar-share" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Share"><i aria-hidden="true" class="icon-share"></i><span class="sr-only">Share</span></a></li></ul></nav></div></div><div data-core-wrapper="content"><div id="abstracts" data-extent="frontmatter" data-location="articleTab_article"><div class="core-container"><section id="summary-abstract" property="abstract" typeof="Text" role="doc-abstract"><h2 property="name">Abstract</h2><section id="abs-sec-1"><h3>Background</h3><div role="paragraph">The efficacy and safety of the anti–programmed death ligand 1 (PD-L1) monoclonal antibody atezolizumab, as compared with those of platinum-based chemotherapy, as first-line treatment for patients with metastatic non–small-cell lung cancer (NSCLC) with PD-L1 expression are not known.</div></section><section id="abs-sec-2"><h3>Methods</h3><div role="paragraph">We conducted a randomized, open-label, phase 3 trial involving patients with metastatic nonsquamous or squamous NSCLC who had not previously received chemotherapy and who had PD-L1 expression on at least 1% of tumor cells or at least 1% of tumor-infiltrating immune cells as assessed by the SP142 immunohistochemical assay. Patients were assigned in a 1:1 ratio to receive atezolizumab or chemotherapy. Overall survival (primary end point) was tested hierarchically according to PD-L1 expression status among patients in the intention-to-treat population whose tumors were wild-type with respect to <i>EGFR</i> mutations or <i>ALK</i> translocations. Within the population with <i>EGFR</i> and <i>ALK</i> wild-type tumors, overall survival and progression-free survival were also prospectively assessed in subgroups defined according to findings on two PD-L1 assays as well as by blood-based tumor mutational burden.</div></section><section id="abs-sec-3"><h3>Results</h3><div role="paragraph">Overall, 572 patients were enrolled. In the subgroup of patients with <i>EGFR</i> and <i>ALK</i> wild-type tumors who had the highest expression of PD-L1 (205 patients), the median overall survival was longer by 7.1 months in the atezolizumab group than in the chemotherapy group (20.2 months vs. 13.1 months; hazard ratio for death, 0.59; P=0.01). Among all the patients who could be evaluated for safety, adverse events occurred in 90.2% of the patients in the atezolizumab group and in 94.7% of those in the chemotherapy group; grade 3 or 4 adverse events occurred in 30.1% and 52.5% of the patients in the respective groups. Overall and progression-free survival favored atezolizumab in the subgroups with a high blood-based tumor mutational burden.</div></section><section id="abs-sec-4"><h3>Conclusions</h3><div role="paragraph">Atezolizumab treatment resulted in significantly longer overall survival than platinum-based chemotherapy among patients with NSCLC with high PD-L1 expression, regardless of histologic type. (Funded by F. Hoffmann–La Roche/Genentech; IMpower110 ClinicalTrials.gov number, <a href="http://clinicaltrials.gov/show/NCT02409342" target="_blank">NCT02409342</a>.)</div></section></section></div></div><section id="bodymatter" data-extent="bodymatter" property="articleBody" typeof="Text" data-location="articleTab_article"><div class="core-container"><div role="paragraph">Inhibitors of programmed death 1 (PD-1) and its ligand PD-L1, either as monotherapy or combined with chemotherapy, with or without bevacizumab, have emerged as a new standard of care for the first-line treatment of patients with advanced non–small-cell lung cancer (NSCLC) without mutations of epidermal growth factor receptor (<i>EGFR</i>) or translocations of anaplastic lymphoma kinase (<i>ALK</i>).<sup><a href="#core-r1" role="doc-biblioref" data-xml-rid="r1 r2 r3 r4 r5 r6 r7" id="body-ref-r7-1" href-manipulated="true">1-7</a></sup> Pembrolizumab monotherapy has been approved as a first-line treatment for patients with tumors with high PD-L1 expression (tumor proportion score [the fraction of tumor cells expressing PD-L1], ≥50%) in the United States and European Union.<sup><a href="#core-r6" role="doc-biblioref" data-xml-rid="r6 r7" id="body-ref-r7-2" href-manipulated="true">6,7</a></sup> In the United States, this approval has been extended to patients with advanced NSCLC with a tumor proportion score of at least 1%; however, most of the clinical benefit appears to be limited to the subgroup with the highest PD-L1 expression.<sup><a href="#core-r8" role="doc-biblioref" data-xml-rid="r8" id="body-ref-r8-1" href-manipulated="true" aria-label="Reference 8">8</a></sup> The phase 2 BIRCH and POPLAR trials as well as the phase 3 OAK trial showed an overall survival benefit with atezolizumab, an anti–PD-L1 monoclonal antibody,<sup><a href="#core-r9" role="doc-biblioref" data-xml-rid="r9" id="body-ref-r9" href-manipulated="true" aria-label="Reference 9">9</a></sup> as a monotherapy in patients with NSCLC with high PD-L1 expression (as assessed by the SP142 PD-L1 immunohistochemical assay) across multiple lines of therapy.<sup><a href="#core-r10" role="doc-biblioref" data-xml-rid="r10 r11 r12" id="body-ref-r12" href-manipulated="true">10-12</a></sup></div><div role="paragraph">Despite advances in the landscape of first-line treatment for metastatic NSCLC, additional treatment options are needed. IMpower110 is a global, randomized, open-label, phase 3 trial designed to evaluate the efficacy and safety of atezolizumab as compared with platinum-based chemotherapy in PD-L1–selected patients (positive for PD-L1 on the SP142 assay) with <i>EGFR</i> and <i>ALK</i> wild-type metastatic NSCLC who had not previously received chemotherapy.</div><div role="paragraph">Currently, several PD-L1 immunohistochemical assays are routinely used to guide decisions about immune-checkpoint inhibitor treatment.<sup><a href="#core-r13" role="doc-biblioref" data-xml-rid="r13" id="body-ref-r13-1" href-manipulated="true" aria-label="Reference 13">13</a></sup> We performed prespecified efficacy analyses of subgroups defined with the use of other frequently used PD-L1 immunohistochemical assays (22C3 and SP263),<sup><a href="#core-r14" role="doc-biblioref" data-xml-rid="r14 r15" id="body-ref-r15-1" href-manipulated="true">14,15</a></sup> allowing for their evaluation within the enrolled population. In addition, we performed efficacy analyses in subgroups defined according to blood-based tumor mutational burden, which is a noninvasive approach for identifying patients who may benefit from immunotherapy.<sup><a href="#core-r16" role="doc-biblioref" data-xml-rid="r16 r17 r18 r19" id="body-ref-r19-1" href-manipulated="true">16-19</a></sup> Here, we report primary efficacy and safety results of the interim analysis of overall survival among patients with high PD-L1 expression as assessed by the SP142 immunohistochemical assay, as well as efficacy in subgroups defined according to additional biomarkers.</div><section id="sec-1" data-type="methods"><h2>Methods</h2><section id="sec-1-1"><h3>Patients</h3><div role="paragraph">Eligible patients were 18 years of age or older; had stage IV nonsquamous or squamous NSCLC, measurable by Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1; had a baseline Eastern Cooperative Oncology Group (ECOG) performance-status score of 0 or 1 (on a 5-point scale in which higher scores indicate greater disability); and had not previously received chemotherapy. PD-L1 expression on at least 1% of tumor cells or tumor-infiltrating immune cells covering at least 1% of the tumor area as determined by the SP142 assay was required.<sup><a href="#core-r20" role="doc-biblioref" data-xml-rid="r20" id="body-ref-r20-1" href-manipulated="true" aria-label="Reference 20">20</a></sup> Immunohistochemical analyses were conducted by a central laboratory on archival tumor tissue or tissue obtained through biopsy at the time of screening. Full details on eligibility are provided in the <a href="#ap1">protocol</a>, available with the full text of this article at NEJM.org. Initially, patients with a known sensitizing <i>EGFR</i> mutation or <i>ALK</i> translocation were eligible provided they had received previous targeted therapy. The protocol was subsequently amended to exclude these patients from the analysis (18 patients) because emerging data suggested that they may not benefit from immune-checkpoint inhibitor monotherapy.<sup><a href="#core-r21" role="doc-biblioref" data-xml-rid="r21 r22 r23" id="body-ref-r23" href-manipulated="true">21-23</a></sup> All the patients were evaluated for central nervous system (CNS) metastasis at the time of screening with the use of computed tomography, magnetic resonance imaging, or both; patients with active or untreated CNS metastases were ineligible for enrollment in the trial.</div></section><section id="sec-1-2"><h3>Trial Design and Oversight</h3><div role="paragraph">Patients were randomly assigned in a 1:1 ratio to receive atezolizumab (1200 mg intravenously) or platinum-based chemotherapy (4 or 6 cycles) once every 3 weeks. In the chemotherapy group, patients with nonsquamous NSCLC received either cisplatin (75 mg per square meter of body-surface area) or carboplatin (area under the concentration−time curve [AUC], 6) in addition to pemetrexed (500 mg per square meter) intravenously; patients with squamous NSCLC received a regimen of cisplatin (75 mg per square meter) plus gemcitabine (1250 mg per square meter) or a regimen of carboplatin (AUC, 5) plus gemcitabine (1000 mg per square meter) intravenously. Randomization was stratified according to sex (male vs. female), ECOG performance-status score (0 vs. 1), histologic type (nonsquamous vs. squamous), and PD-L1 status (≥1% PD-L1 expression on tumor cells and any level of PD-L1 expression on tumor-infiltrating immune cells vs. &lt;1% PD-L1 expression on tumor cells and ≥1% PD-L1 expression on tumor-infiltrating immune cells). Continuation of atezolizumab after disease progression was allowed in patients who had continued clinical benefit. No crossover to the atezolizumab group was permitted.</div><div role="paragraph">Genentech (a member of the Roche Group) funded the trial, provided the trial treatments, and collaborated with the academic authors on the design of the trial and the collection, analysis, and interpretation of the data. The trial was conducted in full accordance with Good Clinical Practice guidelines and the Declaration of Helsinki or the laws and regulations of the country in which the research was conducted, whichever afforded the most protection. Written informed consent was obtained from all the patients. Safety data were regularly reviewed by an independent data monitoring committee. The committee was also responsible for evaluating efficacy data at the prespecified interim analysis of overall survival. The protocol was approved by independent ethics committees for each site. All the authors vouch for the accuracy and completeness of the data and for the adherence of the trial to the protocol. Earlier versions of the manuscript were developed by the authors, with editorial and writing assistance funded by the sponsor.</div></section><section id="sec-1-3"><h3>End Points and Assessments</h3><div role="paragraph">Overall survival was the primary end point in the PD-L1–selected population that excluded patients with <i>EGFR</i> mutations or <i>ALK</i> translocations. Secondary efficacy end points included investigator-assessed progression-free survival according to RECIST, version 1.1; the occurrence and duration of a response; and overall and investigator-assessed progression-free survival according to RECIST, version 1.1, in prespecified subgroups with respect to PD-L1 expression (defined by the SP263 immunohistochemical assay) and blood-based tumor mutational burden. Safety was assessed in all the patients who received a trial agent regardless of PD-L1 expression status or status with respect to <i>EGFR</i> or <i>ALK</i> alterations. Exploratory end points included overall and investigator-assessed progression-free survival according to RECIST, version 1.1, in prespecified subgroups with respect to PD-L1 expression defined by the 22C3 immunohistochemical assay.</div><div role="paragraph">Tumor assessments were conducted at baseline, every 6 weeks for 48 weeks, and every 9 weeks thereafter, until radiographic disease progression (or loss of clinical benefit for patients in the atezolizumab group who were treated beyond disease progression), withdrawal of consent, or death, whichever occurred first. Adverse events were reported according to National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0, and coded according to the <i>Medical Dictionary for Regulatory Activities</i>, version 22.0.</div><div role="paragraph">The scoring algorithm of the SP142 immunohistochemical assay (Ventana) measures PD-L1 expression on tumor cells and tumor-infiltrating immune cells; the algorithms of the 22C3 assay (Dako) and SP263 assay (Ventana) specifically measure PD-L1 expression on tumor cells.<sup><a href="#core-r13" role="doc-biblioref" data-xml-rid="r13 r14 r15 r20" id="body-ref-r20-2" href-manipulated="true">13–15,20</a></sup> The cutoffs of a tumor proportion score of at least 1% and at least 50% were evaluated for the 22C3 assay, and the cutoffs of at least 1% of tumor cells and at least 50% of tumor cells were evaluated for the SP263 assay. The blood-based tumor mutational burden assay (Foundation Medicine) identifies single-nucleotide variants at a variant allele fraction of at least 0.5% across 394 genes and estimates the tumor fraction according to maximum somatic allele frequency, filters out germline events, and counts nondriver somatic mutations to generate a score.<sup><a href="#core-r18" role="doc-biblioref" data-xml-rid="r18" id="body-ref-r18-2" href-manipulated="true" aria-label="Reference 18">18</a></sup> The cutoff scores for blood-based tumor mutational burden that were evaluated were at least 10, at least 16, and at least 20. A score of 16 (16 mutations per 1.1 megabases) equates to approximately 14.5 mutations per megabase.<sup><a href="#core-r18" role="doc-biblioref" data-xml-rid="r18 r24" id="body-ref-r24-1" href-manipulated="true">18,24</a></sup></div></section><section id="sec-1-4"><h3>Statistical Analysis</h3><div role="paragraph">Full details of the statistical analyses, including sample size and power, are provided in the protocol. To control for the overall type I error rate at a two-sided significance level of 0.05, the primary end point of overall survival was tested hierarchically in the population with <i>EGFR</i> and <i>ALK</i> wild-type tumors: high PD-L1 expression (≥50% of tumor cells or ≥10% of tumor-infiltrating immune cells), then combined high and intermediate PD-L1 expression (≥5% of tumor cells or tumor-infiltrating immune cells), and then any PD-L1 expression (≥1% of tumor cells or tumor-infiltrating immune cells; intention-to-treat population) (Fig. S1 in the <a href="#ap2">Supplementary Appendix</a>, available at NEJM.org). If the results for the primary end point of overall survival were significant in all three primary analysis populations, a two-sided significance level of 0.05 would be passed down to compare progression-free survival between the atezolizumab and control groups.</div><div role="paragraph">An interim analysis of overall survival was conducted when approximately 96 deaths and an event–patient ratio of 45% had occurred among patients with <i>EGFR</i> and <i>ALK</i> wild-type tumors who had high PD-L1 expression. Analyses of overall and progression-free survival were performed with the use of a stratified log-rank test. Hazard ratios and 95% confidence intervals were estimated with a stratified Cox regression model. The Kaplan–Meier method was used to estimate medians, and the Brookmeyer–Crowley method was used to generate 95% confidence intervals for the medians. The percentages of patients with a response and 95% confidence intervals were calculated with the Clopper–Pearson method. Response duration was estimated with the Kaplan–Meier method. We performed prespecified subgroup analyses to assess the consistency of the treatment effect using unstratified hazard ratios that were estimated from a Cox proportional-hazards model.</div></section></section><section id="sec-2" data-type="results"><h2>Results</h2><section id="sec-2-1"><h3>Patients</h3><div role="paragraph">Between July 21, 2015, and February 20, 2018, a total of 572 patients underwent randomization at 144 centers in 19 countries, with 285 patients assigned to receive atezolizumab and 287 assigned to receive chemotherapy (Fig. S2). The population with <i>EGFR</i> and <i>ALK</i> wild-type tumors comprised 554 patients (277 patients in each group). A total of 18 patients with an <i>EGFR</i> mutation or <i>ALK</i> translocation were enrolled and were excluded from the primary analysis population but were included in the safety population.</div><div role="paragraph">The baseline characteristics of the patients were generally balanced between the treatment groups (<a href="#t1">Table 1</a> and Table S1). Overall in the population with <i>EGFR</i> and <i>ALK</i> wild-type tumors, 107 patients (38.6%) in the atezolizumab group and 98 (35.4%) in the chemotherapy group had high expression of PD-L1; 166 patients (59.9%) in the atezolizumab group and 162 (58.5%) in the chemotherapy group had high or intermediate PD-L1 expression (<a href="#t1">Table 1</a>, Table S1, and Fig. S3).</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Table 1</div><nav><a href="#t1" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa1917346_t1.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="t1" class="table"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#t1" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa1917346_t1.jpg"><img src="/cms/10.1056/NEJMoa1917346/asset/e0987f4e-9697-45fb-aba5-15f1e3cf5c54/assets/images/large/nejmoa1917346_t1.jpg" height="1723" width="1999" loading="lazy"></a></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Characteristic</th><th class="txxx-borders" colspan="2"><span>Any PD-L1 Expression</span></th><th class="txxx-borders" colspan="2"><span>High or Intermediate PD-L1 Expression</span></th><th class="txxr-borders" colspan="2"><span>High PD-L1 Expression</span></th></tr><tr class="head2" data-type="row head2"><td class="xxlx-borders">&nbsp;</td><th class="xxxx-borders">Atezolizumab <br>(N=277)</th><th class="xxxx-borders">Chemotherapy<br>(N=277)</th><th class="xxxx-borders">Atezolizumab<br>(N=166)</th><th class="xxxx-borders">Chemotherapy<br>(N=162)</th><th class="xxxx-borders">Atezolizumab<br>(N=107)</th><th class="xxxr-borders">Chemotherapy<br>(N=98)</th></tr></thead><tbody><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Median age (range) — yr</td><td class="xxxx-borders shading">64 (30–81)</td><td class="xxxx-borders shading">65 (30–87)</td><td class="xxxx-borders shading">63 (33–81)</td><td class="xxxx-borders shading">65 (33–87)</td><td class="xxxx-borders shading">63 (33–79)</td><td class="xxxr-borders shading">66 (33–87)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Male sex — no. (%)</td><td class="xxxx-borders">196 (70.8)</td><td class="xxxx-borders">193 (69.7)</td><td class="xxxx-borders">122 (73.5)</td><td class="xxxx-borders">107 (66.0)</td><td class="xxxx-borders">79 (73.8)</td><td class="xxxr-borders">64 (65.3)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Race — no. (%)<a href="#t1fn2" role="doc-noteref">†</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">White</td><td class="xxxx-borders">227 (81.9)</td><td class="xxxx-borders">240 (86.6)</td><td class="xxxx-borders">133 (80.1)</td><td class="xxxx-borders">139 (85.8)</td><td class="xxxx-borders">87 (81.3)</td><td class="xxxr-borders">82 (83.7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Asian</td><td class="xxxx-borders shading">45 (16.2)</td><td class="xxxx-borders shading">30 (10.8)</td><td class="xxxx-borders shading">31 (18.7)</td><td class="xxxx-borders shading">20 (12.3)</td><td class="xxxx-borders shading">20 (18.7)</td><td class="xxxr-borders shading">15 (15.3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Black</td><td class="xxxx-borders">2 (0.7)</td><td class="xxxx-borders">2 (0.7)</td><td class="xxxx-borders">1 (0.6)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxr-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Unknown</td><td class="xxxx-borders shading">2 (0.7)</td><td class="xxxx-borders shading">5 (1.8)</td><td class="xxxx-borders shading">1 (0.6)</td><td class="xxxx-borders shading">3 (1.9)</td><td class="xxxx-borders shading">0</td><td class="xxxr-borders shading">1 (1.0)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">ECOG performance-status score — no. (%)<a href="#t1fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">0</td><td class="xxxx-borders shading">97 (35.0)</td><td class="xxxx-borders shading">102 (36.8)</td><td class="xxxx-borders shading">60 (36.1)</td><td class="xxxx-borders shading">62 (38.3)</td><td class="xxxx-borders shading">35 (32.7)</td><td class="xxxr-borders shading">38 (38.8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">1</td><td class="xxxx-borders">180 (65.0)</td><td class="xxxx-borders">175 (63.2)</td><td class="xxxx-borders">106 (63.9)</td><td class="xxxx-borders">100 (61.7)</td><td class="xxxx-borders">72 (67.3)</td><td class="xxxr-borders">60 (61.2)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">History of tobacco use — no. (%)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Never</td><td class="xxxx-borders">37 (13.4)</td><td class="xxxx-borders">35 (12.6)</td><td class="xxxx-borders">21 (12.7)</td><td class="xxxx-borders">17 (10.5)</td><td class="xxxx-borders">9 (8.4)</td><td class="xxxr-borders">15 (15.3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Current</td><td class="xxxx-borders shading">74 (26.7)</td><td class="xxxx-borders shading">81 (29.2)</td><td class="xxxx-borders shading">38 (22.9)</td><td class="xxxx-borders shading">52 (32.1)</td><td class="xxxx-borders shading">20 (18.7)</td><td class="xxxr-borders shading">29 (29.6)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Previous</td><td class="xxxx-borders">166 (59.9)</td><td class="xxxx-borders">161 (58.1)</td><td class="xxxx-borders">107 (64.5)</td><td class="xxxx-borders">93 (57.4)</td><td class="xxxx-borders">78 (72.9)</td><td class="xxxr-borders">54 (55.1)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Histologic type at diagnosis — no. (%)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Nonsquamous</td><td class="xxxx-borders">192 (69.3)</td><td class="xxxx-borders">193 (69.7)</td><td class="xxxx-borders">122 (73.5)</td><td class="xxxx-borders">116 (71.6)</td><td class="xxxx-borders">80 (74.8)</td><td class="xxxr-borders">75 (76.5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging12 shading" data-xml-align="left">Squamous</td><td class="xbxx-borders shading">85 (30.7)</td><td class="xbxx-borders shading">84 (30.3)</td><td class="xbxx-borders shading">44 (26.5)</td><td class="xbxx-borders shading">46 (28.4)</td><td class="xbxx-borders shading">27 (25.2)</td><td class="xbxr-borders shading">23 (23.5)</td></tr></tbody></table></div><figcaption><div class="caption">Demographic and Clinical Characteristics of the Patients at Baseline (Population with <i>EGFR</i> and <i>ALK</i> Wild-Type Tumors).<a href="#t1fn1" role="doc-noteref">*</a></div><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="t1fn1" role="paragraph">This population comprised the patients whose tumors were wild-type with respect to <i>EGFR</i> mutations or <i>ALK</i> translocations. Any programmed death ligand 1 (PD-L1) expression indicates PD-L1 expression on at least 1% of tumor cells or tumor-infiltrating immune cells as assessed by the SP142 assay. High or intermediate PD-L1 expression indicates PD-L1 expression on at least 5% of tumor cells or tumor-infiltrating immune cells. High PD-L1 expression indicates PD-L1 expression on at least 50% of tumor cells or at least 10% of tumor-infiltrating immune cells. Percentages may not total 100 because of rounding.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="t1fn2" role="paragraph">Race was reported by the patients. One patient in the atezolizumab group with any PD-L1 expression was categorized as having multiple races (not shown).</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="t1fn3" role="paragraph">Eastern Cooperative Oncology Group (ECOG) performance-status scores range from 0 to 5, with 0 indicating no symptoms and higher scores indicating greater disability.</div></div></div></figcaption></figure></div></section><section id="sec-2-2"><h3>Interim Analysis of Overall Survival</h3><div role="paragraph">At the data cutoff date (September 10, 2018), the median follow-up times for survival among patients with <i>EGFR</i> and <i>ALK</i> wild-type tumors who had high PD-L1 expression, high or intermediate PD-L1 expression, and any PD-L1 expression were 15.7 months (range, 0 to 35), 15.2 months (range, 0 to 35), and 13.4 months (range, 0 to 35), respectively. In the specified population, 101 of 205 patients (49.3%) who had high PD-L1 expression, 154 of 328 patients (47.0%) who had high or intermediate PD-L1 expression, and 253 of 554 patients (45.7%) who had any PD-L1 expression had died.</div><div role="paragraph">Among patients with <i>EGFR</i> and <i>ALK</i> wild-type tumors who had high PD-L1 expression, the median overall survival was significantly longer — by 7.1 months — in the atezolizumab group than in the chemotherapy group (20.2 months vs. 13.1 months; stratified hazard ratio for death, 0.59; 95% confidence interval [CI], 0.40 to 0.89; P=0.01) (<a href="#f1">Figure 1A</a>). The effect of the treatment in patient subgroups is shown in Figure S4.</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Figure 1</div><nav><a href="#f1" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa1917346_f1.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="f1" class="graphic"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#f1" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa1917346_f1.jpg"><img src="/cms/10.1056/NEJMoa1917346/asset/4ab0fe9d-3f41-4880-900c-a2685477da75/assets/images/large/nejmoa1917346_f1.jpg" height="3281" width="2640" aria-labelledby="f1" loading="lazy"></a><figcaption><div class="caption">Overall Survival in the Atezolizumab Group and the Chemotherapy Group.</div><div class="notes"><div role="doc-footnote">Shown are Kaplan–Meier estimates of overall survival among the patients whose tumors were wild-type with respect to <i>EGFR</i> mutations or <i>ALK</i> translocations. High expression of programmed death ligand 1 (PD-L1) indicates PD-L1 expression on at least 50% of tumor cells or at least 10% of tumor-infiltrating immune cells as assessed by the SP142 immunohistochemical assay (Panel A). High or intermediate PD-L1 expression indicates PD-L1 expression on at least 5% of tumor cells or tumor-infiltrating immune cells (Panel B). Any PD-L1 expression indicates PD-L1 expression on at least 1% of tumor cells or tumor-infiltrating immune cells. Stratified hazard ratios are given according to the level of PD-L1 expression. Treatment comparisons (atezolizumab vs. platinum-based chemotherapy) for the primary end point of overall survival were based on a stratified log-rank test. Medians were estimated with the use of the Kaplan–Meier method. A stratified Cox regression model was used to estimate hazard ratios, and 95% confidence intervals (CIs) were calculated with the use of the Brookmeyer–Crowley method. The results for overall survival among patients who had high or intermediate PD-L1 expression did not cross the prespecified alpha boundary, so overall survival among patients who had any PD-L1 expression was not formally tested. Tick marks indicate censored data. NE denotes could not be estimated.</div></div></figcaption></figure></div><div role="paragraph">The results for overall survival among patients with <i>EGFR</i> and <i>ALK</i> wild-type tumors who had high or intermediate PD-L1 expression did not cross the prespecified alpha boundary (median, 18.2 months in the atezolizumab group and 14.9 months in the chemotherapy group; stratified hazard ratio for death, 0.72; 95% CI, 0.52 to 0.99; P=0.04) (<a href="#f1">Figure 1B</a>); therefore, in accordance with the statistical analysis plan, overall survival among patients with <i>EGFR</i> and <i>ALK</i> wild-type tumors who had any PD-L1 expression was not formally tested. The median overall survival among these patients was 17.5 months with atezolizumab and 14.1 months with chemotherapy (stratified hazard ratio for death, 0.83; 95% CI, 0.65 to 1.07) (<a href="#f1">Figure 1C</a>). The results of an exploratory sensitivity analysis of overall survival with adjustment for patients whose data were censored owing to early withdrawal are shown in Table S2.</div><div role="paragraph">Among patients with <i>EGFR</i> and <i>ALK</i> wild-type tumors who had high PD-L1 expression, 2 patients (1.9%) in the atezolizumab group and 29 patients (29.6%) in the chemotherapy group received subsequent immunotherapy (Table S3). Across subgroups with respect to PD-L1 expression, the percentage of patients receiving different classes of subsequent anticancer therapies was similar.</div></section><section id="sec-2-3"><h3>Analysis of Progression-free Survival</h3><div role="paragraph">At data cutoff, 146 of 205 patients (71.2%) with <i>EGFR</i> and <i>ALK</i> wild-type tumors who had high PD-L1 expression had had disease progression or had died. Progression-free survival was 8.1 months in the atezolizumab group and 5.0 months in the chemotherapy group (stratified hazard ratio for disease progression or death, 0.63; 95% CI, 0.45 to 0.88) (Fig. S5A). Among patients with <i>EGFR</i> and <i>ALK</i> wild-type tumors who had high or intermediate PD-L1 expression, progression-free survival was 7.2 months in the atezolizumab group and 5.5 months in the chemotherapy group (stratified hazard ratio for disease progression or death, 0.67; 95% CI, 0.52 to 0.88) (Fig. S5B).</div></section><section id="sec-2-4"><h3>Occurrence and Duration of Response</h3><div role="paragraph">Among patients with <i>EGFR</i> and <i>ALK</i> wild-type tumors who had high PD-L1 expression, the percentage of patients who had an investigator-assessed confirmed response was 38.3% in the atezolizumab group and 28.6% in the chemotherapy group (Table S4). At data cutoff, confirmed responses were ongoing in 68.3% of the patients in the atezolizumab group and 35.7% of those in the chemotherapy group. Among patients with <i>EGFR</i> and <i>ALK</i> wild-type tumors who had high or intermediate PD-L1 expression, the percentage of patients who had an investigator-assessed confirmed response was 30.7% in the atezolizumab group and 32.1% in the chemotherapy group, with confirmed responses ongoing in 70.6% of the patients in the atezolizumab group and 34.6% of those in the chemotherapy group. Among patients with <i>EGFR</i> and <i>ALK</i> wild-type tumors who had any PD-L1 expression, the percentage of patients who had an investigator-assessed confirmed response was 29.2% in the atezolizumab group and 31.8% in the chemotherapy group, with confirmed responses ongoing in 70.4% of the patients in the atezolizumab group and 33.0% of those in the chemotherapy group.</div></section><section id="sec-2-5"><h3>PD-L1 Immunohistochemical Analyses</h3><div role="paragraph">Of the 554 patients with <i>EGFR</i> and <i>ALK</i> wild-type tumors who had any PD-L1 expression, 534 could be evaluated by the 22C3 assay and 546 by the SP263 assay. Key baseline characteristics for each biomarker subgroup were consistent with those for the patients with <i>EGFR</i> and <i>ALK</i> wild-type tumors who had any PD-L1 expression (Table S5). The prevalence of PD-L1 expression as determined by the 22C3 and SP263 assays was similar (Fig. S6). High overlap was observed between the subgroup with a tumor proportion score of at least 50% on the 22C3 assay and the subgroup with PD-L1 expression on at least 50% of tumor cells on the SP263 assay (<a href="#f2">Figure 2A</a>). In addition, approximately 30% of the patients with <i>EGFR</i> and <i>ALK</i> wild-type tumors who had high PD-L1 expression as assessed by the SP142 assay were encompassed within the subgroup with a tumor proportion score of at least 50% on the 22C3 or the subgroup with PD-L1 expression on at least 50% of tumor cells on the SP263 assay (<a href="#f2">Figure 2A</a>).</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Figure 2</div><nav><a href="#f2" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa1917346_f2.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="f2" class="graphic"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#f2" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa1917346_f2.jpg"><img src="/cms/10.1056/NEJMoa1917346/asset/6823ac0b-3cf5-4753-8876-bd50406faefb/assets/images/large/nejmoa1917346_f2.jpg" height="3058" width="2640" aria-labelledby="f2" loading="lazy"></a><figcaption><div class="caption">Overall Survival among Patients with High PD-L1 Expression, According to Immunohistochemical Assay.</div><div class="notes"><div role="doc-footnote">Panel A shows the overlap among patients with a tumor proportion score of at least 50% as assessed by the 22C3 assay, patients with PD-L1 expression on at least 50% of tumor cells as assessed by the SP263 assay, and patients with PD-L1 expression on at least 50% of tumor cells or at least 10% of tumor-infiltrating immune cells as assessed by the SP142 assay. Each percentage in the Venn diagrams reflects the percentage of that specific subgroup out of the total population of patients who could be evaluated for biomarker levels: 534 patients for the 22C3 and SP142 overlap, 546 for the SP263 and SP142 overlap, and 530 for the 22C3 and SP263 overlap. Panel B shows Kaplan–Meier estimates of overall survival among patients with a tumor proportion score of at least 50% on the 22C3 assay, and Panel C shows Kaplan–Meier estimates of overall survival among patients with PD-L1 expression on at least 50% of tumor cells on the SP263 assay. Medians were estimated with the use of the Kaplan–Meier method. Unstratified hazard ratios are shown for 22C3 and SP263 subgroup analyses. Tick marks indicate censored data.</div></div></figcaption></figure></div><div role="paragraph">Among patients with high PD-L1 expression as assessed by the SP142 assay, the median overall survival was 20.2 months in the atezolizumab group and 13.1 months in the chemotherapy group (stratified hazard ratio for death, 0.59; 95% CI, 0.40 to 0.89) (<a href="#f1">Figure 1A</a>). Patients with a tumor proportion score of at least 50% on the 22C3 assay had an overall survival of 20.2 months in the atezolizumab group and 11.0 months in the chemotherapy group (unstratified hazard ratio for death, 0.60; 95% CI, 0.42 to 0.86) (<a href="#f2">Figure 2B</a>), and patients with PD-L1 expression on at least 50% of tumor cells on the SP263 assay had values of 19.5 months and 16.1 months, respectively (unstratified hazard ratio for death, 0.71; 95% CI, 0.50 to 1.00) (<a href="#f2">Figure 2C</a>).</div><div role="paragraph">In the population of patients who could be evaluated for biomarker levels, those who were PD-L1–positive as assessed by the SP142 assay had a median overall survival of 17.5 months in the atezolizumab group and 14.1 months in the chemotherapy group (stratified hazard ratio for death, 0.83; 95% CI, 0.65 to 1.07). Patients who had a tumor proportion score of at least 1% on the 22C3 assay had an overall survival of 17.8 months in the atezolizumab group and 14.0 months in the chemotherapy group (unstratified hazard ratio for death, 0.73; 95% CI, 0.55 to 0.97), and patients who had PD-L1 expression on at least 1% of tumor cells on the SP263 assay had values of 17.8 months and 14.0 months, respectively (unstratified hazard ratio for death, 0.77; 95% CI, 0.58 to 1.02) (Fig. S7). Among patients who had intermediate or low PD-L1 expression as assessed by the SP142 assay, the median overall survival was 12.9 months in the atezolizumab group and 14.9 months in the chemotherapy group (unstratified hazard ratio for death, 1.04; 95% CI, 0.76 to 1.44). Patients with a tumor proportion score of 1 to 49% on the 22C3 assay had an overall survival of 16.5 months in the atezolizumab group and 15.7 months in the chemotherapy group (unstratified hazard ratio for death, 1.00; 95% CI, 0.63 to 1.58), and patients with PD-L1 expression on 1 to 49% of tumor cells on the SP263 assay had values of 13.3 months and 10.6 months, respectively (unstratified hazard ratio for death, 0.94; 95% CI, 0.58 to 1.53) (Fig. S8). Progression-free survival with atezolizumab as compared with chemotherapy across subgroups of patients who could be evaluated for PD-L1 biomarker levels is shown in Figure S9.</div></section><section id="sec-2-6"><h3>Analyses of Blood-Based Tumor Mutational Burden</h3><div role="paragraph">Of the 554 patients with <i>EGFR</i> and <i>ALK</i> wild-type tumors who had any PD-L1 expression, 389 could be evaluated for blood-based tumor mutational burden. Baseline characteristics were consistent between the patients with <i>EGFR</i> and <i>ALK</i> wild-type tumors who had any PD-L1 expression and those who could be evaluated for blood-based tumor mutational burden (Table S6). A total of 22.4% of the patients with <i>EGFR</i> and <i>ALK</i> wild-type tumors who could be evaluated for mutational burden had a blood-based tumor mutational burden score of at least 16, and this burden level appeared to identify a distinct population as compared with the population identified as having high PD-L1 expression on the SP142 or 22C3 immunohistochemical assay (<a href="#f3">Figure 3A</a>). The median overall survival among patients with a blood-based tumor mutational burden score of at least 16 was 13.9 months in the atezolizumab group and 8.5 months in the chemotherapy group (unstratified hazard ratio for death, 0.75; 95% CI, 0.41 to 1.35) (Fig. S10). The median progression-free survival among patients with a blood-based tumor mutational burden score of at least 16 was 6.8 months in the atezolizumab group and 4.4 months in the chemotherapy group (unstratified hazard ratio for disease progression or death, 0.55; 95% CI, 0.33 to 0.92) (<a href="#f3">Figure 3B</a>).</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Figure 3</div><nav><a href="#f3" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa1917346_f3.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="f3" class="graphic"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#f3" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa1917346_f3.jpg"><img src="/cms/10.1056/NEJMoa1917346/asset/7c71a9e8-7620-4602-a156-107a1e7e432f/assets/images/large/nejmoa1917346_f3.jpg" height="1783" width="2640" aria-labelledby="f3" loading="lazy"></a><figcaption><div class="caption">Progression-free Survival in Subgroups Defined According to Blood-Based Tumor Mutational Burden (TMB).</div><div class="notes"><div role="doc-footnote">Panel A shows the overlap between patients with a blood-based TMB of at least 16 (16 mutations per 1.1 megabase, equivalent to approximately 14.5 mutations per megabase) and patients with high PD-L1 expression. Each percentage in the Venn diagrams reflects the percentage of that specific subgroup out of the total population of patients who could be evaluated for biomarker levels: 375 patients for the 22C3 assay and blood-based TMB overlap and 389 for the SP142 assay and blood-based TMB overlap. Panel B shows progression-free survival in subgroups defined according to blood-based TMB. Any PD-L1 expression was defined as PD-L1 expression on at least 1% of tumor cells or tumor-infiltrating immune cells as assessed by the SP142 assay. A total of 165 patients could not be evaluated for blood-based TMB: 88 patients had a blood-based TMB result with a maximum somatic allele frequency of less than 1%, 39 patients had a sample that failed quality control at the testing vendor or had a median exon coverage of less than 800, and 38 patients had not provided a baseline plasma sample. A stratified hazard ratio is shown for any PD-L1 expression, and unstratified hazard ratios are shown for the other subgroups.</div></div></figcaption></figure></div></section><section id="sec-2-7"><h3>Safety</h3><div role="paragraph">Safety analysis was performed in all the patients who received a trial agent, including patients who received any amount of atezolizumab (286 patients) and those who received chemotherapy only (263 patients). The median treatment duration for atezolizumab was 5.3 months. In the chemotherapy group, the median treatment duration was 2.1 months for cisplatin, 2.3 months for carboplatin, 2.6 months for gemcitabine, and 3.5 months for pemetrexed.</div><div role="paragraph">Adverse events occurred in 90.2% of the patients receiving atezolizumab and in 94.7% of those receiving chemotherapy (<a href="#t2">Table 2</a> and Tables S7 and S8). Adverse events with a 5-percentage-point difference in incidence between the treatment groups are described in Figure S11. Grade 3 or 4 adverse events occurred in 30.1% of the patients in the atezolizumab group and in 52.5% of those in the chemotherapy group (<a href="#t2">Table 2</a>), with the most common (≥5% in either group) being anemia, neutropenia, and thrombocytopenia (all with chemotherapy). Serious adverse events occurred in 28.3% of the patients in the atezolizumab group and in 28.5% of those in the chemotherapy group (Table S7). A total of 11 patients (3.8%) in the atezolizumab group and 11 patients (4.2%) in the chemotherapy group had a grade 5 adverse event (<a href="#t2">Table 2</a> and Table S7).</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Table 2</div><nav><a href="#t2" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa1917346_t2.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="t2" class="table"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#t2" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa1917346_t2.jpg"><img src="/cms/10.1056/NEJMoa1917346/asset/56688587-20ee-44ca-81f3-d16e31da301d/assets/images/large/nejmoa1917346_t2.jpg" height="1480" width="1711" loading="lazy"></a></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Adverse Event</th><th class="txxx-borders" colspan="3"><span>Atezolizumab<br>(N=286)</span></th><th class="txxr-borders" colspan="3"><span>Chemotherapy<br>(N=263)</span></th></tr><tr class="head2" data-type="row head2"><td class="xxlx-borders">&nbsp;</td><th class="xxxx-borders">All Grades</th><th class="xxxx-borders">Grade 3 or 4</th><th class="xxxx-borders">Grade 5</th><th class="xxxx-borders">All Grades</th><th class="xxxx-borders">Grade 3 or 4</th><th class="xxxr-borders">Grade 5</th></tr><tr class="head3" data-type="row head3"><td class="xxlx-borders">&nbsp;</td><th class="xxxr-borders" colspan="6"><span>number (percent)</span></th></tr></thead><tbody><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Any adverse event</td><td class="xxxx-borders shading">258 (90.2)</td><td class="xxxx-borders shading">86 (30.1)</td><td class="xxxx-borders shading">11 (3.8)</td><td class="xxxx-borders shading">249 (94.7)</td><td class="xxxx-borders shading">138 (52.5)</td><td class="xxxr-borders shading">11 (4.2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Anemia</td><td class="xxxx-borders">44 (15.4)</td><td class="xxxx-borders">5 (1.7)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">125 (47.5)</td><td class="xxxx-borders">48 (18.3)</td><td class="xxxr-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Decreased appetite</td><td class="xxxx-borders shading">44 (15.4)</td><td class="xxxx-borders shading">2 (0.7)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">50 (19.0)</td><td class="xxxx-borders shading">0</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Nausea</td><td class="xxxx-borders">39 (13.6)</td><td class="xxxx-borders">1 (0.3)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">89 (33.8)</td><td class="xxxx-borders">5 (1.9)</td><td class="xxxr-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Asthenia</td><td class="xxxx-borders shading">37 (12.9)</td><td class="xxxx-borders shading">2 (0.7)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">46 (17.5)</td><td class="xxxx-borders shading">5 (1.9)</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Fatigue</td><td class="xxxx-borders">37 (12.9)</td><td class="xxxx-borders">2 (0.7)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">46 (17.5)</td><td class="xxxx-borders">6 (2.3)</td><td class="xxxr-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Constipation</td><td class="xxxx-borders shading">35 (12.2)</td><td class="xxxx-borders shading">3 (1.0)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">57 (21.7)</td><td class="xxxx-borders shading">2 (0.8)</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Hyponatremia</td><td class="xxxx-borders">17 (5.9)</td><td class="xxxx-borders">6 (2.1)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">12 (4.6)</td><td class="xxxx-borders">6 (2.3)</td><td class="xxxr-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Pneumonia</td><td class="xxxx-borders shading">14 (4.9)</td><td class="xxxx-borders shading">7 (2.4)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">17 (6.5)</td><td class="xxxx-borders shading">9 (3.4)</td><td class="xxxr-borders shading">1 (0.4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Hyperkalemia</td><td class="xxxx-borders">12 (4.2)</td><td class="xxxx-borders">6 (2.1)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">8 (3.0)</td><td class="xxxx-borders">3 (1.1)</td><td class="xxxr-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Thrombocytopenia</td><td class="xxxx-borders shading">7 (2.4)</td><td class="xxxx-borders shading">1 (0.3)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">44 (16.7)</td><td class="xxxx-borders shading">19 (7.2)</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Neutropenia</td><td class="xxxx-borders">4 (1.4)</td><td class="xxxx-borders">2 (0.7)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">74 (28.1)</td><td class="xxxx-borders">46 (17.5)</td><td class="xxxr-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Death</td><td class="xxxx-borders shading">2 (0.7)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">2 (0.7)</td><td class="xxxx-borders shading">3 (1.1)</td><td class="xxxx-borders shading">0</td><td class="xxxr-borders shading">3 (1.1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Decreased platelet count</td><td class="xxxx-borders">1 (0.3)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxx-borders">22 (8.4)</td><td class="xxxx-borders">11 (4.2)</td><td class="xxxr-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Decreased neutrophil count</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">19 (7.2)</td><td class="xxxx-borders shading">10 (3.8)</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging01" data-xml-align="left">Febrile neutropenia</td><td class="xbxx-borders">0</td><td class="xbxx-borders">0</td><td class="xbxx-borders">0</td><td class="xbxx-borders">9 (3.4)</td><td class="xbxx-borders">9 (3.4)</td><td class="xbxr-borders">0</td></tr></tbody></table></div><figcaption><div class="caption">Reported Adverse Events (Safety Population).<a href="#t2fn1" role="doc-noteref">*</a></div><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="t2fn1" role="paragraph">The safety population comprised all the patients who received atezolizumab or chemotherapy, regardless of PD-L1 expression or <i>EGFR</i> and <i>ALK</i> alterations. Shown are adverse events with an incidence of at least 15% in any group, events of grade 3 or 4 severity with an incidence of at least 2% in any group, and events of grade 5 severity with an incidence of at least 1% in any group.</div></div></div></figcaption></figure></div><div role="paragraph">Immune-mediated adverse events, which were defined according to a list of sponsor-specified terms, regardless of whether these events led to use of systemic glucocorticoids, endocrine therapy, or other immunosuppressants, occurred in 40.2% of the patients in the atezolizumab group and in 16.7% of those in the chemotherapy group; grade 3 or 4 immune-mediated adverse events occurred in 6.6% and 1.5% of the patients in the respective groups (Table S9). No grade 5 immune-mediated adverse events were noted. Hepatic laboratory abnormalities, rash, and hypothyroidism were the most commonly reported immune-mediated adverse events (≥5% in either group) (Table S9). Immune-mediated adverse events that resulted in systemic glucocorticoid treatment are reported in Table S10.</div></section></section><section id="sec-3" data-type="discussion"><h2>Discussion</h2><div role="paragraph">We conducted a phase 3 trial of atezolizumab monotherapy as a first-line treatment in patients with nonsquamous or squamous metastatic NSCLC who had not previously received chemotherapy. The median overall survival was significantly longer — by 7.1 months — with atezolizumab than with chemotherapy among patients with <i>EGFR</i> and <i>ALK</i> wild-type tumors who had high PD-L1 expression. The observed safety profile was consistent with that observed in previous studies of atezolizumab monotherapy across indications, histologic type, and lines of therapy.</div><div role="paragraph">The testing boundary for overall survival was not crossed among patients with <i>EGFR</i> and <i>ALK</i> wild-type tumors who had high or intermediate PD-L1 expression; therefore, patients with <i>EGFR</i> and <i>ALK</i> wild-type tumors who had any PD-L1 expression could not be formally tested. The trial is ongoing to provide data on the final analysis of overall survival. Among patients with <i>EGFR</i> and <i>ALK</i> wild-type tumors who received atezolizumab, observed results for overall survival according to level of PD-L1 expression were similar to those seen in the phase 3 KEYNOTE-042 trial comparing pembrolizumab with chemotherapy; in both trials, the patients with high PD-L1 expression had the most benefit.<sup><a href="#core-r8" role="doc-biblioref" data-xml-rid="r8" id="body-ref-r8-2" href-manipulated="true" aria-label="Reference 8">8</a></sup></div><div role="paragraph">Our trial evaluated as exploratory end points how different PD-L1 scoring methods perform to predict the activity of atezolizumab as compared with chemotherapy. The analytic performance and concordance of the different assays were evaluated previously<sup><a href="#core-r13" role="doc-biblioref" data-xml-rid="r13 r25" id="body-ref-r25" href-manipulated="true">13,25</a></sup>; these analyses have shown that the 22C3 and SP263 PD-L1 assays were highly concordant, whereas the SP142 assay was less sensitive for staining of both tumor cells and tumor-infiltrating immune cells. In the clinical setting, the 22C3 and SP263 assays evaluate PD-L1 expression on tumor cells only, whereas the SP142 assay evaluates expression on both tumor cells and tumor-infiltrating immune cells.<sup><a href="#core-r13" role="doc-biblioref" data-xml-rid="r13 r14 r15 r20" id="body-ref-r20-3" href-manipulated="true">13–15,20</a></sup> Our trial selected patients who had any level of PD-L1 expression as assessed by the SP142 assay. Hence, the assessment of additional biomarkers provided results from a double-selected patient population, which is a limitation of the analysis. A benefit favoring atezolizumab was observed in patients with high PD-L1 expression across all three assays, despite different analytic sensitivities and scoring algorithms.</div><div role="paragraph">The role of tumor mutational burden (in blood and tissue) as a predictive biomarker of response to cancer immunotherapy in patients with metastatic NSCLC remains uncertain. Although the predictive value of tumor mutational burden in patients receiving the cancer immunotherapy–chemotherapy combination appears to be limited,<sup><a href="#core-r26" role="doc-biblioref" data-xml-rid="r26" id="body-ref-r26" href-manipulated="true" aria-label="Reference 26">26</a></sup> recent data suggest its predictive value in the context of immunotherapy without chemotherapy. Various cutoffs (≥20 and ≥10 mutations per megabase and ≥175 mutations per exome) have been used retrospectively across cancer immunotherapy studies and have been shown to be predictive of overall survival, progression-free survival, or both in this context.<sup><a href="#core-r17" role="doc-biblioref" data-xml-rid="r17 r19 r27 r28 r29" id="body-ref-r29" href-manipulated="true">17,19,27–29</a></sup> It is difficult to compare results across trials owing to differences in the assays and cutoffs used. The prospective, phase 2 B-F1RST trial examined blood-based tumor mutational burden as a potential biomarker in patients with metastatic NSCLC receiving atezolizumab monotherapy as a first-line treatment. The median progression-free survival was 5.0 months among patients with a blood-based tumor mutational burden score of at least 16 and 3.5 months among those with a blood-based tumor mutational burden score of less than 16 (unstratified hazard ratio for disease progression or death, 0.80; 90% CI, 0.54 to 1.18), and the median overall survival was 23.9 months and 13.4 months, respectively (unstratified hazard ratio for death, 0.66; 90% CI, 0.40 to 1.10).<sup><a href="#core-r24" role="doc-biblioref" data-xml-rid="r24" id="body-ref-r24-2" href-manipulated="true" aria-label="Reference 24">24</a></sup> In our trial, outcomes also favored atezolizumab, with an apparent plateau of clinical benefit in the subgroup with a blood-based tumor mutational burden score of at least 16; the greatest magnitude of benefit was seen for progression-free survival, a finding consistent with those of previous trials.<sup><a href="#core-r18" role="doc-biblioref" data-xml-rid="r18" id="body-ref-r18-4" href-manipulated="true" aria-label="Reference 18">18</a></sup> The ongoing randomized, phase 3 Blood-First Assay Screening Trial (BFAST; ClinicalTrials.gov number, <a href="http://clinicaltrials.gov/show/NCT03178552" target="_blank">NCT03178552</a>) is prospectively evaluating first-line treatment with atezolizumab monotherapy as compared with platinum-based chemotherapy in patients with advanced or metastatic NSCLC who have a positive blood-based tumor mutational burden score.</div><div role="paragraph">We found that atezolizumab monotherapy resulted in longer overall survival than platinum-based combination chemotherapy among patients with previously untreated metastatic NSCLC with high expression of PD-L1. Toxic effects were consistent with those that have been reported previously.</div></section>



        
        
</div></section><section id="backmatter" data-extent="backmatter" data-location="articleTab_article"><div class="core-container"><section id="backnotes" data-location="notes_article"><h2>Notes</h2><div data-type="data-sharing" role="paragraph">A <a href="#ap4">data sharing statement</a> provided by the authors is available with the full text of this article at NEJM.org.</div><div role="paragraph">Supported by <span class="named-content" data-type="funder">F. Hoffmann–La Roche/Genentech</span>, a member of the Roche Group.</div><div role="paragraph"><a href="#ap3">Disclosure forms</a> provided by the authors are available with the full text of this article at NEJM.org.</div><div role="paragraph">We thank See Phan of Genentech for clinical expertise and guidance, Eugene Kim of Genentech and Kosei Tajima of Chugai Pharmaceutical for biostatistical analysis, Maureen Peterson of Genentech for biomarker operations, Hina Patel and Monette Villalobos of Genentech for guidance and support for the trial, and Kia C.E. Walcott of Health Interactions for medical writing assistance with an earlier version of the manuscript.</div></section><section id="supplementary-materials" class="core-supplementary-materials"><h2>Supplementary Material</h2><div role="list"><div id="ap1" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Protocol</span> <span class="core-filename">(nejmoa1917346_protocol.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa1917346/suppl_file/nejmoa1917346_protocol.pdf" download="nejmoa1917346_protocol.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa1917346_protocol.pdf" data-doi="10.1056/NEJMoa1917346">Download</a></li><li>10.74 MB</li></ul></div></div><div id="ap2" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Supplementary Appendix</span> <span class="core-filename">(nejmoa1917346_appendix.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa1917346/suppl_file/nejmoa1917346_appendix.pdf" download="nejmoa1917346_appendix.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa1917346_appendix.pdf" data-doi="10.1056/NEJMoa1917346">Download</a></li><li>1.78 MB</li></ul></div></div><div id="ap3" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Disclosure Forms</span> <span class="core-filename">(nejmoa1917346_disclosures.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa1917346/suppl_file/nejmoa1917346_disclosures.pdf" download="nejmoa1917346_disclosures.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa1917346_disclosures.pdf" data-doi="10.1056/NEJMoa1917346">Download</a></li><li>1.05 MB</li></ul></div></div><div id="ap4" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Data Sharing Statement</span> <span class="core-filename">(nejmoa1917346_data-sharing.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa1917346/suppl_file/nejmoa1917346_data-sharing.pdf" download="nejmoa1917346_data-sharing.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa1917346_data-sharing.pdf" data-doi="10.1056/NEJMoa1917346">Download</a></li><li>70.07 KB</li></ul></div></div></div></section><section id="bibliography" class="core-reference-list" role="doc-bibliography" data-location="references_article"><h2>References</h2><div role="list" data-method="clamp" id="collapsible-text"><div role="listitem" data-has="label"><div class="label">1.</div><div id="r1" class="citations"><div class="citation"><div class="citation-content">Socinski MA, Jotte RM, Cappuzzo F, et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. <em>N Engl J Med</em> 2018;378:2288-2301.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r7-1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_2_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa1917346&amp;key=10.1056%2FNEJMoa1716948&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29863955/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000435099900006" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Atezolizumab+for+first-line+treatment+of+metastatic+nonsquamous+NSCLC.&amp;publication_year=2018&amp;journal=N+Engl+J+Med&amp;pages=2288-2301&amp;doi=10.1056%2FNEJMoa1716948&amp;pmid=29863955" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">2.</div><div id="r2" class="citations"><div class="citation"><div class="citation-content">Reck M, Mok TSK, Nishio M, et al. Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial. <em>Lancet Respir Med</em> 2019;7:387-401.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r7-1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S2213-2600(19)30084-0" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30922878/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000466494600015" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Atezolizumab+plus+bevacizumab+and+chemotherapy+in+non-small-cell+lung+cancer+%28IMpower150%29%3A+key+subgroup+analyses+of+patients+with+EGFR+mutations+or+baseline+liver+metastases+in+a+randomised%2C+open-label+phase+3+trial.&amp;publication_year=2019&amp;journal=Lancet+Respir+Med&amp;pages=387-401&amp;doi=10.1016%2FS2213-2600%2819%2930084-0&amp;pmid=30922878" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">3.</div><div id="r3" class="citations"><div class="citation"><div class="citation-content">Gandhi L, Rodríguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer. <em>N Engl J Med</em> 2018;378:2078-2092.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r7-1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_4_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa1917346&amp;key=10.1056%2FNEJMoa1801005&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29658856/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000433428000006" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Pembrolizumab+plus+chemotherapy+in+metastatic+non%E2%80%93small-cell+lung+cancer.&amp;publication_year=2018&amp;journal=N+Engl+J+Med&amp;pages=2078-2092&amp;doi=10.1056%2FNEJMoa1801005&amp;pmid=29658856" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">4.</div><div id="r4" class="citations"><div class="citation"><div class="citation-content">Paz-Ares L, Luft A, Vicente D, et al. Pembrolizumab plus chemotherapy for squamous non–small-cell lung cancer. <em>N Engl J Med</em> 2018;379:2040-2051.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r7-1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_5_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa1917346&amp;key=10.1056%2FNEJMoa1810865&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30280635/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000450816900009" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Pembrolizumab+plus+chemotherapy+for+squamous+non%E2%80%93small-cell+lung+cancer.&amp;publication_year=2018&amp;journal=N+Engl+J+Med&amp;pages=2040-2051&amp;doi=10.1056%2FNEJMoa1810865&amp;pmid=30280635" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">5.</div><div id="r5" class="citations"><div class="citation"><div class="citation-content">West H, McCleod M, Hussein M, et al. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. <em>Lancet Oncol</em> 2019;20:924-937.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r7-1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S1470-2045(19)30167-6" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31122901/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000473253800037" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Atezolizumab+in+combination+with+carboplatin+plus+nab-paclitaxel+chemotherapy+compared+with+chemotherapy+alone+as+first-line+treatment+for+metastatic+non-squamous+non-small-cell+lung+cancer+%28IMpower130%29%3A+a+multicentre%2C+randomised%2C+open-label%2C+phase+3+trial.&amp;publication_year=2019&amp;journal=Lancet+Oncol&amp;pages=924-937&amp;doi=10.1016%2FS1470-2045%2819%2930167-6&amp;pmid=31122901" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">6.</div><div id="r6" class="citations"><div class="citation"><div class="citation-content">Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1–positive non–small-cell lung cancer. <em>N Engl J Med</em> 2016;375:1823-1833.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r6" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_7_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa1917346&amp;key=10.1056%2FNEJMoa1606774&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27718847/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000387534200006" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Pembrolizumab+versus+chemotherapy+for+PD-L1%E2%80%93positive+non%E2%80%93small-cell+lung+cancer.&amp;publication_year=2016&amp;journal=N+Engl+J+Med&amp;pages=1823-1833&amp;doi=10.1056%2FNEJMoa1606774&amp;pmid=27718847" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r6" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r7-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] ALK). </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r7-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] in the United States and European Union. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">7.</div><div id="r7" class="citations"><div class="citation"><div class="citation-content">Reck M, Rodríguez-Abreu D, Robinson AG, et al. Updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater. <em>J Clin Oncol</em> 2019;37:537-546.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r7" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1200/JCO.18.00149" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30620668/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000460356200002" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Updated+analysis+of+KEYNOTE-024%3A+pembrolizumab+versus+platinum-based+chemotherapy+for+advanced+non-small-cell+lung+cancer+with+PD-L1+tumor+proportion+score+of+50%25+or+greater.&amp;publication_year=2019&amp;journal=J+Clin+Oncol&amp;pages=537-546&amp;doi=10.1200%2FJCO.18.00149&amp;pmid=30620668" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r7" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r7-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] ALK). </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r7-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] in the United States and European Union. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">8.</div><div id="r8" class="citations"><div class="citation"><div class="citation-content">Mok TSK, Wu Y-L, Kudaba I, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. <em>Lancet</em> 2019;393:1819-1830.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r8" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S0140-6736(18)32409-7" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30955977/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000466858700032" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Pembrolizumab+versus+chemotherapy+for+previously+untreated%2C+PD-L1-expressing%2C+locally+advanced+or+metastatic+non-small-cell+lung+cancer+%28KEYNOTE-042%29%3A+a+randomised%2C+open-label%2C+controlled%2C+phase+3+trial.&amp;publication_year=2019&amp;journal=Lancet&amp;pages=1819-1830&amp;doi=10.1016%2FS0140-6736%2818%2932409-7&amp;pmid=30955977" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r8" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r8-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] subgroup with the highest PD-L1 expression. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r8-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] high PD-L1 expression had the most benefit. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">9.</div><div id="r9" class="citations"><div class="citation"><div class="citation-content">Herbst RS, Soria J-C, Kowanetz M, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. <em>Nature</em> 2014;515:563-567.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r9"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/nature14011" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25428504/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000346247600053" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Predictive+correlates+of+response+to+the+anti-PD-L1+antibody+MPDL3280A+in+cancer+patients.&amp;publication_year=2014&amp;journal=Nature&amp;pages=563-567&amp;doi=10.1038%2Fnature14011&amp;pmid=25428504" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">10.</div><div id="r10" class="citations"><div class="citation"><div class="citation-content">Peters S, Gettinger S, Johnson ML, et al. Phase II trial of atezolizumab as first-line or subsequent therapy for patients with programmed death-ligand 1-selected advanced non-small-cell lung cancer (BIRCH). <em>J Clin Oncol</em> 2017;35:2781-2789.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r12"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1200/JCO.2016.71.9476" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28609226/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000407824700011" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Phase+II+trial+of+atezolizumab+as+first-line+or+subsequent+therapy+for+patients+with+programmed+death-ligand+1-selected+advanced+non-small-cell+lung+cancer+%28BIRCH%29.&amp;publication_year=2017&amp;journal=J+Clin+Oncol&amp;pages=2781-2789&amp;doi=10.1200%2FJCO.2016.71.9476&amp;pmid=28609226" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">11.</div><div id="r11" class="citations"><div class="citation"><div class="citation-content">Fehrenbacher L, Spira A, Ballinger M, et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. <em>Lancet</em> 2016;387:1837-1846.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r12"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S0140-6736(16)00587-0" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26970723/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000375056100032" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Atezolizumab+versus+docetaxel+for+patients+with+previously+treated+non-small-cell+lung+cancer+%28POPLAR%29%3A+a+multicentre%2C+open-label%2C+phase+2+randomised+controlled+trial.&amp;publication_year=2016&amp;journal=Lancet&amp;pages=1837-1846&amp;doi=10.1016%2FS0140-6736%2816%2900587-0&amp;pmid=26970723" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">12.</div><div id="r12" class="citations"><div class="citation"><div class="citation-content">Rittmeyer A, Barlesi F, Waterkamp D, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. <em>Lancet</em> 2017;389:255-265.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r12"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S0140-6736(16)32517-X" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27979383/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000392801200027" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Atezolizumab+versus+docetaxel+in+patients+with+previously+treated+non-small-cell+lung+cancer+%28OAK%29%3A+a+phase+3%2C+open-label%2C+multicentre+randomised+controlled+trial.&amp;publication_year=2017&amp;journal=Lancet&amp;pages=255-265&amp;doi=10.1016%2FS0140-6736%2816%2932517-X&amp;pmid=27979383" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">13.</div><div id="r13" class="citations"><div class="citation"><div class="citation-content">Hirsch FR, McElhinny A, Stanforth D, et al. PD-L1 immunohistochemistry assays for lung cancer: results from phase 1 of the Blueprint PD-L1 IHC assay comparison project. <em>J Thorac Oncol</em> 2017;12:208-222.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r13" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.jtho.2016.11.2228" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27913228/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000393266000006" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=PD-L1+immunohistochemistry+assays+for+lung+cancer%3A+results+from+phase+1+of+the+Blueprint+PD-L1+IHC+assay+comparison+project.&amp;publication_year=2017&amp;journal=J+Thorac+Oncol&amp;pages=208-222&amp;doi=10.1016%2Fj.jtho.2016.11.2228&amp;pmid=27913228" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r13" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r13-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] immune-checkpoint inhibitor treatment. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r20-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] measure PD-L1 expression on tumor cells. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r25" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] different assays were evaluated previously </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r20-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>d [...] cells and tumor-infiltrating immune cells. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">14.</div><div id="r14" class="citations"><div class="citation"><div class="citation-content">Roach C, Zhang N, Corigliano E, et al. Development of a companion diagnostic PD-L1 immunohistochemistry assay for pembrolizumab therapy in non-small-cell lung cancer. <em>Appl Immunohistochem Mol Morphol</em> 2016;24:392-397.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r14" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1097/PAI.0000000000000408" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27333219/" target="_blank">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Development+of+a+companion+diagnostic+PD-L1+immunohistochemistry+assay+for+pembrolizumab+therapy+in+non-small-cell+lung+cancer.&amp;publication_year=2016&amp;journal=Appl+Immunohistochem+Mol+Morphol&amp;pages=392-397&amp;doi=10.1097%2FPAI.0000000000000408&amp;pmid=27333219" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r14" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r15-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] assays (22C3 and SP263), </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r20-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] measure PD-L1 expression on tumor cells. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r20-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] cells and tumor-infiltrating immune cells. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">15.</div><div id="r15" class="citations"><div class="citation"><div class="citation-content">Rebelatto MC, Midha A, Mistry A, et al. Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma. <em>Diagn Pathol</em> 2016;11:95-95.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r15" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1186/s13000-016-0545-8" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27717372/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000385452700001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Development+of+a+programmed+cell+death+ligand-1+immunohistochemical+assay+validated+for+analysis+of+non-small+cell+lung+cancer+and+head+and+neck+squamous+cell+carcinoma.&amp;publication_year=2016&amp;journal=Diagn+Pathol&amp;pages=95-95&amp;doi=10.1186%2Fs13000-016-0545-8&amp;pmid=27717372" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r15" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r15-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] assays (22C3 and SP263), </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r20-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] measure PD-L1 expression on tumor cells. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r20-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] cells and tumor-infiltrating immune cells. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">16.</div><div id="r16" class="citations"><div class="citation"><div class="citation-content">Greillier L, Tomasini P, Barlesi F. The clinical utility of tumor mutational burden in non-small cell lung cancer. <em>Transl Lung Cancer Res</em> 2018;7:639-646.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r19-1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.21037/tlcr.2018.10.08" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30505708/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000450328200004" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=The+clinical+utility+of+tumor+mutational+burden+in+non-small+cell+lung+cancer.&amp;publication_year=2018&amp;journal=Transl+Lung+Cancer+Res&amp;pages=639-646&amp;doi=10.21037%2Ftlcr.2018.10.08&amp;pmid=30505708" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">17.</div><div id="r17" class="citations"><div class="citation"><div class="citation-content">Hellmann MD, Ciuleanu T-E, Pluzanski A, et al. Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden. <em>N Engl J Med</em> 2018;378:2093-2104.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r17" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_18_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa1917346&amp;key=10.1056%2FNEJMoa1801946&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29658845/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000433428000007" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Nivolumab+plus+ipilimumab+in+lung+cancer+with+a+high+tumor+mutational+burden.&amp;publication_year=2018&amp;journal=N+Engl+J+Med&amp;pages=2093-2104&amp;doi=10.1056%2FNEJMoa1801946&amp;pmid=29658845" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r17" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r19-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] who may benefit from immunotherapy. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r29" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] survival, or both in this context. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">18.</div><div id="r18" class="citations"><div class="citation"><div class="citation-content">Gandara DR, Paul SM, Kowanetz M, et al. Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab. <em>Nat Med</em> 2018;24:1441-1448.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r18" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/s41591-018-0134-3" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30082870/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000444174100029" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Blood-based+tumor+mutational+burden+as+a+predictor+of+clinical+benefit+in+non-small-cell+lung+cancer+patients+treated+with+atezolizumab.&amp;publication_year=2018&amp;journal=Nat+Med&amp;pages=1441-1448&amp;doi=10.1038%2Fs41591-018-0134-3&amp;pmid=30082870" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r18" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r19-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] who may benefit from immunotherapy. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r18-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] somatic mutations to generate a score. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r24-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] approximately 14.5 mutations per megabase. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r18-4" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>d [...] consistent with those of previous trials. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">19.</div><div id="r19" class="citations"><div class="citation"><div class="citation-content">Rizvi NA, Cho BC, Reinmuth N, et al. Blood tumor mutational burden (bTMB) and tumor PD-L1 as predictive biomarkers of survival in MYSTIC: first-line durvalumab (D) ± tremelimumab (T) versus chemotherapy (CT) in metastatic (m) NSCLC. <em>J Clin Oncol</em> 2019;37:Suppl 15:9016-9016. abstract.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r19" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1200/JCO.2019.37.15_suppl.9016" target="_blank">Crossref</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000487345806460" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Blood+tumor+mutational+burden+%28bTMB%29+and+tumor+PD-L1+as+predictive+biomarkers+of+survival+in+MYSTIC%3A+first-line+durvalumab+%28D%29+%C2%B1+tremelimumab+%28T%29+versus+chemotherapy+%28CT%29+in+metastatic+%28m%29+NSCLC.&amp;publication_year=2019&amp;journal=J+Clin+Oncol&amp;pages=9016-9016&amp;doi=10.1200%2FJCO.2019.37.15_suppl.9016" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r19" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r19-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] who may benefit from immunotherapy. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r29" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] survival, or both in this context. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">20.</div><div id="r20" class="citations"><div class="citation"><div class="citation-content">Vennapusa B, Baker B, Kowanetz M, et al. Development of a PD-L1 complementary diagnostic immunohistochemistry assay (SP142) for atezolizumab. <em>Appl Immunohistochem Mol Morphol</em> 2019;27:92-100.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r20" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1097/PAI.0000000000000594" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29346180/" target="_blank">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Development+of+a+PD-L1+complementary+diagnostic+immunohistochemistry+assay+%28SP142%29+for+atezolizumab.&amp;publication_year=2019&amp;journal=Appl+Immunohistochem+Mol+Morphol&amp;pages=92-100&amp;doi=10.1097%2FPAI.0000000000000594&amp;pmid=29346180" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r20" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r20-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] determined by the SP142 assay was required. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r20-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] measure PD-L1 expression on tumor cells. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r20-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] cells and tumor-infiltrating immune cells. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">21.</div><div id="r21" class="citations"><div class="citation"><div class="citation-content">Barlesi F, Nishio M, Cobo M, et al. IMpower132: efficacy of atezolizumab (atezo) carboplatin (carbo)/cisplatin (cis) + pemetrexed (pem) as 1L treatment in key subgroups with stage IV non-squamous non-small cell lung cancer (NSCLC). <em>Ann Oncol</em> 2018;29:Suppl 8:LBA54-LBA54. abstract.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r23"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1093/annonc/mdy424.066" target="_blank">Crossref</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000459277305002" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=IMpower132%3A+efficacy+of+atezolizumab+%28atezo%29+carboplatin+%28carbo%29%2Fcisplatin+%28cis%29+%2B+pemetrexed+%28pem%29+as+1L+treatment+in+key+subgroups+with+stage+IV+non-squamous+non-small+cell+lung+cancer+%28NSCLC%29.&amp;publication_year=2018&amp;journal=Ann+Oncol&amp;pages=LBA54-LBA54&amp;doi=10.1093%2Fannonc%2Fmdy424.066" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">22.</div><div id="r22" class="citations"><div class="citation"><div class="citation-content">Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non–small-cell lung cancer. <em>N Engl J Med</em> 2015;373:1627-1639.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r23"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_23_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa1917346&amp;key=10.1056%2FNEJMoa1507643&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26412456/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000363317800008" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Nivolumab+versus+docetaxel+in+advanced+nonsquamous+non%E2%80%93small-cell+lung+cancer.&amp;publication_year=2015&amp;journal=N+Engl+J+Med&amp;pages=1627-1639&amp;doi=10.1056%2FNEJMoa1507643&amp;pmid=26412456" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">23.</div><div id="r23" class="citations"><div class="citation"><div class="citation-content">Herbst RS, Baas P, Kim D-W, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. <em>Lancet</em> 2016;387:1540-1550.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r23"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S0140-6736(15)01281-7" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26712084/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000373741600030" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Pembrolizumab+versus+docetaxel+for+previously+treated%2C+PD-L1-positive%2C+advanced+non-small-cell+lung+cancer+%28KEYNOTE-010%29%3A+a+randomised+controlled+trial.&amp;publication_year=2016&amp;journal=Lancet&amp;pages=1540-1550&amp;doi=10.1016%2FS0140-6736%2815%2901281-7&amp;pmid=26712084" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">24.</div><div id="r24" class="citations"><div class="citation"><div class="citation-content">Socinski M, Velcheti V, Mekhail T, et al. Final efficacy results from B-F1RST, a prospective phase II trial evaluating blood-based tumour mutational burden (bTMB) as a predictive biomarker for atezolizumab (atezo) in 1L non-small cell lung cancer (NSCLC). <em>Ann Oncol</em> 2019;30:Suppl 5:LBA83-LBA83. abstract.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r24" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1093/annonc/mdz394.081" target="_blank">Crossref</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000491295500207" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Final+efficacy+results+from+B-F1RST%2C+a+prospective+phase+II+trial+evaluating+blood-based+tumour+mutational+burden+%28bTMB%29+as+a+predictive+biomarker+for+atezolizumab+%28atezo%29+in+1L+non-small+cell+lung+cancer+%28NSCLC%29.&amp;publication_year=2019&amp;journal=Ann+Oncol&amp;pages=LBA83-LBA83&amp;doi=10.1093%2Fannonc%2Fmdz394.081" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r24" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r24-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] approximately 14.5 mutations per megabase. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r24-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] for death, 0.66; 90% CI, 0.40 to 1.10). </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">25.</div><div id="r25" class="citations"><div class="citation"><div class="citation-content">Tsao MS, Kerr KM, Kockx M, et al. PD-L1 immunohistochemistry comparability study in real-life clinical samples: results of Blueprint phase 2 project. <em>J Thorac Oncol</em> 2018;13:1302-1311.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r25"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.jtho.2018.05.013" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29800747/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000444520200022" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=PD-L1+immunohistochemistry+comparability+study+in+real-life+clinical+samples%3A+results+of+Blueprint+phase+2+project.&amp;publication_year=2018&amp;journal=J+Thorac+Oncol&amp;pages=1302-1311&amp;doi=10.1016%2Fj.jtho.2018.05.013&amp;pmid=29800747" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">26.</div><div id="r26" class="citations"><div class="citation"><div class="citation-content">Garassino M, Rodriguez-Abreu D, Gadgeel S, et al. Evaluation of TMB in KEYNOTE-189: pembrolizumab plus chemotherapy vs placebo plus chemotherapy for nonsquamous NSCLC. <em>J Thorac Oncol</em> 2019;14:Suppl:OA04.6-OA04.6. abstract.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r26"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.jtho.2019.08.427" target="_blank">Crossref</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000492162201112" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Evaluation+of+TMB+in+KEYNOTE-189%3A+pembrolizumab+plus+chemotherapy+vs+placebo+plus+chemotherapy+for+nonsquamous+NSCLC&amp;publication_year=2019&amp;journal=J+Thorac+Oncol&amp;pages=OA04.6-OA04.6&amp;doi=10.1016%2Fj.jtho.2019.08.427" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">27.</div><div id="r27" class="citations"><div class="citation"><div class="citation-content">Peters S, Cho BC, Reinmuth N, et al. Tumor mutational burden (TMB) as a biomarker of survival in metastatic non-small cell lung cancer (mNSCLC): blood and tissue TMB analysis from MYSTIC, a Phase III study of first-line durvalumab ± tremelimumab vs chemotherapy. <em>Cancer Res</em> 2019;79:Suppl 13:CT074-CT074. abstract.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r29"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1158/1538-7445.AM2019-CT074" target="_blank">Crossref</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000488129900065" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Tumor+mutational+burden+%28TMB%29+as+a+biomarker+of+survival+in+metastatic+non-small+cell+lung+cancer+%28mNSCLC%29%3A+blood+and+tissue+TMB+analysis+from+MYSTIC%2C+a+Phase+III+study+of+first-line+durvalumab+%C2%B1+tremelimumab+vs+chemotherapy.&amp;publication_year=2019&amp;journal=Cancer+Res&amp;pages=CT074-CT074&amp;doi=10.1158%2F1538-7445.AM2019-CT074" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">28.</div><div id="r28" class="citations"><div class="citation"><div class="citation-content">Hellmann MD, Paz-Ares L, Bernabe Caro R, et al. Nivolumab plus ipilimumab in advanced non–small-cell lung cancer. <em>N Engl J Med</em> 2019;381:2020-2031.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r29"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_29_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa1917346&amp;key=10.1056%2FNEJMoa1910231&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31562796/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000505218800006" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Nivolumab+plus+ipilimumab+in+advanced+non%E2%80%93small-cell+lung+cancer.&amp;publication_year=2019&amp;journal=N+Engl+J+Med&amp;pages=2020-2031&amp;doi=10.1056%2FNEJMoa1910231&amp;pmid=31562796" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">29.</div><div id="r29" class="citations"><div class="citation"><div class="citation-content">Herbst RS, Lopes G, Kowalski DM, et al. Association between tissue TMB (tTMB) and clinical outcomes with pembrolizumab monotherapy (pembro) in PD-L1-positive advanced NSCLC in the KEYNOTE-010 and -042 trials. <em>Ann Oncol</em> 2019;30:Suppl 5:v916-v917. abstract.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r29"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1093/annonc/mdz394.077" target="_blank">Crossref</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000491295500203" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Association+between+tissue+TMB+%28tTMB%29+and+clinical+outcomes+with+pembrolizumab+monotherapy+%28pembro%29+in+PD-L1-positive+advanced+NSCLC+in+the+KEYNOTE-010+and+-042+trials.&amp;publication_year=2019&amp;journal=Ann+Oncol&amp;pages=v916-v917&amp;doi=10.1093%2Fannonc%2Fmdz394.077" target="_blank">Google Scholar</a></div></div></div></div></div></div><div class="citations-truncation"><button data-label-expand="Show all references" data-label-collapse="Show fewer" data-label-remaining="references remaining" class="btn btn--secondary" aria-expanded="false" aria-controls="collapsible-text"><span>Show all references</span></button></div></section></div></section></div><div class="core-collateral"><div id="core-collateral-info" role="tabpanel" data-core-tabs="core-collateral-info" tabindex="-1" aria-labelledby="pane-core-collateral-info"><header><h2 id="pane-core-collateral-info"><i class="icon-info" aria-hidden="true"></i>Information &amp; Authors</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div role="tablist"><button aria-controls="tab-information" role="tab" id="tab-information-label" aria-selected="true" class="active">Information</button><button aria-controls="tab-contributors" role="tab" id="tab-contributors-label" tabindex="-1" aria-selected="false">Authors</button></div><section id="tab-information" aria-labelledby="tab-information-label" role="tabpanel" tabindex="0"><h3>Information</h3><section class="core-self-citation"><h4>Published In</h4><div class="core-journal-presentation"><div class="core-journal-description"><div property="isPartOf" typeof="Periodical"><span property="name">New England Journal of Medicine</span></div><div class="core-enumeration"><a href="/toc/nejm/383/14"><span property="isPartOf" typeof="PublicationVolume">Volume <span property="volumeNumber">383</span></span> • <span property="isPartOf" typeof="PublicationIssue">Number <span property="issueNumber">14</span></span> • <span property="datePublished">October 1, 2020</span></a></div><div class="core-pagination"><span class="heading">Pages</span>: <span class="content"><span property="pageStart">1328</span>-<span property="pageEnd">1339</span></span></div></div></div></section><section class="core-copyright"><h4>Copyright</h4><div role="paragraph">Copyright © 2020 Massachusetts Medical Society. All rights reserved.</div><div>For personal use only. Any commercial reuse of NEJM Group content requires <a href="mailto:permissions@nejm.org">permission</a>.</div></section><section data-translation="YXQYoa1917346" class="core-component-translation"><h4>Translation</h4><div role="paragraph"><a target="_blank" href="https://nejmqianyan.cn/article/YXQYoa1917346?sg=AbW1N">Chinese Translation 中文翻译</a></div></section><section class="core-history"><h4>History</h4><div><b class="core-label">Published online</b>: September 30, 2020</div><div><b class="core-label">Published in issue</b>: October 1, 2020</div></section><section data-location="recirc_topics_article" class="core-classifications"><h4>Topics</h4><div class="keywords"><ol><li><a href="/browse/topic/lung-cancer" alt="View article keyword Lung Cancer" data-interactiontype="article_recirculation_click">Lung Cancer</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li><li><a href="/browse/topic/treatments-in-oncology" alt="View article keyword Treatments in Oncology" data-interactiontype="article_recirculation_click">Treatments in Oncology</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li></ol></div></section></section><section id="tab-contributors" aria-labelledby="tab-contributors-label" role="tabpanel" tabindex="-1"><h3>Authors</h3><section class="core-authors"><h4>Authors</h4><div role="paragraph"><span property="author" typeof="Person"><span property="givenName">Roy S.</span> <span property="familyName">Herbst</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Giuseppe</span> <span property="familyName">Giaccone</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Filippo</span> <span property="familyName">de Marinis</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Niels</span> <span property="familyName">Reinmuth</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Alain</span> <span property="familyName">Vergnenegre</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Carlos H.</span> <span property="familyName">Barrios</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Masahiro</span> <span property="familyName">Morise</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Enriqueta</span> <span property="familyName">Felip</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Zoran</span> <span property="familyName">Andric</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Sarayut</span> <span property="familyName">Geater</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Mustafa</span> <span property="familyName">Özgüroğlu</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Wei</span> <span property="familyName">Zou</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Alan</span> <span property="familyName">Sandler</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Ida</span> <span property="familyName">Enquist</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Kimberly</span> <span property="familyName">Komatsubara</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Yu</span> <span property="familyName">Deng</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Hiroshi</span> <span property="familyName">Kuriki</span>, <span property="honorificSuffix">M.Sc.</span></span>, <span property="author" typeof="Person"><span property="givenName">Xiaohui</span> <span property="familyName">Wen</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Mark</span> <span property="familyName">McCleland</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Simonetta</span> <span property="familyName">Mocci</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Jacek</span> <span property="familyName">Jassem</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, and <span property="author" typeof="Person"><span property="givenName">David R.</span> <span property="familyName">Spigel</span>, <span property="honorificSuffix">M.D.</span></span></div></section><section class="core-affiliations"><h4>Affiliations</h4><div property="affiliation" typeof="Organization"><span property="name">From the Yale School of Medicine, New Haven, CT (R.S.H.); Weill Cornell Medical Center, New York (G.G.); the European Institute of Oncology, IRCCS, Milan (F.M.); Asklepios Lung Clinic, Munich-Gauting, Germany (N.R.); University Hospital Limoges, Limoges, France (A.V.); Centro de Pesquisa Clínica, Hospital São Lucas, Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre, Brazil (C.H.B.); Nagoya University Graduate School of Medicine, Aichi, Japan (M. Morise); Vall d’Hebron University Hospital, Barcelona (E.F.); Clinical Hospital Center Bezanijska Kosa, Belgrade, Serbia (Z.A.); Prince of Songkla University–Hat Yai, Songkhla, Thailand (S.G.); Istanbul University–Cerrahpaşa, Cerrahpaşa Faculty of Medicine, Istanbul, Turkey (M.O.); Genentech, South San Francisco, CA (W.Z., A.S., I.E., K.K., Y.D., H.K., X.W., M. McCleland, S.M.); the Medical University of Gdańsk, Gdansk, Poland (J.J.); and the Sarah Cannon Research Institute at Tennessee Oncology, Nashville (D.R.S.).</span></div></section><section class="core-authors-notes"><h4>Notes</h4><div role="doc-footnote">Address reprint requests to Dr. Herbst at Medical Oncology, Yale Cancer Center, Yale School of Medicine, 333 Cedar St., P.O. Box 208028, New Haven, CT 06520-8028, or at <a href="mailto:roy.herbst@yale.edu">roy.herbst@yale.edu</a>.</div></section></section></div><div id="core-collateral-metrics" role="tabpanel" data-core-tabs="core-collateral-metrics" tabindex="-1" aria-labelledby="pane-core-collateral-metrics"><header><h2 id="pane-core-collateral-metrics"><i class="icon-timeline" aria-hidden="true"></i>Metrics &amp; Citations</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div role="tablist"><button aria-controls="tab-metrics-inner" role="tab" id="tab-metrics-inner-label" aria-selected="true" class="active" data-interactiontype="article_tab" data-tabname="metricsWindow">Metrics</button><button aria-controls="tab-citations" role="tab" id="tab-citations-label" tabindex="-1" aria-selected="false" data-interactiontype="article_tab" data-tabname="metricsWindow">Citations<span class="citations-count">1161</span></button></div><section id="tab-metrics-inner" aria-labelledby="tab-metrics-inner-label" role="tabpanel" tabindex="0"><h3>Metrics</h3><section>









    
    
        <div data-widget-def="UX3HTMLWidget" data-widget-id="95ea9f58-ec0e-4db2-b2ab-280fc876af53" data-location="article_metrics_article">
        



        
            <h4 class="">
                Altmetrics
            </h4>
        
        <div data-badge-details="right" data-badge-type="large-donut" data-doi="10.1056/NEJMoa1917346" data-hide-no-mentions="true" data-link-target="_blank" class="altmetric-embed" data-uuid="0404d6eb-d4bb-cef9-e51d-8bcad11944e2"><div style="overflow:hidden;">
    <div class="altmetric-normal-legend">
        <a target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=91496892" style="display:inline-block;">
                <img alt="Article has an altmetric score of 169" src="https://badges.altmetric.com/?size=320&amp;score=169&amp;types=mabcrtwd" width="180" height="180" style="border:0; margin:0; max-width: none;">
        </a>
        <p class="altmetric-see-more-details" style="padding-top: 10px; text-align: center;"><a target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=91496892">See more details</a></p>
    </div>
    <div id="_altmetric_popover_el_0404d6eb-d4bb-cef9-e51d-8bcad11944e2" class="altmetric-embed right" style="margin:0; padding:0; display:inline-block; float:left; position:relative;">
        <div class="altmetric_container">
            <div class="altmetric-embed altmetric-popover-inner right">
                <div style="padding:0; margin: 0;" class="altmetric-embed altmetric-popover-content">
                        <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #FF0000;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=91496892&amp;tab=news">
          Picked up by <b>11</b> news outlets
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #ffd140;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=91496892&amp;tab=blogs">
          Blogged by <b>2</b>
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #9f79f2;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=91496892&amp;tab=policy-documents">
          Referenced in <b>4</b> policy sources
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #74CFED;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=91496892&amp;tab=twitter">
          Posted by <b>96</b> X users
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #f27700;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=91496892&amp;tab=patents">
          Referenced in <b>2</b> patents
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #958899;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=91496892&amp;tab=wikipedia">
          Referenced in <b>1</b> Wikipedia pages
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #D5E8F0;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=91496892&amp;tab=reddit">
          Reddited by <b>1</b>
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #94DB5E;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=91496892&amp;tab=video">
          On <b>1</b> videos
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #A1E3E4;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=91496892&amp;tab=guidelines">
          Referenced in <b>4</b> clinical guideline sources
      </a>
    </div>

    <div class="altmetric-embed readers" style="margin-top: 10px;">
          <div class="altmetric-embed tip_mendeley" style="padding-left: 10px; line-height:18px; border-left: 16px solid #A60000;">
              <b>778</b> readers on Mendeley
          </div>
    </div>

                </div>
            </div>
        </div>
    </div>
</div></div>
<script async="" type="text/javascript" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" nonce="94d64c3dc210a517-SJC"></script>

        </div>
    

</section></section><section id="tab-citations" aria-labelledby="tab-citations-label" role="tabpanel" tabindex="-1"><h3>Citations</h3><section>



        
            <h4 class="">
                Export citation
            </h4>
        
        <div class="citation-download cd-sec">
<p class="citation-download_msg">Select the format you want to export the citation of this publication.</p>
<form action="/action/downloadCitation" name="frmCitmgr" method="post" target="_self" class="citation-download_form"><input type="hidden" name="doi" value="10.1056/NEJMoa1917346"> <input type="hidden" name="downloadFileName" value="csp_383_"> <input type="hidden" name="include" value="abs">
<div class="dropdown dropdown-selectable dropdown-selectable--form-control"><input type="hidden" name="format" value=""> <label class="form-label">Format*</label> <button id="slct_format" type="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false" class="btn dropdown-toggle d-flex align-items-center justify-content-between">Please Select </button>
<div aria-labelledby="slct_format" role="listbox" class="dropdown-menu"><a href="#" data-value="ris" class="dropdown-item">RIS (ProCite, Reference Manager)</a><a href="#" data-value="endnote" class="dropdown-item">EndNote</a><a href="#" data-value="bibtex" class="dropdown-item">BibTex</a><a href="#" data-value="medlars" class="dropdown-item">Medlars</a><a href="#" data-value="refworks" class="dropdown-item">RefWorks</a></div>
<div class="invalid-feedback">Please select an item in the list</div>
</div>
<div class="citation-download_checkbox"><label class="checkbox--primary"><input type="checkbox" name="direct" value="true"><span class="checkbox--primary-icons"><span class="checkbox--primary-unchecked"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#toggles-checboxUnchecked"></use></svg></span></span><span class="checkbox--primary-checked"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#toggles-checboxChecked"></use></svg></span></span></span><span class="checkbox--primary-label"><span class="checkbox--primary-label-text">Direct Import</span></span></label></div>
<div class="citation-download_btn"><button type="submit" name="submit" value="Download" class="ng-btn_default ng-btn_iconLeft" data-interactiontype="article_tools_citation_download" data-multimedia-type="Citation"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#citations"></use></svg></span><span class="ng-btn_text">Export citation</span></button></div>
</form></div>
</section><section>









    
    
        <div data-widget-def="UX3CitedByWidget" data-widget-id="efb4df9a-8e1a-47f9-bfb7-271959277a9f" data-location="citedby_article">
        



        
            <h4 class="">
                Cited by
            </h4>
        
        <section id="cited-by" class="cited-by"><div class="cited-by__wrapper"><div id="cited-by__content" class="cited-by__content"><ol data-source="/pb/widgets/citedBy?page=1&amp;widgetId=efb4df9a-8e1a-47f9-bfb7-271959277a9f&amp;pbContext=%3BrequestedJournal%3Ajournal%3Anejm%3Bpage%3Astring%3AArticle%2FChapter+View%3Bissue%3Aissue%3Adoi%5C%3A10.1056%2Fnejm_2020.383.issue-14%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3Adoi%5C%3A10.1056%2FNEJMoa1917346%3Bwgroup%3Astring%3AMMS+NextGen+Website+Group%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bwebsite%3Awebsite%3Amms-site%3Bjournal%3Ajournal%3Anejms" data-lazyload="false" data-total="1161" class="cited-by__list list-unstyled"><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Zhenzhen Su, </li><li class="list-inline-item cited-by__entry__author">Liyan Zhang, </li><li class="list-inline-item cited-by__entry__author">Xuemin Lian, </li><li class="list-inline-item cited-by__entry__author">Yixuan Wang, </li></ul><span class="cited-by__entry__title">Risk factors associated with immune-related severe adverse events in patients with cancer: A scoping review, </span><span class="cited-by__entry__series-title">Asia-Pacific Journal of Oncology Nursing, </span><span class="cited-by__entry__volume"><strong>12</strong>, </span><span class="cited-by__entry__page-range">(100661), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.apjon.2025.100661" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.apjon.2025.100661</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.apjon.2025.100661" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Micah Tratt, </li><li class="list-inline-item cited-by__entry__author">Anshu Bandhlish, </li><li class="list-inline-item cited-by__entry__author">Keith D. Eaton, </li><li class="list-inline-item cited-by__entry__author">Ted Gooley, </li><li class="list-inline-item cited-by__entry__author">Nicholas Giustini, </li><li class="list-inline-item cited-by__entry__author">Lei Deng, </li></ul><span class="cited-by__entry__title">Survival Outcomes of Lung Adenocarcinoma With Intestinal Differentiation in the Era of Immunotherapy, </span><span class="cited-by__entry__series-title">JTO Clinical and Research Reports, </span><span class="cited-by__entry__volume"><strong>6</strong>, </span><span class="cited-by__entry__issue">7, </span><span class="cited-by__entry__page-range">(100827), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.jtocrr.2025.100827" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.jtocrr.2025.100827</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.jtocrr.2025.100827" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Lu Chen, </li><li class="list-inline-item cited-by__entry__author">Jie Yin, </li><li class="list-inline-item cited-by__entry__author">Ke Xu, </li><li class="list-inline-item cited-by__entry__author">YuTing Cui, </li><li class="list-inline-item cited-by__entry__author">SuHua Zhu, </li><li class="list-inline-item cited-by__entry__author">Tian Li, </li><li class="list-inline-item cited-by__entry__author">Tangfeng Lv, </li><li class="list-inline-item cited-by__entry__author">Yong Song, </li><li class="list-inline-item cited-by__entry__author">Ping Zhan, </li></ul><span class="cited-by__entry__title">Novel bioengineered drugs with immunotherapies for malignant pleural effusion: Remodulate tumor immune microenvironment and activate immune system, </span><span class="cited-by__entry__series-title">Critical Reviews in Oncology/Hematology, </span><span class="cited-by__entry__volume"><strong>211</strong>, </span><span class="cited-by__entry__page-range">(104717), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.critrevonc.2025.104717" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.critrevonc.2025.104717</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.critrevonc.2025.104717" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Li-Bo Tang, </li><li class="list-inline-item cited-by__entry__author">Ying-Long Peng, </li><li class="list-inline-item cited-by__entry__author">Ji Chen, </li><li class="list-inline-item cited-by__entry__author">Jia-Ting Li, </li><li class="list-inline-item cited-by__entry__author">Mei-Mei Zheng, </li><li class="list-inline-item cited-by__entry__author">Lv Wu, </li><li class="list-inline-item cited-by__entry__author">Chang Lu, </li><li class="list-inline-item cited-by__entry__author">Xue-Wu Wei, </li><li class="list-inline-item cited-by__entry__author">Dong-Xuan Cai, </li><li class="list-inline-item cited-by__entry__author">Zhi Guo, </li><li class="list-inline-item cited-by__entry__author">Zi-Rui Ren, </li><li class="list-inline-item cited-by__entry__author">Si-Di Lv, </li><li class="list-inline-item cited-by__entry__author">Yu Deng, </li><li class="list-inline-item cited-by__entry__author">Zhi-Hong Chen, </li><li class="list-inline-item cited-by__entry__author">Chong-Rui Xu, </li><li class="list-inline-item cited-by__entry__author">Qing Zhou, </li></ul><span class="cited-by__entry__title">Rechallenge with immune-checkpoint inhibitors in patients with advanced-stage lung cancer, </span><span class="cited-by__entry__series-title">Nature Reviews Clinical Oncology, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1038/s41571-025-01029-7" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1038/s41571-025-01029-7</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1038/s41571-025-01029-7" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Kendra Wilson, </li><li class="list-inline-item cited-by__entry__author">Jesus Salvador Flores Banda, </li><li class="list-inline-item cited-by__entry__author">Fatima Raza, </li><li class="list-inline-item cited-by__entry__author">Sanjana Bukkapatnam, </li><li class="list-inline-item cited-by__entry__author">Sanjana Gangane, </li><li class="list-inline-item cited-by__entry__author">Erminia Massarelli, </li></ul><span class="cited-by__entry__title">
              Treating
              KRAS G12C
              lung cancer: therapeutic potential of investigation drugs in early clinical study
            , </span><span class="cited-by__entry__series-title">Expert Opinion on Investigational Drugs, </span><span class="cited-by__entry__page-range">(1-13), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1080/13543784.2025.2511175" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1080/13543784.2025.2511175</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1080/13543784.2025.2511175" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Susumu Tanaka, </li><li class="list-inline-item cited-by__entry__author">Koichiro Nozaki, </li><li class="list-inline-item cited-by__entry__author">Satoshi Watanabe, </li><li class="list-inline-item cited-by__entry__author">Naohiro Yanagimura, </li><li class="list-inline-item cited-by__entry__author">Masashi Arita, </li><li class="list-inline-item cited-by__entry__author">Miyuki Sato, </li><li class="list-inline-item cited-by__entry__author">Tomohiro Tanaka, </li><li class="list-inline-item cited-by__entry__author">Yu Saida, </li><li class="list-inline-item cited-by__entry__author">Yuka Goto, </li><li class="list-inline-item cited-by__entry__author">Kohei Kushiro, </li><li class="list-inline-item cited-by__entry__author">Toshiya Fujisaki, </li><li class="list-inline-item cited-by__entry__author">Ko Sato, </li><li class="list-inline-item cited-by__entry__author">Daisuke Ishikawa, </li><li class="list-inline-item cited-by__entry__author">Takao Miyabayashi, </li><li class="list-inline-item cited-by__entry__author">Kosuke Ichikawa, </li><li class="list-inline-item cited-by__entry__author">Takeshi Ota, </li><li class="list-inline-item cited-by__entry__author">Yoshiki Hayashi, </li><li class="list-inline-item cited-by__entry__author">Kenichi Koyama, </li><li class="list-inline-item cited-by__entry__author">Akira Ishida, </li><li class="list-inline-item cited-by__entry__author">Toshiaki Kikuchi, </li></ul><span class="cited-by__entry__title">Risk of lung injury with immune checkpoint inhibitors after talc pleurodesis: A retrospective study, </span><span class="cited-by__entry__series-title">Lung Cancer, </span><span class="cited-by__entry__volume"><strong>204</strong>, </span><span class="cited-by__entry__page-range">(108590), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.lungcan.2025.108590" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.lungcan.2025.108590</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.lungcan.2025.108590" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Mayu Sugai, </li><li class="list-inline-item cited-by__entry__author">Yoshiaki Amino, </li><li class="list-inline-item cited-by__entry__author">Shunsuke Fujishima, </li><li class="list-inline-item cited-by__entry__author">Kyujiro Nibuya, </li><li class="list-inline-item cited-by__entry__author">Hirokazu Iso, </li><li class="list-inline-item cited-by__entry__author">Masahiro Ito, </li><li class="list-inline-item cited-by__entry__author">Ryosuke Tsugitomi, </li><li class="list-inline-item cited-by__entry__author">Ryo Ariyasu, </li><li class="list-inline-item cited-by__entry__author">Ken Uchibori, </li><li class="list-inline-item cited-by__entry__author">Noriko Yanagitani, </li><li class="list-inline-item cited-by__entry__author">Makoto Nishio, </li></ul><span class="cited-by__entry__title">Impact of immune-related adverse event severity on overall survival in patients with advanced NSCLC receiving immune checkpoint inhibitors therapy, with a focus on combination regimens, </span><span class="cited-by__entry__series-title">Lung Cancer, </span><span class="cited-by__entry__volume"><strong>204</strong>, </span><span class="cited-by__entry__page-range">(108555), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.lungcan.2025.108555" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.lungcan.2025.108555</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.lungcan.2025.108555" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Yifei Zhang, </li><li class="list-inline-item cited-by__entry__author">Keyu Yin, </li><li class="list-inline-item cited-by__entry__author">Runsheng Ma, </li><li class="list-inline-item cited-by__entry__author">Yuxiao Sun, </li><li class="list-inline-item cited-by__entry__author">Longlong Wang, </li><li class="list-inline-item cited-by__entry__author">Detao Yin, </li></ul><span class="cited-by__entry__title">Complex regulatory network of programmed death-ligand 1 in cancer: Cancer immunomodulation from molecular mechanisms to clinical applications, </span><span class="cited-by__entry__series-title">iScience, </span><span class="cited-by__entry__volume"><strong>28</strong>, </span><span class="cited-by__entry__issue">6, </span><span class="cited-by__entry__page-range">(112615), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.isci.2025.112615" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.isci.2025.112615</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.isci.2025.112615" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">A. Miyazaki, </li><li class="list-inline-item cited-by__entry__author">K. Kunimasa, </li><li class="list-inline-item cited-by__entry__author">T. Morishima, </li><li class="list-inline-item cited-by__entry__author">M. Tamiya, </li><li class="list-inline-item cited-by__entry__author">T. Inoue, </li><li class="list-inline-item cited-by__entry__author">T. Kawamura, </li><li class="list-inline-item cited-by__entry__author">T. Tanaka, </li><li class="list-inline-item cited-by__entry__author">K. Komuta, </li><li class="list-inline-item cited-by__entry__author">S. Futamura, </li><li class="list-inline-item cited-by__entry__author">K. Nishino, </li><li class="list-inline-item cited-by__entry__author">I. Miyashiro, </li></ul><span class="cited-by__entry__title">Comparative effectiveness of immunotherapeutic regimens for untreated advanced non-small-cell lung cancer in real-world clinical practice: a&nbsp;Japanese cancer registry cohort study, </span><span class="cited-by__entry__series-title">ESMO Real World Data and Digital Oncology, </span><span class="cited-by__entry__volume"><strong>8</strong>, </span><span class="cited-by__entry__page-range">(100137), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.esmorw.2025.100137" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.esmorw.2025.100137</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.esmorw.2025.100137" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Rudolf Stadler, </li><li class="list-inline-item cited-by__entry__author">Gabriele Roccuzzo, </li><li class="list-inline-item cited-by__entry__author">Pablo Ortiz-Romero, </li><li class="list-inline-item cited-by__entry__author">Martine Bagot, </li><li class="list-inline-item cited-by__entry__author">Pietro Quaglino, </li><li class="list-inline-item cited-by__entry__author">Emmanuella Guenova, </li><li class="list-inline-item cited-by__entry__author">Constanze Jonak, </li><li class="list-inline-item cited-by__entry__author">Evangelia Papadavid, </li><li class="list-inline-item cited-by__entry__author">René Stranzenbach, </li><li class="list-inline-item cited-by__entry__author">Sandrine Marreaud, </li><li class="list-inline-item cited-by__entry__author">Jammbe Musoro, </li><li class="list-inline-item cited-by__entry__author">Jose Casas-Martin, </li><li class="list-inline-item cited-by__entry__author">Duncan Murray, </li><li class="list-inline-item cited-by__entry__author">Samantha Drennan, </li><li class="list-inline-item cited-by__entry__author">Jimmy Van Hear, </li><li class="list-inline-item cited-by__entry__author">Paul Moss, </li><li class="list-inline-item cited-by__entry__author">Delphine Sartori, </li><li class="list-inline-item cited-by__entry__author">Maxime Battistella, </li><li class="list-inline-item cited-by__entry__author">Rein Willemze, </li><li class="list-inline-item cited-by__entry__author">Julia Scarisbrick, </li><li class="list-inline-item cited-by__entry__author">Robert Knobler, </li></ul><span class="cited-by__entry__title">Phase II trial of atezolizumab (Anti-PD-L1) in the treatment of relapsed/refractory IIB/IVB mycosis fungoides/Sézary syndrome patients after previous systemic treatment. EORTC-1652-CLTG “PARCT”, </span><span class="cited-by__entry__series-title">European Journal of Cancer, </span><span class="cited-by__entry__volume"><strong>222</strong>, </span><span class="cited-by__entry__page-range">(115484), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.ejca.2025.115484" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.ejca.2025.115484</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.ejca.2025.115484" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry--see-more"><a href="javascript:void(0)" data-source="/pb/widgets/citedBy?page=1&amp;widgetId=efb4df9a-8e1a-47f9-bfb7-271959277a9f&amp;pbContext=%3BrequestedJournal%3Ajournal%3Anejm%3Bpage%3Astring%3AArticle%2FChapter+View%3Bissue%3Aissue%3Adoi%5C%3A10.1056%2Fnejm_2020.383.issue-14%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3Adoi%5C%3A10.1056%2FNEJMoa1917346%3Bwgroup%3Astring%3AMMS+NextGen+Website+Group%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bwebsite%3Awebsite%3Amms-site%3Bjournal%3Ajournal%3Anejms" class="cited-by__see-more">See more</a></li></ol></div><div class="cited-by__spinner justify-content-center align-items-center d-none"><div role="status" class="spinner-border text-gray"><span class="sr-only">Loading...</span></div></div></div></section>

        </div>
    

</section></section></div><div id="core-collateral-fulltext-options" role="tabpanel" data-core-tabs="core-collateral-fulltext-options" tabindex="-1" aria-labelledby="pane-core-collateral-fulltext-options"><header><h2 id="pane-core-collateral-fulltext-options"><i class="icon-eye" aria-hidden="true"></i>View Options</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div class="section--wrapper"><h3>View options</h3><section class="format--pdf"><h4> <abbr title="Portable Document Format">PDF</abbr></h4><a href="https://www.nejm.org/doi/pdf/10.1056/NEJMoa1917346" class="btn btn--pdf" aria-label="View PDF" data-behavior="trackDownloadEvent" data-doi="10.1056/NEJMoa1917346" data-interactiontype="article_tools_download_pdf" data-multimedia-type="Article PDF" data-multimedia-filename="nejmoa1917346.pdf"><i aria-hidden="true" class="icon-pdf"></i><span>View PDF</span></a></section></div><!-- Its needed to duplicate this for PB check Collateral.js as well--></div><div id="core-collateral-media" role="tabpanel" data-core-tabs="core-collateral-media" tabindex="-1" aria-labelledby="pane-core-collateral-media"><header><h2 id="pane-core-collateral-media"><i class="icon-photo" aria-hidden="true"></i>Media</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div role="tablist"><button aria-controls="tab-figures" role="tab" id="tab-figures-label" aria-selected="true" class="active">Figures</button><button aria-controls="tab-other" role="tab" id="tab-other-label" tabindex="-1" aria-selected="false" class="inactive" aria-disabled="true">Other</button></div><section id="tab-figures" aria-labelledby="tab-figures-label" role="tabpanel" tabindex="0"><h3>Figures</h3><div class="text-right"><a class="btn btn--inverse  open-in-viewer" href="#figures"><span>Open all in viewer</span><i class="icon-open_in_new" aria-hidden="true"></i></a></div><div id="core-f1"><figure class="graphic"><a class="open-in-viewer" href="#f1" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa1917346_f1.jpg"><img src="/cms/10.1056/NEJMoa1917346/asset/4ab0fe9d-3f41-4880-900c-a2685477da75/assets/images/large/nejmoa1917346_f1.jpg" height="3281" width="2640" aria-labelledby="f1" loading="lazy"></a><figcaption><div class="caption">Overall Survival in the Atezolizumab Group and the Chemotherapy Group.</div><div class="notes"><div role="doc-footnote">Shown are Kaplan–Meier estimates of overall survival among the patients whose tumors were wild-type with respect to <i>EGFR</i> mutations or <i>ALK</i> translocations. High expression of programmed death ligand 1 (PD-L1) indicates PD-L1 expression on at least 50% of tumor cells or at least 10% of tumor-infiltrating immune cells as assessed by the SP142 immunohistochemical assay (Panel A). High or intermediate PD-L1 expression indicates PD-L1 expression on at least 5% of tumor cells or tumor-infiltrating immune cells (Panel B). Any PD-L1 expression indicates PD-L1 expression on at least 1% of tumor cells or tumor-infiltrating immune cells. Stratified hazard ratios are given according to the level of PD-L1 expression. Treatment comparisons (atezolizumab vs. platinum-based chemotherapy) for the primary end point of overall survival were based on a stratified log-rank test. Medians were estimated with the use of the Kaplan–Meier method. A stratified Cox regression model was used to estimate hazard ratios, and 95% confidence intervals (CIs) were calculated with the use of the Brookmeyer–Crowley method. The results for overall survival among patients who had high or intermediate PD-L1 expression did not cross the prespecified alpha boundary, so overall survival among patients who had any PD-L1 expression was not formally tested. Tick marks indicate censored data. NE denotes could not be estimated.</div></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#f1"><i class="icon-return" aria-hidden="true"></i><span>Go to Figure</span></a><a class="open-in-viewer" href="#f1" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa1917346_f1.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-f2"><figure class="graphic"><a class="open-in-viewer" href="#f2" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa1917346_f2.jpg"><img src="/cms/10.1056/NEJMoa1917346/asset/6823ac0b-3cf5-4753-8876-bd50406faefb/assets/images/large/nejmoa1917346_f2.jpg" height="3058" width="2640" aria-labelledby="f2" loading="lazy"></a><figcaption><div class="caption">Overall Survival among Patients with High PD-L1 Expression, According to Immunohistochemical Assay.</div><div class="notes"><div role="doc-footnote">Panel A shows the overlap among patients with a tumor proportion score of at least 50% as assessed by the 22C3 assay, patients with PD-L1 expression on at least 50% of tumor cells as assessed by the SP263 assay, and patients with PD-L1 expression on at least 50% of tumor cells or at least 10% of tumor-infiltrating immune cells as assessed by the SP142 assay. Each percentage in the Venn diagrams reflects the percentage of that specific subgroup out of the total population of patients who could be evaluated for biomarker levels: 534 patients for the 22C3 and SP142 overlap, 546 for the SP263 and SP142 overlap, and 530 for the 22C3 and SP263 overlap. Panel B shows Kaplan–Meier estimates of overall survival among patients with a tumor proportion score of at least 50% on the 22C3 assay, and Panel C shows Kaplan–Meier estimates of overall survival among patients with PD-L1 expression on at least 50% of tumor cells on the SP263 assay. Medians were estimated with the use of the Kaplan–Meier method. Unstratified hazard ratios are shown for 22C3 and SP263 subgroup analyses. Tick marks indicate censored data.</div></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#f2"><i class="icon-return" aria-hidden="true"></i><span>Go to Figure</span></a><a class="open-in-viewer" href="#f2" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa1917346_f2.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-f3"><figure class="graphic"><a class="open-in-viewer" href="#f3" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa1917346_f3.jpg"><img src="/cms/10.1056/NEJMoa1917346/asset/7c71a9e8-7620-4602-a156-107a1e7e432f/assets/images/large/nejmoa1917346_f3.jpg" height="1783" width="2640" aria-labelledby="f3" loading="lazy"></a><figcaption><div class="caption">Progression-free Survival in Subgroups Defined According to Blood-Based Tumor Mutational Burden (TMB).</div><div class="notes"><div role="doc-footnote">Panel A shows the overlap between patients with a blood-based TMB of at least 16 (16 mutations per 1.1 megabase, equivalent to approximately 14.5 mutations per megabase) and patients with high PD-L1 expression. Each percentage in the Venn diagrams reflects the percentage of that specific subgroup out of the total population of patients who could be evaluated for biomarker levels: 375 patients for the 22C3 assay and blood-based TMB overlap and 389 for the SP142 assay and blood-based TMB overlap. Panel B shows progression-free survival in subgroups defined according to blood-based TMB. Any PD-L1 expression was defined as PD-L1 expression on at least 1% of tumor cells or tumor-infiltrating immune cells as assessed by the SP142 assay. A total of 165 patients could not be evaluated for blood-based TMB: 88 patients had a blood-based TMB result with a maximum somatic allele frequency of less than 1%, 39 patients had a sample that failed quality control at the testing vendor or had a median exon coverage of less than 800, and 38 patients had not provided a baseline plasma sample. A stratified hazard ratio is shown for any PD-L1 expression, and unstratified hazard ratios are shown for the other subgroups.</div></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#f3"><i class="icon-return" aria-hidden="true"></i><span>Go to Figure</span></a><a class="open-in-viewer" href="#f3" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa1917346_f3.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div></section><section id="tab-other" aria-labelledby="tab-other-label" role="tabpanel" tabindex="-1"><h3>Other</h3></section></div><div id="core-collateral-tables" role="tabpanel" data-core-tabs="core-collateral-tables" tabindex="-1" aria-labelledby="pane-core-collateral-tables"><header><h2 id="pane-core-collateral-tables"><i class="icon-tables" aria-hidden="true"></i>Tables</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><!-- There is no content. --><div class="section--wrapper"><div class="text-right"><a class="btn btn--inverse  open-in-viewer" href="#tables"><span>Open all in viewer</span><i class="icon-open_in_new" aria-hidden="true"></i></a></div><div id="core-t1"><figure class="table"><a class="open-in-viewer" href="#t1" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa1917346_t1.jpg"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><img src="/cms/10.1056/NEJMoa1917346/asset/e0987f4e-9697-45fb-aba5-15f1e3cf5c54/assets/images/large/nejmoa1917346_t1.jpg" height="1723" width="1999" loading="lazy"></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Characteristic</th><th class="txxx-borders" colspan="2"><span>Any PD-L1 Expression</span></th><th class="txxx-borders" colspan="2"><span>High or Intermediate PD-L1 Expression</span></th><th class="txxr-borders" colspan="2"><span>High PD-L1 Expression</span></th></tr><tr class="head2" data-type="row head2"><td class="xxlx-borders">&nbsp;</td><th class="xxxx-borders">Atezolizumab <br>(N=277)</th><th class="xxxx-borders">Chemotherapy<br>(N=277)</th><th class="xxxx-borders">Atezolizumab<br>(N=166)</th><th class="xxxx-borders">Chemotherapy<br>(N=162)</th><th class="xxxx-borders">Atezolizumab<br>(N=107)</th><th class="xxxr-borders">Chemotherapy<br>(N=98)</th></tr></thead><tbody><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Median age (range) — yr</td><td class="xxxx-borders shading">64 (30–81)</td><td class="xxxx-borders shading">65 (30–87)</td><td class="xxxx-borders shading">63 (33–81)</td><td class="xxxx-borders shading">65 (33–87)</td><td class="xxxx-borders shading">63 (33–79)</td><td class="xxxr-borders shading">66 (33–87)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Male sex — no. (%)</td><td class="xxxx-borders">196 (70.8)</td><td class="xxxx-borders">193 (69.7)</td><td class="xxxx-borders">122 (73.5)</td><td class="xxxx-borders">107 (66.0)</td><td class="xxxx-borders">79 (73.8)</td><td class="xxxr-borders">64 (65.3)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Race — no. (%)<a href="#core-t1fn2" role="doc-noteref">†</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">White</td><td class="xxxx-borders">227 (81.9)</td><td class="xxxx-borders">240 (86.6)</td><td class="xxxx-borders">133 (80.1)</td><td class="xxxx-borders">139 (85.8)</td><td class="xxxx-borders">87 (81.3)</td><td class="xxxr-borders">82 (83.7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Asian</td><td class="xxxx-borders shading">45 (16.2)</td><td class="xxxx-borders shading">30 (10.8)</td><td class="xxxx-borders shading">31 (18.7)</td><td class="xxxx-borders shading">20 (12.3)</td><td class="xxxx-borders shading">20 (18.7)</td><td class="xxxr-borders shading">15 (15.3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Black</td><td class="xxxx-borders">2 (0.7)</td><td class="xxxx-borders">2 (0.7)</td><td class="xxxx-borders">1 (0.6)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxr-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Unknown</td><td class="xxxx-borders shading">2 (0.7)</td><td class="xxxx-borders shading">5 (1.8)</td><td class="xxxx-borders shading">1 (0.6)</td><td class="xxxx-borders shading">3 (1.9)</td><td class="xxxx-borders shading">0</td><td class="xxxr-borders shading">1 (1.0)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">ECOG performance-status score — no. (%)<a href="#core-t1fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">0</td><td class="xxxx-borders shading">97 (35.0)</td><td class="xxxx-borders shading">102 (36.8)</td><td class="xxxx-borders shading">60 (36.1)</td><td class="xxxx-borders shading">62 (38.3)</td><td class="xxxx-borders shading">35 (32.7)</td><td class="xxxr-borders shading">38 (38.8)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">1</td><td class="xxxx-borders">180 (65.0)</td><td class="xxxx-borders">175 (63.2)</td><td class="xxxx-borders">106 (63.9)</td><td class="xxxx-borders">100 (61.7)</td><td class="xxxx-borders">72 (67.3)</td><td class="xxxr-borders">60 (61.2)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">History of tobacco use — no. (%)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Never</td><td class="xxxx-borders">37 (13.4)</td><td class="xxxx-borders">35 (12.6)</td><td class="xxxx-borders">21 (12.7)</td><td class="xxxx-borders">17 (10.5)</td><td class="xxxx-borders">9 (8.4)</td><td class="xxxr-borders">15 (15.3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Current</td><td class="xxxx-borders shading">74 (26.7)</td><td class="xxxx-borders shading">81 (29.2)</td><td class="xxxx-borders shading">38 (22.9)</td><td class="xxxx-borders shading">52 (32.1)</td><td class="xxxx-borders shading">20 (18.7)</td><td class="xxxr-borders shading">29 (29.6)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Previous</td><td class="xxxx-borders">166 (59.9)</td><td class="xxxx-borders">161 (58.1)</td><td class="xxxx-borders">107 (64.5)</td><td class="xxxx-borders">93 (57.4)</td><td class="xxxx-borders">78 (72.9)</td><td class="xxxr-borders">54 (55.1)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Histologic type at diagnosis — no. (%)</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Nonsquamous</td><td class="xxxx-borders">192 (69.3)</td><td class="xxxx-borders">193 (69.7)</td><td class="xxxx-borders">122 (73.5)</td><td class="xxxx-borders">116 (71.6)</td><td class="xxxx-borders">80 (74.8)</td><td class="xxxr-borders">75 (76.5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging12 shading" data-xml-align="left">Squamous</td><td class="xbxx-borders shading">85 (30.7)</td><td class="xbxx-borders shading">84 (30.3)</td><td class="xbxx-borders shading">44 (26.5)</td><td class="xbxx-borders shading">46 (28.4)</td><td class="xbxx-borders shading">27 (25.2)</td><td class="xbxr-borders shading">23 (23.5)</td></tr></tbody></table></div><figcaption><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="core-t1fn1" role="paragraph" data-to-manipulate="true">This population comprised the patients whose tumors were wild-type with respect to <i>EGFR</i> mutations or <i>ALK</i> translocations. Any programmed death ligand 1 (PD-L1) expression indicates PD-L1 expression on at least 1% of tumor cells or tumor-infiltrating immune cells as assessed by the SP142 assay. High or intermediate PD-L1 expression indicates PD-L1 expression on at least 5% of tumor cells or tumor-infiltrating immune cells. High PD-L1 expression indicates PD-L1 expression on at least 50% of tumor cells or at least 10% of tumor-infiltrating immune cells. Percentages may not total 100 because of rounding.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="core-t1fn2" role="paragraph" data-to-manipulate="true">Race was reported by the patients. One patient in the atezolizumab group with any PD-L1 expression was categorized as having multiple races (not shown).</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="core-t1fn3" role="paragraph" data-to-manipulate="true">Eastern Cooperative Oncology Group (ECOG) performance-status scores range from 0 to 5, with 0 indicating no symptoms and higher scores indicating greater disability.</div></div></div></figcaption></a><figcaption><div class="caption">Demographic and Clinical Characteristics of the Patients at Baseline (Population with <i>EGFR</i> and <i>ALK</i> Wild-Type Tumors).<a href="#core-t1fn1" role="doc-noteref">*</a></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#t1"><i class="icon-return" aria-hidden="true"></i><span>Go to Table</span></a><a class="open-in-viewer" href="#t1" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa1917346_t1.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-t2"><figure class="table"><a class="open-in-viewer" href="#t2" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa1917346_t2.jpg"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><img src="/cms/10.1056/NEJMoa1917346/asset/56688587-20ee-44ca-81f3-d16e31da301d/assets/images/large/nejmoa1917346_t2.jpg" height="1480" width="1711" loading="lazy"></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Adverse Event</th><th class="txxx-borders" colspan="3"><span>Atezolizumab<br>(N=286)</span></th><th class="txxr-borders" colspan="3"><span>Chemotherapy<br>(N=263)</span></th></tr><tr class="head2" data-type="row head2"><td class="xxlx-borders">&nbsp;</td><th class="xxxx-borders">All Grades</th><th class="xxxx-borders">Grade 3 or 4</th><th class="xxxx-borders">Grade 5</th><th class="xxxx-borders">All Grades</th><th class="xxxx-borders">Grade 3 or 4</th><th class="xxxr-borders">Grade 5</th></tr><tr class="head3" data-type="row head3"><td class="xxlx-borders">&nbsp;</td><th class="xxxr-borders" colspan="6"><span>number (percent)</span></th></tr></thead><tbody><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Any adverse event</td><td class="xxxx-borders shading">258 (90.2)</td><td class="xxxx-borders shading">86 (30.1)</td><td class="xxxx-borders shading">11 (3.8)</td><td class="xxxx-borders shading">249 (94.7)</td><td class="xxxx-borders shading">138 (52.5)</td><td class="xxxr-borders shading">11 (4.2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Anemia</td><td class="xxxx-borders">44 (15.4)</td><td class="xxxx-borders">5 (1.7)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">125 (47.5)</td><td class="xxxx-borders">48 (18.3)</td><td class="xxxr-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Decreased appetite</td><td class="xxxx-borders shading">44 (15.4)</td><td class="xxxx-borders shading">2 (0.7)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">50 (19.0)</td><td class="xxxx-borders shading">0</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Nausea</td><td class="xxxx-borders">39 (13.6)</td><td class="xxxx-borders">1 (0.3)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">89 (33.8)</td><td class="xxxx-borders">5 (1.9)</td><td class="xxxr-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Asthenia</td><td class="xxxx-borders shading">37 (12.9)</td><td class="xxxx-borders shading">2 (0.7)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">46 (17.5)</td><td class="xxxx-borders shading">5 (1.9)</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Fatigue</td><td class="xxxx-borders">37 (12.9)</td><td class="xxxx-borders">2 (0.7)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">46 (17.5)</td><td class="xxxx-borders">6 (2.3)</td><td class="xxxr-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Constipation</td><td class="xxxx-borders shading">35 (12.2)</td><td class="xxxx-borders shading">3 (1.0)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">57 (21.7)</td><td class="xxxx-borders shading">2 (0.8)</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Hyponatremia</td><td class="xxxx-borders">17 (5.9)</td><td class="xxxx-borders">6 (2.1)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">12 (4.6)</td><td class="xxxx-borders">6 (2.3)</td><td class="xxxr-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Pneumonia</td><td class="xxxx-borders shading">14 (4.9)</td><td class="xxxx-borders shading">7 (2.4)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">17 (6.5)</td><td class="xxxx-borders shading">9 (3.4)</td><td class="xxxr-borders shading">1 (0.4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Hyperkalemia</td><td class="xxxx-borders">12 (4.2)</td><td class="xxxx-borders">6 (2.1)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">8 (3.0)</td><td class="xxxx-borders">3 (1.1)</td><td class="xxxr-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Thrombocytopenia</td><td class="xxxx-borders shading">7 (2.4)</td><td class="xxxx-borders shading">1 (0.3)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">44 (16.7)</td><td class="xxxx-borders shading">19 (7.2)</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Neutropenia</td><td class="xxxx-borders">4 (1.4)</td><td class="xxxx-borders">2 (0.7)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">74 (28.1)</td><td class="xxxx-borders">46 (17.5)</td><td class="xxxr-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Death</td><td class="xxxx-borders shading">2 (0.7)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">2 (0.7)</td><td class="xxxx-borders shading">3 (1.1)</td><td class="xxxx-borders shading">0</td><td class="xxxr-borders shading">3 (1.1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Decreased platelet count</td><td class="xxxx-borders">1 (0.3)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxx-borders">22 (8.4)</td><td class="xxxx-borders">11 (4.2)</td><td class="xxxr-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Decreased neutrophil count</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">19 (7.2)</td><td class="xxxx-borders shading">10 (3.8)</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging01" data-xml-align="left">Febrile neutropenia</td><td class="xbxx-borders">0</td><td class="xbxx-borders">0</td><td class="xbxx-borders">0</td><td class="xbxx-borders">9 (3.4)</td><td class="xbxx-borders">9 (3.4)</td><td class="xbxr-borders">0</td></tr></tbody></table></div><figcaption><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="core-t2fn1" role="paragraph" data-to-manipulate="true">The safety population comprised all the patients who received atezolizumab or chemotherapy, regardless of PD-L1 expression or <i>EGFR</i> and <i>ALK</i> alterations. Shown are adverse events with an incidence of at least 15% in any group, events of grade 3 or 4 severity with an incidence of at least 2% in any group, and events of grade 5 severity with an incidence of at least 1% in any group.</div></div></div></figcaption></a><figcaption><div class="caption">Reported Adverse Events (Safety Population).<a href="#core-t2fn1" role="doc-noteref">*</a></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#t2"><i class="icon-return" aria-hidden="true"></i><span>Go to Table</span></a><a class="open-in-viewer" href="#t2" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa1917346_t2.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div></div></div><div id="core-collateral-share" role="tabpanel" data-core-tabs="core-collateral-share" tabindex="-1" aria-labelledby="pane-core-collateral-share"><header><h2 id="pane-core-collateral-share"><i class="icon-share" aria-hidden="true"></i>Share</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><h3>Share</h3><div class="section--wrapper"><section><h4>CONTENT LINK</h4><div id="share-self"><p data-id="article-share-self-link" class="share-self__source">https://www.nejm.org/doi/full/10.1056/NEJMoa1917346</p><button data-id="article-share-access" aria-label="CONTENT LINK" class="share-self__action btn btn--inverse"><i aria-hidden="true" class="icon-copy-o"></i><span>Copy Link</span></button><div aria-live="polite" class="share-self__status"><p class="share-self__success"><i aria-hidden="true" class="icon-check_circle"></i><span>Copied!</span></p><p class="share-self__failed"><i aria-hidden="true" class="icon-x_btnclose"></i><span>Copying failed.</span></p></div></div></section><section data-location="share_tools_article"><h4>Share</h4><div class="share-buttons a2a a2a_kit" style="line-height: 16px;"><a href="/#facebook" aria-label="Share on Facebook" data-id="article-share-facebook" rel="nofollow noopener" role="link" target="_blank" title="Share on Facebook" class="btn btn--facebook a2a_button_facebook" data-interactiontype="social"><i aria-hidden="true" class="icon-facebook"></i><span>Facebook</span></a><a href="/#twitter" aria-label="Share on X (formerly Twitter)" data-id="article-share-twitter" rel="nofollow noopener" role="link" target="_blank" title="Share on X (formerly Twitter)" class="btn btn--twitter a2a_button_twitter" data-interactiontype="social"><i aria-hidden="true" class="icon-twitter"></i><span>X (formerly Twitter)</span></a><a href="/#linkedin" aria-label="Share on LinkedIn" data-id="article-share-linkedin" rel="nofollow noopener" role="link" target="_blank" title="Share on LinkedIn" class="btn btn--linkedin a2a_button_linkedin" data-interactiontype="social"><i aria-hidden="true" class="icon-linkedin"></i><span>LinkedIn</span></a><a href="/#email" aria-label="Share on email" data-id="article-share-email" rel="nofollow noopener" role="link" target="_blank" title="Share on email" class="btn btn--email a2a_button_email" data-interactiontype="content_email_click"><i aria-hidden="true" class="icon-mail"></i><span>email</span></a><a href="/#bluesky" aria-label="Share on Bluesky" data-id="article-share-bluesky" rel="nofollow noopener" role="link" target="_blank" title="Share on Bluesky" class="btn btn--bluesky a2a_button_bluesky" data-interactiontype="social"><i aria-hidden="true" class="icon-bluesky"></i><span>Bluesky</span></a></div></section></div></div><div data-location="references_article" id="core-collateral-references" role="tabpanel" aria-labelledby="pane-core-collateral-references" data-core-tabs="core-collateral-references" tabindex="-1"><header><h2 id="pane-core-collateral-references"><i aria-hidden="true" class="icon-references"></i>References</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><h3>References</h3><div role="list" class="section--wrapper"><div role="listitem" data-has="label"><div class="label">1.</div><div id="core-r1" class="citations"><div class="citation"><div class="citation-content">Socinski MA, Jotte RM, Cappuzzo F, et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. <em>N Engl J Med</em> 2018;378:2288-2301.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r7-1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_2_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa1917346&amp;key=10.1056%2FNEJMoa1716948&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29863955/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000435099900006" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Atezolizumab+for+first-line+treatment+of+metastatic+nonsquamous+NSCLC.&amp;publication_year=2018&amp;journal=N+Engl+J+Med&amp;pages=2288-2301&amp;doi=10.1056%2FNEJMoa1716948&amp;pmid=29863955" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">2.</div><div id="core-r2" class="citations"><div class="citation"><div class="citation-content">Reck M, Mok TSK, Nishio M, et al. Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial. <em>Lancet Respir Med</em> 2019;7:387-401.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r7-1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S2213-2600(19)30084-0" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30922878/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000466494600015" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Atezolizumab+plus+bevacizumab+and+chemotherapy+in+non-small-cell+lung+cancer+%28IMpower150%29%3A+key+subgroup+analyses+of+patients+with+EGFR+mutations+or+baseline+liver+metastases+in+a+randomised%2C+open-label+phase+3+trial.&amp;publication_year=2019&amp;journal=Lancet+Respir+Med&amp;pages=387-401&amp;doi=10.1016%2FS2213-2600%2819%2930084-0&amp;pmid=30922878" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">3.</div><div id="core-r3" class="citations"><div class="citation"><div class="citation-content">Gandhi L, Rodríguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer. <em>N Engl J Med</em> 2018;378:2078-2092.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r7-1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_4_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa1917346&amp;key=10.1056%2FNEJMoa1801005&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29658856/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000433428000006" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Pembrolizumab+plus+chemotherapy+in+metastatic+non%E2%80%93small-cell+lung+cancer.&amp;publication_year=2018&amp;journal=N+Engl+J+Med&amp;pages=2078-2092&amp;doi=10.1056%2FNEJMoa1801005&amp;pmid=29658856" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">4.</div><div id="core-r4" class="citations"><div class="citation"><div class="citation-content">Paz-Ares L, Luft A, Vicente D, et al. Pembrolizumab plus chemotherapy for squamous non–small-cell lung cancer. <em>N Engl J Med</em> 2018;379:2040-2051.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r7-1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_5_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa1917346&amp;key=10.1056%2FNEJMoa1810865&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30280635/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000450816900009" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Pembrolizumab+plus+chemotherapy+for+squamous+non%E2%80%93small-cell+lung+cancer.&amp;publication_year=2018&amp;journal=N+Engl+J+Med&amp;pages=2040-2051&amp;doi=10.1056%2FNEJMoa1810865&amp;pmid=30280635" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">5.</div><div id="core-r5" class="citations"><div class="citation"><div class="citation-content">West H, McCleod M, Hussein M, et al. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. <em>Lancet Oncol</em> 2019;20:924-937.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r7-1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S1470-2045(19)30167-6" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31122901/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000473253800037" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Atezolizumab+in+combination+with+carboplatin+plus+nab-paclitaxel+chemotherapy+compared+with+chemotherapy+alone+as+first-line+treatment+for+metastatic+non-squamous+non-small-cell+lung+cancer+%28IMpower130%29%3A+a+multicentre%2C+randomised%2C+open-label%2C+phase+3+trial.&amp;publication_year=2019&amp;journal=Lancet+Oncol&amp;pages=924-937&amp;doi=10.1016%2FS1470-2045%2819%2930167-6&amp;pmid=31122901" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">6.</div><div id="core-r6" class="citations"><div class="citation"><div class="citation-content">Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1–positive non–small-cell lung cancer. <em>N Engl J Med</em> 2016;375:1823-1833.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r6-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_7_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa1917346&amp;key=10.1056%2FNEJMoa1606774&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27718847/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000387534200006" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Pembrolizumab+versus+chemotherapy+for+PD-L1%E2%80%93positive+non%E2%80%93small-cell+lung+cancer.&amp;publication_year=2016&amp;journal=N+Engl+J+Med&amp;pages=1823-1833&amp;doi=10.1056%2FNEJMoa1606774&amp;pmid=27718847" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r6-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r7-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] ALK). </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r7-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] in the United States and European Union. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">7.</div><div id="core-r7" class="citations"><div class="citation"><div class="citation-content">Reck M, Rodríguez-Abreu D, Robinson AG, et al. Updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater. <em>J Clin Oncol</em> 2019;37:537-546.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r7-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1200/JCO.18.00149" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30620668/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000460356200002" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Updated+analysis+of+KEYNOTE-024%3A+pembrolizumab+versus+platinum-based+chemotherapy+for+advanced+non-small-cell+lung+cancer+with+PD-L1+tumor+proportion+score+of+50%25+or+greater.&amp;publication_year=2019&amp;journal=J+Clin+Oncol&amp;pages=537-546&amp;doi=10.1200%2FJCO.18.00149&amp;pmid=30620668" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r7-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r7-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] ALK). </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r7-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] in the United States and European Union. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">8.</div><div id="core-r8" class="citations"><div class="citation"><div class="citation-content">Mok TSK, Wu Y-L, Kudaba I, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. <em>Lancet</em> 2019;393:1819-1830.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r8-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S0140-6736(18)32409-7" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30955977/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000466858700032" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Pembrolizumab+versus+chemotherapy+for+previously+untreated%2C+PD-L1-expressing%2C+locally+advanced+or+metastatic+non-small-cell+lung+cancer+%28KEYNOTE-042%29%3A+a+randomised%2C+open-label%2C+controlled%2C+phase+3+trial.&amp;publication_year=2019&amp;journal=Lancet&amp;pages=1819-1830&amp;doi=10.1016%2FS0140-6736%2818%2932409-7&amp;pmid=30955977" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r8-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r8-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] subgroup with the highest PD-L1 expression. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r8-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] high PD-L1 expression had the most benefit. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">9.</div><div id="core-r9" class="citations"><div class="citation"><div class="citation-content">Herbst RS, Soria J-C, Kowanetz M, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. <em>Nature</em> 2014;515:563-567.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r9"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/nature14011" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25428504/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000346247600053" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Predictive+correlates+of+response+to+the+anti-PD-L1+antibody+MPDL3280A+in+cancer+patients.&amp;publication_year=2014&amp;journal=Nature&amp;pages=563-567&amp;doi=10.1038%2Fnature14011&amp;pmid=25428504" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">10.</div><div id="core-r10" class="citations"><div class="citation"><div class="citation-content">Peters S, Gettinger S, Johnson ML, et al. Phase II trial of atezolizumab as first-line or subsequent therapy for patients with programmed death-ligand 1-selected advanced non-small-cell lung cancer (BIRCH). <em>J Clin Oncol</em> 2017;35:2781-2789.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r12"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1200/JCO.2016.71.9476" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28609226/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000407824700011" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Phase+II+trial+of+atezolizumab+as+first-line+or+subsequent+therapy+for+patients+with+programmed+death-ligand+1-selected+advanced+non-small-cell+lung+cancer+%28BIRCH%29.&amp;publication_year=2017&amp;journal=J+Clin+Oncol&amp;pages=2781-2789&amp;doi=10.1200%2FJCO.2016.71.9476&amp;pmid=28609226" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">11.</div><div id="core-r11" class="citations"><div class="citation"><div class="citation-content">Fehrenbacher L, Spira A, Ballinger M, et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. <em>Lancet</em> 2016;387:1837-1846.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r12"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S0140-6736(16)00587-0" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26970723/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000375056100032" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Atezolizumab+versus+docetaxel+for+patients+with+previously+treated+non-small-cell+lung+cancer+%28POPLAR%29%3A+a+multicentre%2C+open-label%2C+phase+2+randomised+controlled+trial.&amp;publication_year=2016&amp;journal=Lancet&amp;pages=1837-1846&amp;doi=10.1016%2FS0140-6736%2816%2900587-0&amp;pmid=26970723" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">12.</div><div id="core-r12" class="citations"><div class="citation"><div class="citation-content">Rittmeyer A, Barlesi F, Waterkamp D, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. <em>Lancet</em> 2017;389:255-265.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r12"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S0140-6736(16)32517-X" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27979383/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000392801200027" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Atezolizumab+versus+docetaxel+in+patients+with+previously+treated+non-small-cell+lung+cancer+%28OAK%29%3A+a+phase+3%2C+open-label%2C+multicentre+randomised+controlled+trial.&amp;publication_year=2017&amp;journal=Lancet&amp;pages=255-265&amp;doi=10.1016%2FS0140-6736%2816%2932517-X&amp;pmid=27979383" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">13.</div><div id="core-r13" class="citations"><div class="citation"><div class="citation-content">Hirsch FR, McElhinny A, Stanforth D, et al. PD-L1 immunohistochemistry assays for lung cancer: results from phase 1 of the Blueprint PD-L1 IHC assay comparison project. <em>J Thorac Oncol</em> 2017;12:208-222.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r13-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.jtho.2016.11.2228" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27913228/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000393266000006" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=PD-L1+immunohistochemistry+assays+for+lung+cancer%3A+results+from+phase+1+of+the+Blueprint+PD-L1+IHC+assay+comparison+project.&amp;publication_year=2017&amp;journal=J+Thorac+Oncol&amp;pages=208-222&amp;doi=10.1016%2Fj.jtho.2016.11.2228&amp;pmid=27913228" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r13-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r13-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] immune-checkpoint inhibitor treatment. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r20-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] measure PD-L1 expression on tumor cells. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r25" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] different assays were evaluated previously </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r20-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>d [...] cells and tumor-infiltrating immune cells. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">14.</div><div id="core-r14" class="citations"><div class="citation"><div class="citation-content">Roach C, Zhang N, Corigliano E, et al. Development of a companion diagnostic PD-L1 immunohistochemistry assay for pembrolizumab therapy in non-small-cell lung cancer. <em>Appl Immunohistochem Mol Morphol</em> 2016;24:392-397.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r14-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1097/PAI.0000000000000408" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27333219/" target="_blank">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Development+of+a+companion+diagnostic+PD-L1+immunohistochemistry+assay+for+pembrolizumab+therapy+in+non-small-cell+lung+cancer.&amp;publication_year=2016&amp;journal=Appl+Immunohistochem+Mol+Morphol&amp;pages=392-397&amp;doi=10.1097%2FPAI.0000000000000408&amp;pmid=27333219" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r14-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r15-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] assays (22C3 and SP263), </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r20-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] measure PD-L1 expression on tumor cells. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r20-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] cells and tumor-infiltrating immune cells. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">15.</div><div id="core-r15" class="citations"><div class="citation"><div class="citation-content">Rebelatto MC, Midha A, Mistry A, et al. Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma. <em>Diagn Pathol</em> 2016;11:95-95.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r15-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1186/s13000-016-0545-8" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27717372/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000385452700001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Development+of+a+programmed+cell+death+ligand-1+immunohistochemical+assay+validated+for+analysis+of+non-small+cell+lung+cancer+and+head+and+neck+squamous+cell+carcinoma.&amp;publication_year=2016&amp;journal=Diagn+Pathol&amp;pages=95-95&amp;doi=10.1186%2Fs13000-016-0545-8&amp;pmid=27717372" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r15-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r15-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] assays (22C3 and SP263), </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r20-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] measure PD-L1 expression on tumor cells. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r20-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] cells and tumor-infiltrating immune cells. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">16.</div><div id="core-r16" class="citations"><div class="citation"><div class="citation-content">Greillier L, Tomasini P, Barlesi F. The clinical utility of tumor mutational burden in non-small cell lung cancer. <em>Transl Lung Cancer Res</em> 2018;7:639-646.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r19-1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.21037/tlcr.2018.10.08" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30505708/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000450328200004" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=The+clinical+utility+of+tumor+mutational+burden+in+non-small+cell+lung+cancer.&amp;publication_year=2018&amp;journal=Transl+Lung+Cancer+Res&amp;pages=639-646&amp;doi=10.21037%2Ftlcr.2018.10.08&amp;pmid=30505708" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">17.</div><div id="core-r17" class="citations"><div class="citation"><div class="citation-content">Hellmann MD, Ciuleanu T-E, Pluzanski A, et al. Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden. <em>N Engl J Med</em> 2018;378:2093-2104.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r17-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_18_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa1917346&amp;key=10.1056%2FNEJMoa1801946&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29658845/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000433428000007" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Nivolumab+plus+ipilimumab+in+lung+cancer+with+a+high+tumor+mutational+burden.&amp;publication_year=2018&amp;journal=N+Engl+J+Med&amp;pages=2093-2104&amp;doi=10.1056%2FNEJMoa1801946&amp;pmid=29658845" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r17-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r19-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] who may benefit from immunotherapy. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r29" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] survival, or both in this context. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">18.</div><div id="core-r18" class="citations"><div class="citation"><div class="citation-content">Gandara DR, Paul SM, Kowanetz M, et al. Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab. <em>Nat Med</em> 2018;24:1441-1448.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r18-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/s41591-018-0134-3" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30082870/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000444174100029" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Blood-based+tumor+mutational+burden+as+a+predictor+of+clinical+benefit+in+non-small-cell+lung+cancer+patients+treated+with+atezolizumab.&amp;publication_year=2018&amp;journal=Nat+Med&amp;pages=1441-1448&amp;doi=10.1038%2Fs41591-018-0134-3&amp;pmid=30082870" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r18-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r19-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] who may benefit from immunotherapy. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r18-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] somatic mutations to generate a score. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r24-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] approximately 14.5 mutations per megabase. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r18-4" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>d [...] consistent with those of previous trials. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">19.</div><div id="core-r19" class="citations"><div class="citation"><div class="citation-content">Rizvi NA, Cho BC, Reinmuth N, et al. Blood tumor mutational burden (bTMB) and tumor PD-L1 as predictive biomarkers of survival in MYSTIC: first-line durvalumab (D) ± tremelimumab (T) versus chemotherapy (CT) in metastatic (m) NSCLC. <em>J Clin Oncol</em> 2019;37:Suppl 15:9016-9016. abstract.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r19-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1200/JCO.2019.37.15_suppl.9016" target="_blank">Crossref</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000487345806460" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Blood+tumor+mutational+burden+%28bTMB%29+and+tumor+PD-L1+as+predictive+biomarkers+of+survival+in+MYSTIC%3A+first-line+durvalumab+%28D%29+%C2%B1+tremelimumab+%28T%29+versus+chemotherapy+%28CT%29+in+metastatic+%28m%29+NSCLC.&amp;publication_year=2019&amp;journal=J+Clin+Oncol&amp;pages=9016-9016&amp;doi=10.1200%2FJCO.2019.37.15_suppl.9016" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r19-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r19-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] who may benefit from immunotherapy. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r29" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] survival, or both in this context. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">20.</div><div id="core-r20" class="citations"><div class="citation"><div class="citation-content">Vennapusa B, Baker B, Kowanetz M, et al. Development of a PD-L1 complementary diagnostic immunohistochemistry assay (SP142) for atezolizumab. <em>Appl Immunohistochem Mol Morphol</em> 2019;27:92-100.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r20-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1097/PAI.0000000000000594" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29346180/" target="_blank">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Development+of+a+PD-L1+complementary+diagnostic+immunohistochemistry+assay+%28SP142%29+for+atezolizumab.&amp;publication_year=2019&amp;journal=Appl+Immunohistochem+Mol+Morphol&amp;pages=92-100&amp;doi=10.1097%2FPAI.0000000000000594&amp;pmid=29346180" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r20-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r20-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] determined by the SP142 assay was required. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r20-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] measure PD-L1 expression on tumor cells. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r20-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] cells and tumor-infiltrating immune cells. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">21.</div><div id="core-r21" class="citations"><div class="citation"><div class="citation-content">Barlesi F, Nishio M, Cobo M, et al. IMpower132: efficacy of atezolizumab (atezo) carboplatin (carbo)/cisplatin (cis) + pemetrexed (pem) as 1L treatment in key subgroups with stage IV non-squamous non-small cell lung cancer (NSCLC). <em>Ann Oncol</em> 2018;29:Suppl 8:LBA54-LBA54. abstract.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r23"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1093/annonc/mdy424.066" target="_blank">Crossref</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000459277305002" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=IMpower132%3A+efficacy+of+atezolizumab+%28atezo%29+carboplatin+%28carbo%29%2Fcisplatin+%28cis%29+%2B+pemetrexed+%28pem%29+as+1L+treatment+in+key+subgroups+with+stage+IV+non-squamous+non-small+cell+lung+cancer+%28NSCLC%29.&amp;publication_year=2018&amp;journal=Ann+Oncol&amp;pages=LBA54-LBA54&amp;doi=10.1093%2Fannonc%2Fmdy424.066" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">22.</div><div id="core-r22" class="citations"><div class="citation"><div class="citation-content">Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non–small-cell lung cancer. <em>N Engl J Med</em> 2015;373:1627-1639.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r23"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_23_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa1917346&amp;key=10.1056%2FNEJMoa1507643&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26412456/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000363317800008" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Nivolumab+versus+docetaxel+in+advanced+nonsquamous+non%E2%80%93small-cell+lung+cancer.&amp;publication_year=2015&amp;journal=N+Engl+J+Med&amp;pages=1627-1639&amp;doi=10.1056%2FNEJMoa1507643&amp;pmid=26412456" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">23.</div><div id="core-r23" class="citations"><div class="citation"><div class="citation-content">Herbst RS, Baas P, Kim D-W, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. <em>Lancet</em> 2016;387:1540-1550.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r23"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S0140-6736(15)01281-7" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/26712084/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000373741600030" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Pembrolizumab+versus+docetaxel+for+previously+treated%2C+PD-L1-positive%2C+advanced+non-small-cell+lung+cancer+%28KEYNOTE-010%29%3A+a+randomised+controlled+trial.&amp;publication_year=2016&amp;journal=Lancet&amp;pages=1540-1550&amp;doi=10.1016%2FS0140-6736%2815%2901281-7&amp;pmid=26712084" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">24.</div><div id="core-r24" class="citations"><div class="citation"><div class="citation-content">Socinski M, Velcheti V, Mekhail T, et al. Final efficacy results from B-F1RST, a prospective phase II trial evaluating blood-based tumour mutational burden (bTMB) as a predictive biomarker for atezolizumab (atezo) in 1L non-small cell lung cancer (NSCLC). <em>Ann Oncol</em> 2019;30:Suppl 5:LBA83-LBA83. abstract.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r24-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1093/annonc/mdz394.081" target="_blank">Crossref</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000491295500207" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Final+efficacy+results+from+B-F1RST%2C+a+prospective+phase+II+trial+evaluating+blood-based+tumour+mutational+burden+%28bTMB%29+as+a+predictive+biomarker+for+atezolizumab+%28atezo%29+in+1L+non-small+cell+lung+cancer+%28NSCLC%29.&amp;publication_year=2019&amp;journal=Ann+Oncol&amp;pages=LBA83-LBA83&amp;doi=10.1093%2Fannonc%2Fmdz394.081" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r24-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r24-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] approximately 14.5 mutations per megabase. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r24-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] for death, 0.66; 90% CI, 0.40 to 1.10). </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">25.</div><div id="core-r25" class="citations"><div class="citation"><div class="citation-content">Tsao MS, Kerr KM, Kockx M, et al. PD-L1 immunohistochemistry comparability study in real-life clinical samples: results of Blueprint phase 2 project. <em>J Thorac Oncol</em> 2018;13:1302-1311.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r25"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.jtho.2018.05.013" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29800747/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000444520200022" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=PD-L1+immunohistochemistry+comparability+study+in+real-life+clinical+samples%3A+results+of+Blueprint+phase+2+project.&amp;publication_year=2018&amp;journal=J+Thorac+Oncol&amp;pages=1302-1311&amp;doi=10.1016%2Fj.jtho.2018.05.013&amp;pmid=29800747" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">26.</div><div id="core-r26" class="citations"><div class="citation"><div class="citation-content">Garassino M, Rodriguez-Abreu D, Gadgeel S, et al. Evaluation of TMB in KEYNOTE-189: pembrolizumab plus chemotherapy vs placebo plus chemotherapy for nonsquamous NSCLC. <em>J Thorac Oncol</em> 2019;14:Suppl:OA04.6-OA04.6. abstract.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r26"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.jtho.2019.08.427" target="_blank">Crossref</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000492162201112" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Evaluation+of+TMB+in+KEYNOTE-189%3A+pembrolizumab+plus+chemotherapy+vs+placebo+plus+chemotherapy+for+nonsquamous+NSCLC&amp;publication_year=2019&amp;journal=J+Thorac+Oncol&amp;pages=OA04.6-OA04.6&amp;doi=10.1016%2Fj.jtho.2019.08.427" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">27.</div><div id="core-r27" class="citations"><div class="citation"><div class="citation-content">Peters S, Cho BC, Reinmuth N, et al. Tumor mutational burden (TMB) as a biomarker of survival in metastatic non-small cell lung cancer (mNSCLC): blood and tissue TMB analysis from MYSTIC, a Phase III study of first-line durvalumab ± tremelimumab vs chemotherapy. <em>Cancer Res</em> 2019;79:Suppl 13:CT074-CT074. abstract.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r29"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1158/1538-7445.AM2019-CT074" target="_blank">Crossref</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000488129900065" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Tumor+mutational+burden+%28TMB%29+as+a+biomarker+of+survival+in+metastatic+non-small+cell+lung+cancer+%28mNSCLC%29%3A+blood+and+tissue+TMB+analysis+from+MYSTIC%2C+a+Phase+III+study+of+first-line+durvalumab+%C2%B1+tremelimumab+vs+chemotherapy.&amp;publication_year=2019&amp;journal=Cancer+Res&amp;pages=CT074-CT074&amp;doi=10.1158%2F1538-7445.AM2019-CT074" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">28.</div><div id="core-r28" class="citations"><div class="citation"><div class="citation-content">Hellmann MD, Paz-Ares L, Bernabe Caro R, et al. Nivolumab plus ipilimumab in advanced non–small-cell lung cancer. <em>N Engl J Med</em> 2019;381:2020-2031.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r29"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_29_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa1917346&amp;key=10.1056%2FNEJMoa1910231&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31562796/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000505218800006" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Nivolumab+plus+ipilimumab+in+advanced+non%E2%80%93small-cell+lung+cancer.&amp;publication_year=2019&amp;journal=N+Engl+J+Med&amp;pages=2020-2031&amp;doi=10.1056%2FNEJMoa1910231&amp;pmid=31562796" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">29.</div><div id="core-r29" class="citations"><div class="citation"><div class="citation-content">Herbst RS, Lopes G, Kowalski DM, et al. Association between tissue TMB (tTMB) and clinical outcomes with pembrolizumab monotherapy (pembro) in PD-L1-positive advanced NSCLC in the KEYNOTE-010 and -042 trials. <em>Ann Oncol</em> 2019;30:Suppl 5:v916-v917. abstract.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r29"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1093/annonc/mdz394.077" target="_blank">Crossref</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000491295500203" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Association+between+tissue+TMB+%28tTMB%29+and+clinical+outcomes+with+pembrolizumab+monotherapy+%28pembro%29+in+PD-L1-positive+advanced+NSCLC+in+the+KEYNOTE-010+and+-042+trials.&amp;publication_year=2019&amp;journal=Ann+Oncol&amp;pages=v916-v917&amp;doi=10.1093%2Fannonc%2Fmdz394.077" target="_blank">Google Scholar</a></div></div></div></div></div></div></div></div><aside data-core-aside="right-rail">



        
        <div id="DTM_Position_MedRectangle" class="ad">
 <!--emptycomment-->
</div>




        
        <div class="ng-page_layout-sidebarSpacing"></div>










    
    
        <div data-widget-def="relatedArticlesWidget" data-widget-id="8206d5cd-cb8c-4ff9-8c46-3d22e0dee215" data-location="recirc_curatedRelated_article">
        



        
        <div class="ng-related-articles"><h3 class="ng-subsection-title"><span class="ng-subsection-title_text">Related articles</span></h3><ul class="ng-related-articles_list"><li class="ng-related-articles_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/correspondence" class="issue-item_type">Correspondence</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Feb 10, 2021</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMc2032432" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Atezolizumab for PD-L1–Selected Patients with NSCLC</a></h4><div class="issue-item_authors-and-text"></div></div></div></div></div></li></ul></div>

        </div>
    





        
        <div class="ng-page_layout-sidebarSpacing"></div>




        
        <div id="nejm_jobs" class="nejm_jobs"> <!-- top red rectangle --><div id="nejm-widget" class="nejm-widget" style="display: block;"><div class="nejm-widget_logo">	<a target="nejm-win" href="https://www.nejmcareercenter.org/?query=fjw">		<img alt="CareerCenter" src="https://apps1.nejmcareercenter.org/images/nejmCCID-JobsWidget.gif" width="140" height="36">	</a></div><div class="nejm-widget_cont"> <!-- content --><div class="nejm-widget_title">PHYSICIAN JOBS</div><div class="nejm-widget_date">June 9, 2025</div><div class="nejm-widget_item"><div><span> New York</span></div><div><span>Dermatology</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/824124/seeking-various-dermatologists-across-northwell-health/?query=fjwp&amp;rid=3059">Seeking Various Dermatologists Across Northwell Health</a></div></div><div class="nejm-widget_item"><div><span> Gainesville, Florida</span></div><div><span>Hematology / Oncology</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/889005/university-of-florida-seeking-hematologist-oncologist-w-interest-in-lymphoid-malignancies-/?query=fjwp&amp;rid=68409">University of Florida Seeking Hematologist/Oncologist w/ Interest in Lymphoid Malignancies </a></div></div><div class="nejm-widget_item"><div><span> Brewster, New York</span></div><div><span>Rheumatology</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/878388/rheumatology-physician-offering-flexible-schedule-32-patient-facing-hours-/?query=fjwf&amp;rid=220874">Rheumatology Physician - Offering Flexible Schedule (32 patient facing hours)</a></div></div><div class="nejm-widget_item"><div><span> Toledo, Ohio</span></div><div><span>Endocrinology</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/883912/endocrinologist-320k-/?query=fjwf&amp;rid=346908">Endocrinologist - 320K!</a></div></div><div class="nejm-widget_item"><div><span> New Mexico</span></div><div><span>Cardiology</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/890927/non-invasive-cardiologist-nationally-recognized-program-in-albuquerque-nm/?query=fjwf&amp;rid=5127">Non-Invasive Cardiologist - Nationally Recognized Program in Albuquerque, NM</a></div></div><div class="nejm-widget_item"><div><span> San Antonio, Texas</span></div><div><span>Family Medicine</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/854977/family-internal-medicine-physician/?query=fjwf&amp;rid=12619">Family/Internal Medicine Physician</a></div></div></div> <!-- content --> <!-- footer --></div> <!-- nejm-widget --></div><script src="https://apps1.nejmcareercenter.org/?width=300&amp;sp=all"></script>




        
        <div class="ng-page_layout-sidebarSpacing"></div>










    
    
        <div data-widget-def="literatumAd" data-widget-id="001e4aa7-b6fe-4b21-9d5b-5bde81227c67" id="ad-article-right-rail-300x250-1">
        



        
        



    
        <div class="pb-house-message adplaceholder exists">
            <a href="/action/clickThrough?id=128129&amp;url=https%3A%2F%2Fstore.nejm.org%2Fsignup%2Fnejm%2Fregister%2Falerts%3Fpromo%3DONFQSR51%26query%3Dcm_rr%26utm_source%3Dnejm%26utm_medium%3Dcm%26utm_campaign%3Dalerts23&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa1917346&amp;pubId=41289147&amp;placeholderId=101337&amp;productId=1035"><img src="/sda/128129/rightRail--SpecialtyUpdates23-001.jpg" width="300" height="250"></a>
            
        </div>
    

    

    



        </div>
    





        
        <div class="ng-page_layout-sidebarSpacing"></div>




        
        <script src="https://widgets.nejm.org/onepub-widgets/loader/webcomponents-loader.js" async="" nonce="94d64c3dc210a517-SJC">
<script src="https://widgets.nejm.org/onepub-widgets/loader/polyfill-support.js"  nonce="94d64c3dc210a517-SJC"></script>
<script src="https://widgets.nejm.org/onepub-widgets/more-like-this.js" type="module" nonce="94d64c3dc210a517-SJC"></script>

<more-like-this class="onepub-widget" dataid="onepub-more-like-this" collections="catalyst-article, clinician-article, evidence-article, nejm-ai-article, nejm-article" headertitle="More Like This" maxitems="5"><!----><div class="more-like-this onepub-more-like-this_"><!--?lit$784262775$--><onepub-fonts><wc-fetch></wc-fetch><!--?lit$784262775$--><div class="mlt-wrapper"><div class="mlt-header-container"><div class="mlt-header-content-left"><div class="mlt-header-title-container"><span class="mlt-header-title">More Like This</span></div><!--?lit$784262775$--></div></div><div class="mlt-body"><!--?lit$784262775$--><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/original-article" target="_self"><!--?lit$784262775$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$784262775$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$784262775$-->Sep 07, 2023</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2303383?query=recirc_Semantic" target="_self">Atezolizumab for Advanced Alveolar Soft Part Sarcoma</a></div><div class="mlt-article-authors"><!--?lit$784262775$-->A.P. Chen and Others</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/original-article" target="_self"><!--?lit$784262775$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$784262775$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$784262775$-->May 14, 2020</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMoa1915745?query=recirc_Semantic" target="_self">Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma</a></div><div class="mlt-article-authors"><!--?lit$784262775$-->R.S. Finn and Others</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/original-article" target="_self"><!--?lit$784262775$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$784262775$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$784262775$-->Jan 02, 2025</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2401726?query=recirc_Semantic" target="_self">Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma</a></div><div class="mlt-article-authors"><!--?lit$784262775$-->A.B. Apolo and Others</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/editorial" target="_self"><!--?lit$784262775$-->Editorial</a> <span class="mlt-article-site-label"><!--?lit$784262775$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$784262775$-->May 16, 2024</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMe2403723?query=recirc_Semantic" target="_self">Neoadjuvant or Perioperative Approach in Lung Cancer</a></div><div class="mlt-article-authors"><!--?lit$784262775$-->M.C. Garassino and V. Torri</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/original-article" target="_self"><!--?lit$784262775$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$784262775$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$784262775$-->Apr 18, 2024</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2312695?query=recirc_Semantic" target="_self">Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma</a></div><div class="mlt-article-authors"><!--?lit$784262775$-->T.K. Choueiri and Others</div></div><!----></div><div class="mlt-footer"></div></div></onepub-fonts><style>:host{display:block}@keyframes fadeIn{0%{opacity:0}100%{opacity:1}}.more-like-this{max-width:25rem}.more-like-this *{font-variant-numeric:lining-nums}.mlt-wrapper{animation:fadeIn 1s}.mlt-header-container{border-bottom:#4d4d4d solid .0625rem;border-top:#4d4d4d solid .125rem}.mlt-header-title{color:#1a1a1a;display:block;font-family:var(--sans-serif);font-size:1rem;font-weight:700;letter-spacing:.02rem;line-height:1.5rem;padding-bottom:.94rem;padding-top:.94rem;text-transform:uppercase}.mlt-header-description{color:#333;display:block;font-family:ff-scala-sans-pro;font-size:.75rem;letter-spacing:.05rem;margin-top:-.5rem;padding-bottom:1rem;text-transform:uppercase}.mlt-article-container{border-bottom:#e5e5e5 solid .0625rem;margin-top:1.38rem}.mlt-article-container-header{font-family:var(--sans-serif);font-size:.6875rem;letter-spacing:.04em;line-height:1.125rem;margin:0 0 1rem;text-transform:uppercase}.mlt-article-type{font-weight:700;line-height:1.25rem;letter-spacing:.04rem;text-decoration:none}.mlt-article-type:hover{text-decoration:underline}.nejm{color:#f30}.nejm-ai{color:#006197}.nejm-catalyst{color:#5708a6}.nejm-evidence{color:#69a323}.mlt-article-site-label::after,.mlt-article-type::after{border-right:1px solid #e5e5e5;content:'';display:inline;padding:.1875rem .375rem .125rem 0;margin:0 .375rem 0 0}.mlt-article-pubdate{color:#666;font-style:normal;font-weight:700;line-height:1.25rem;letter-spacing:.04em}.mlt-article-authors{color:#666;font-family:var(--sans-serif);font-size:1rem;font-style:normal;font-weight:400;letter-spacing:normal;line-height:1.5rem;margin-bottom:1.38rem}.mlt-article-site-label{color:#666;font-style:normal;font-weight:700;letter-spacing:.04em}.mlt-article-title{margin-bottom:.5rem}.mlt-article-title>a{background-image:linear-gradient(#f30,#f30);background-position:0 90%;background-repeat:no-repeat;background-size:0 0;color:#1a1a1a;font-family:var(--quadraat-web);font-size:1.25rem;font-style:normal;font-weight:700;letter-spacing:normal;line-height:1.8rem;margin:1.5rem 0 .35rem 0;text-decoration:none;transition:background .25s ease-in-out}.mlt-article-title>a:hover{background-position:0 98%;background-size:100% .125rem;text-decoration:none}.skeleton-card{box-shadow:0 0 4px 1px rgba(0,0,0,.1);margin:1rem 0;padding:1rem}</style></div></more-like-this>




        
        <div><div class="pb-dropzone" data-pb-dropzone="col-0" title="col-0"></div></div>










    
    
        <div data-widget-def="UX3HTMLWidget" data-widget-id="ad06db99-f228-4c92-9ad7-c4ae0fdbdbf1" id="bc-web-rec">
        



        
        <!-- BlueConic TEST empty HTML widget with DIV wrapper with id=bc-web-rec -->

        </div>
    

</aside></article><div data-extent="article-wrapper"><div class="core-container"></div><div class="after-credits"><div class="core-container"><a href="/doi/pdf/10.1056/NEJMoa1917346?download=true" id="downloadPdfUrl" data-doi="10.1056/NEJMoa1917346" data-behavior="trackDownloadEvent" data-interactiontype="article_tools_download_pdf" data-multimedia-type="Article PDF" data-multimedia-filename="nejmoa1917346.pdf"><span>Download PDF</span></a></div></div></div><script id="axel-publication-metadata" type="application/json">{"doi":"10.1056/NEJMoa1917346"}
</script><script type="text/javascript" data-ot-ignore="data-ot-ignore" defer="defer" src="https://static.addtoany.com/menu/page.js" class="optanon-category-C0004 ot-vscat-C0004"></script><div class="articles-nav"></div><template id="figure_nav_template"><nav><a href="#" title="Open in viewer" class="open-in-viewer"><i aria-hidden="true" class="icon-expand"></i></a></nav></template><template id="fv_panel_template" data-sharesocial="Share"><div class="fv__panel js--hidden"><div class="fv__panel__text"><div class="fv__panel__contentTitle"></div><div class="fv__panel__contentText"></div></div></div></template>
<template id="fv_directory_template" data-overlay="View figure"><div class="fv__directory"><div class="fv__header"><nav class="tab__nav"></nav><a href="#" title="Close figure viewer" class="fv__close"><i aria-hidden="true" class="icon-close"></i></a></div><div class="fv__content tab__content"></div></div></template><template id="fv_directory_tabItem_template" data-figures="Figures" data-others="Others" data-tables="Tables"><button role="tab" data-toggle="tab" class="tab__nav__item"></button></template>
<template id="fv_lightbox_template" data-sr-back="Go to figure location within the article" data-sr-closealt="Close" data-sr-download="Toggle download panel" data-sr-download-pptx="Download PPT" data-sr-info="Toggle information panel" data-sr-panel="Close panel" data-sr-share="Toggle share panel" data-sr-zoom="Zoom" data-text-close="Back to article" data-text-nav-figures="All figures" data-text-nav-others="All others" data-text-nav-tables="All tables" data-text-viewall="View all material" data-title-back="Back to article" data-title-closealt="Close" data-title-download="Download" data-title-download-pptx="Download PPT" data-title-info="Info" data-title-share="Share" data-title-zoom="Zoom"></template>
<template id="fv_toolbar_template"><div class="fv__toolbar__info"><strong class="fv__toolbar__contentTitle uppercase"></strong><p class="fv__toolbar__contentText"></p></div></template><template id="toCitationLink" data-citation="Citation" data-footnote="Footnote"><div class="to-citation__wrapper"><a class="to-citation"><i aria-hidden="true" class="icon-return"></i><span>Go to</span></a></div></template><template id="toCitationButton" data-citation="Citation" data-footnote="Footnote"><div class="to-citation__wrapper"><button class="to-citation"><i aria-hidden="true" class="icon-return"></i><span>Go to</span></button></div></template><template id="toCitationAccordion" data-collapse-citation="Hide Citations" data-expand-citation="Show Citations" data-collapse-footnote="Hide Footnotes" data-expand-footnote="Show Footnotes"><div class="to-citation__wrapper"><button aria-controls="aria-controls" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="data-expand-title" data-collapsed-title="data-collapsed-title" class="accordion__toggle__title"></span></button><div role="menu" aria-label="links" class="to-citation__accordion no-separator"><ul></ul></div></div></template><template id="toCitationAccordionItem"><li><a class="to-citation"><i aria-hidden="true" class="icon-return"></i><span></span></a></li></template><template id="citations_truncate_template"><div class="citations-truncation"><button data-label-expand="Show all references" data-label-collapse="Show fewer" data-label-remaining="references remaining" class="btn btn--secondary"><span>Show all references</span></button></div></template><template id="collateral_texts_template" data-references="References" data-figure="Go to Figure" data-media="Go to Media" data-more="More" data-original="Go to original" data-table="Go to Table" data-inviewer="Open in Viewer" data-allinviewer="Open all in viewer"><svg data-tags="copyright" viewBox="0 0 24 24"><path d="M12 20.016q3.281 0 5.648-2.368T20.016 12t-2.368-5.648T12 3.984 6.352 6.352 3.984 12t2.368 5.648T12 20.016zm0-18q4.125 0 7.055 2.93T21.985 12t-2.93 7.055T12 21.985t-7.055-2.93T2.015 12t2.93-7.055T12 2.015zm-.14 7.125q-1.876 0-1.876 2.718v.282q0 2.718 1.875 2.718.704 0 1.172-.398t.469-1.008h1.781q0 1.172-1.031 2.063-.984.843-2.39.843-1.876 0-2.86-1.125t-.984-3.093v-.282q0-1.921.937-3 1.125-1.265 2.906-1.265 1.547 0 2.438.89.984.985.984 2.297H13.5q0-.328-.14-.61-.235-.468-.329-.562-.469-.468-1.172-.468z"></path></svg><span>Request permissions</span><i aria-hidden="true" class="icon-open_in_new"></i></template><template id="collapsible_authors_template"><button aria-expanded="false" data-expandable="all" data-label-expand="Expand All" data-label-collapse="Collapse All" class="collateral-contributors-control"><span>Expand All</span></button></template>
<template id="collapsible_tables_collapse_template"><div class="collapsible-figure-btn__wrapper expanded"><button aria-expanded="true" class="btn collapsible-figure-btn btn--inverse"><i aria-hidden="true" class="icon-arrow-up"></i><span class="text-uppercase">Collapse</span></button></div></template>
<template id="collapsible_tables_expand_template"><div class="collapsible-figure-btn__wrapper collapsed"><button aria-expanded="false" class="btn collapsible-figure-btn btn--inverse"><i aria-hidden="true" class="icon-arrow-down"></i><span class="text-uppercase">Expand Table</span></button></div></template><template id="authorsAffiliationsLink"><a href="#tab-contributors" class="to-authors-affiliations">Authors Info &amp; Affiliations</a></template>

        <div role="navigation" aria-label="Sticky Navigation" class="st-header"><div class="st-header__content"><div class="st-header__item st-header__menu"></div><div class="st-header__current st-header__item"><div class="st-header__label">Now Reading:</div><div class="st-header__title">Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC</div></div><div class="st-header__share st-header__item"><div class="share-dropblock dropdown"><a id="sticky-header-dropBlock" href="#" role="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false" class="dropdown-toggle"><span title="" data-toggle="tooltip" data-trigger="hover" data-original-title="Share options"><span class="sr-only">Share</span><i aria-hidden="true" class="icon-share"></i></span></a><div aria-labelledby="sticky-header-dropBlock" data-location="share_tools_article" class="dropdown-menu"><ul class="rlist--inline a2a a2a_kit" style="line-height: 16px;"><li><a href="/#facebook" aria-label="Share on Facebook" data-id="article-share-facebook" rel="nofollow noopener" role="link" target="_blank" title="Share on Facebook" class="btn btn--facebook a2a_button_facebook" data-interactiontype="social"><i aria-hidden="true" class="icon-facebook"></i></a></li><li><a href="/#twitter" aria-label="Share on X (formerly Twitter)" data-id="article-share-twitter" rel="nofollow noopener" role="link" target="_blank" title="Share on X (formerly Twitter)" class="btn btn--twitter a2a_button_twitter" data-interactiontype="social"><i aria-hidden="true" class="icon-twitter"></i></a></li><li><a href="/#linkedin" aria-label="Share on LinkedIn" data-id="article-share-linkedin" rel="nofollow noopener" role="link" target="_blank" title="Share on LinkedIn" class="btn btn--linkedin a2a_button_linkedin" data-interactiontype="social"><i aria-hidden="true" class="icon-linkedin"></i></a></li><li><a href="/#email" aria-label="Share on email" data-id="article-share-email" rel="nofollow noopener" role="link" target="_blank" title="Share on email" class="btn btn--email a2a_button_email" data-interactiontype="content_email_click"><i aria-hidden="true" class="icon-mail"></i></a></li><li><a href="/#bluesky" aria-label="Share on Bluesky" data-id="article-share-bluesky" rel="nofollow noopener" role="link" target="_blank" title="Share on Bluesky" class="btn btn--bluesky a2a_button_bluesky" data-interactiontype="social"><i aria-hidden="true" class="icon-bluesky"></i></a></li></ul></div></div></div><div class="st-header__nav st-header__item"><div class="content-navigation"><a href="/doi/full/10.1056/NEJMoa2019910" aria-label="Previous article" aria-disabled="false" class="content-navigation__prev"><div aria-hidden="true" class="content-navigation__hint"><div class="content-navigation__hint__content"><h6>PREVIOUS ARTICLE</h6><div>Evolocumab in Pediatric Heterozygous Familial Hypercholesterolemia</div></div></div><i aria-hidden="true" class="icon-arrow-left"></i><span>Previous</span></a><a href="/doi/full/10.1056/NEJMoa1917338" aria-label="Next article" aria-disabled="false" class="content-navigation__next"><div aria-hidden="true" class="content-navigation__hint"><div class="content-navigation__hint__content"><h6>NEXT ARTICLE</h6><div>HPV Vaccination and the Risk of Invasive Cervical Cancer</div></div></div><span>Next</span><i aria-hidden="true" class="icon-arrow-right"></i></a></div></div></div><div class="st-header__track"><div id="progress-tracker" class="st-header__tracker" style="width: 0px;"></div></div></div><div class="fv figureViewer js--has-focus-mode"><div class="fv__directory" data-core-tabs="default" style="display: flex;"><div class="fv__header"><nav class="tab__nav" role="tablist"><button role="tab" data-toggle="tab" class="tab__nav__item active" aria-controls="#tab-pane-figures" aria-selected="true">Figures</button><button role="tab" data-toggle="tab" class="tab__nav__item" aria-controls="#tab-pane-tables" tabindex="-1" aria-selected="false">Tables</button></nav><a href="#" title="Close figure viewer" class="fv__close"><i aria-hidden="true" class="icon-close"></i></a></div><div class="fv__content tab__content"><div class="tab__pane fv__list fv__list--figures" id="tab-pane-figures" aria-label="All figures" tabindex="0" role="tabpanel"><div class="fv__item"><a class="fv__open-item fv__item__view fv__fit" href="#fv-f1" data-type="figures" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa1917346_f1.jpg"><img src="/cms/10.1056/NEJMoa1917346/asset/4ab0fe9d-3f41-4880-900c-a2685477da75/assets/images/large/nejmoa1917346_f1.jpg" height="3281" width="2640" aria-labelledby="f1" loading="lazy"><span class="fv__fit--overlay"><span>View figure</span></span></a><div class="fv__item__title">Figure 1</div><div class="fv__item__description"><figcaption><div class="caption">Overall Survival in the Atezolizumab Group and the Chemotherapy Group.</div><div class="notes"><div role="doc-footnote">Shown are Kaplan–Meier estimates of overall survival among the patients whose tumors were wild-type with respect to <i>EGFR</i> mutations or <i>ALK</i> translocations. High expression of programmed death ligand 1 (PD-L1) indicates PD-L1 expression on at least 50% of tumor cells or at least 10% of tumor-infiltrating immune cells as assessed by the SP142 immunohistochemical assay (Panel A). High or intermediate PD-L1 expression indicates PD-L1 expression on at least 5% of tumor cells or tumor-infiltrating immune cells (Panel B). Any PD-L1 expression indicates PD-L1 expression on at least 1% of tumor cells or tumor-infiltrating immune cells. Stratified hazard ratios are given according to the level of PD-L1 expression. Treatment comparisons (atezolizumab vs. platinum-based chemotherapy) for the primary end point of overall survival were based on a stratified log-rank test. Medians were estimated with the use of the Kaplan–Meier method. A stratified Cox regression model was used to estimate hazard ratios, and 95% confidence intervals (CIs) were calculated with the use of the Brookmeyer–Crowley method. The results for overall survival among patients who had high or intermediate PD-L1 expression did not cross the prespecified alpha boundary, so overall survival among patients who had any PD-L1 expression was not formally tested. Tick marks indicate censored data. NE denotes could not be estimated.</div></div></figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view fv__fit" href="#fv-f2" data-type="figures" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa1917346_f2.jpg"><img src="/cms/10.1056/NEJMoa1917346/asset/6823ac0b-3cf5-4753-8876-bd50406faefb/assets/images/large/nejmoa1917346_f2.jpg" height="3058" width="2640" aria-labelledby="f2" loading="lazy"><span class="fv__fit--overlay"><span>View figure</span></span></a><div class="fv__item__title">Figure 2</div><div class="fv__item__description"><figcaption><div class="caption">Overall Survival among Patients with High PD-L1 Expression, According to Immunohistochemical Assay.</div><div class="notes"><div role="doc-footnote">Panel A shows the overlap among patients with a tumor proportion score of at least 50% as assessed by the 22C3 assay, patients with PD-L1 expression on at least 50% of tumor cells as assessed by the SP263 assay, and patients with PD-L1 expression on at least 50% of tumor cells or at least 10% of tumor-infiltrating immune cells as assessed by the SP142 assay. Each percentage in the Venn diagrams reflects the percentage of that specific subgroup out of the total population of patients who could be evaluated for biomarker levels: 534 patients for the 22C3 and SP142 overlap, 546 for the SP263 and SP142 overlap, and 530 for the 22C3 and SP263 overlap. Panel B shows Kaplan–Meier estimates of overall survival among patients with a tumor proportion score of at least 50% on the 22C3 assay, and Panel C shows Kaplan–Meier estimates of overall survival among patients with PD-L1 expression on at least 50% of tumor cells on the SP263 assay. Medians were estimated with the use of the Kaplan–Meier method. Unstratified hazard ratios are shown for 22C3 and SP263 subgroup analyses. Tick marks indicate censored data.</div></div></figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view fv__fit" href="#fv-f3" data-type="figures" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa1917346_f3.jpg"><img src="/cms/10.1056/NEJMoa1917346/asset/7c71a9e8-7620-4602-a156-107a1e7e432f/assets/images/large/nejmoa1917346_f3.jpg" height="1783" width="2640" aria-labelledby="f3" loading="lazy"><span class="fv__fit--overlay"><span>View figure</span></span></a><div class="fv__item__title">Figure 3</div><div class="fv__item__description"><figcaption><div class="caption">Progression-free Survival in Subgroups Defined According to Blood-Based Tumor Mutational Burden (TMB).</div><div class="notes"><div role="doc-footnote">Panel A shows the overlap between patients with a blood-based TMB of at least 16 (16 mutations per 1.1 megabase, equivalent to approximately 14.5 mutations per megabase) and patients with high PD-L1 expression. Each percentage in the Venn diagrams reflects the percentage of that specific subgroup out of the total population of patients who could be evaluated for biomarker levels: 375 patients for the 22C3 assay and blood-based TMB overlap and 389 for the SP142 assay and blood-based TMB overlap. Panel B shows progression-free survival in subgroups defined according to blood-based TMB. Any PD-L1 expression was defined as PD-L1 expression on at least 1% of tumor cells or tumor-infiltrating immune cells as assessed by the SP142 assay. A total of 165 patients could not be evaluated for blood-based TMB: 88 patients had a blood-based TMB result with a maximum somatic allele frequency of less than 1%, 39 patients had a sample that failed quality control at the testing vendor or had a median exon coverage of less than 800, and 38 patients had not provided a baseline plasma sample. A stratified hazard ratio is shown for any PD-L1 expression, and unstratified hazard ratios are shown for the other subgroups.</div></div></figcaption></div></div></div><div class="tab__pane fv__list fv__list--tables" id="tab-pane-tables" aria-label="All tables" tabindex="-1" role="tabpanel"><div class="fv__item"><a class="fv__open-item fv__item__view" href="#fv-t1" data-type="tables" data-interactiontype="multimedia_click" data-multimedia-type="Table"><i class="icon-tables"></i></a><div class="fv__item__title">Table 1</div><div class="fv__item__description"><figcaption><div class="caption">Demographic and Clinical Characteristics of the Patients at Baseline (Population with <i>EGFR</i> and <i>ALK</i> Wild-Type Tumors).<a href="#fv-t1fn1" role="doc-noteref">*</a></div></figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view" href="#fv-t2" data-type="tables" data-interactiontype="multimedia_click" data-multimedia-type="Table"><i class="icon-tables"></i></a><div class="fv__item__title">Table 2</div><div class="fv__item__description"><figcaption><div class="caption">Reported Adverse Events (Safety Population).<a href="#fv-t2fn1" role="doc-noteref">*</a></div></figcaption></div></div></div></div></div></div><div class="references-pop-up fade" aria-hidden="true"><div class="references-pop-up__heading text-dark d-flex align-items-center"><div class="references-pop-up__title flex-grow-1">Reference <span class="references-pop-up__heading-number">1</span></div><a class="references-pop-up__close text-dark" href="#" title="close pop-up" tabindex="-1" aria-hidden="true"><i class="icon-close" aria-hidden="true"></i></a></div><div class="references-pop-up__items citations to-citation__accordion external-links"></div></div></main>
    

</div>

                    
                        



        
        <div class="ng-page_layout ng-page_layout-fullWidth"><div class="container-fluid"><div class="row"><div class="col-12">



        
        




        
        <div class="ng-page_layout-contentSpacing"></div>










    
    
        <div data-widget-def="oneSearchMultiSearch" data-widget-id="778b3ad8-1a8d-43d8-8196-63b03df4a138" data-location="recirc_inIssue_bottom_article">
        



        
        <div class="os-ms os-ms-more-from-issue"><h3 class="ng-subsection-title"><a href="/toc/nejm/383/14" class="ng-subsection-title_link animation-icon-shift"><span class="ng-subsection-title_text">More from Vol. 383 No. 14</span><span class="ng-subsection-title_icon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-longArrowRight"></use></svg></span></span></a></h3><ul class="os-ms-more-from-issue_list"><li class="os-ms-more-from-issue_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/original-article" class="issue-item_type">Original Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Oct 01, 2020</span></li><li data-toggle="tooltip" data-original-title="Video" class="issue-item_meta-item"><span role="img" aria-label="Video" tabindex="0" class="issue-item_video"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#tooltip-video"></use></svg></span></span></li><li class="issue-item_meta-item"><span class="issue-item_free">FREE</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMoa2019422" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Early Rhythm-Control Therapy in Patients with Atrial Fibrillation</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">P. Kirchhof and Others</span></div></div></div></div></div></li><li class="os-ms-more-from-issue_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/original-article" class="issue-item_type">Original Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Oct 01, 2020</span></li><li class="issue-item_meta-item"><span class="issue-item_free">FREE</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMoa1917338" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">HPV Vaccination and the Risk of Invasive Cervical Cancer</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">J. Lei and Others</span></div></div></div></div></div></li><li class="os-ms-more-from-issue_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/original-article" class="issue-item_type">Original Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Oct 01, 2020</span></li><li data-toggle="tooltip" data-original-title="Visual Abstract" class="issue-item_meta-item"><span role="img" aria-label="Visual Abstract" tabindex="0" class="issue-item_visualAbstract"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#tooltip-visual"></use></svg></span></span></li><li class="issue-item_meta-item"><span class="issue-item_free">FREE</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMoa2019910" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Evolocumab in Pediatric Heterozygous Familial Hypercholesterolemia</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">R.D. Santos and Others</span></div></div></div></div></div></li></ul></div>

        </div>
    

</div></div></div></div>

                    
                        



        
        <div class="ng-page_layout-bottomAd"><div class="container-fluid"><div class="row"><div class="col-12">









    
    
        <div data-widget-def="literatumAd" data-widget-id="7e022d0d-4a48-44a7-af66-033cf5c13eb8" id="ad-article-bottom-FULLx320-1">
        



        
        



    
        <div class="pb-house-message adplaceholder exists">
            <!-- START: Circulation Footer 3 -->
<aside class="g-cta-subscribe">
	<style>
.bads_footer-banner24-ONJQNRF1{background:url(/pb-assets/contextual_messaging/footer-yel-background-2x-1513629627453.jpg) center center no-repeat;padding:20px;display:block;margin:0;min-height:inherit;background-size:cover;text-decoration:none!important;color:#1a1a1a;text-align:left}.bads_footer-banner24-ONJQNRF1 .g-cta-subscribe__title{font-size:42px;line-height:44px;letter-spacing:.2px;margin:0 0 20px;font-family:ff-quadraat-web-pro,sans-serif;font-weight:600}.bads_footer-banner24-ONJQNRF1-inner{max-width:1300px;margin:0 auto}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__actions .a-btn{width:130px;padding-left:12px}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login{position:static;color:#000;font-size:18px;line-height:27px;border:0}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__actions{margin:20px 0 20px 0;list-style-type:none;padding:0}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login a{color:#0a68ad}.bads_clearfix:after{visibility:hidden;display:block;font-size:0;content:" ";clear:both;height:0}.bads_clearfix{display:block}.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{float:left;width:50%;padding:30px 0}.bads_footer-banner24-ONJQNRF1-inner .bads_device-img{float:left;padding-left:30px;width:50%}.bads_footer-banner24-ONJQNRF1 .bads_device-img>img{display:block;max-width:100%;height:auto}.bads_footer-banner24-ONJQNRF1 .bads_h5{font-size:18px;text-transform:uppercase;line-height:24px;font-weight:600;margin:-15px 0 0;letter-spacing:.2px}@media only screen and (max-width:480px){.bads_footer-banner24-ONJQNRF1-inner .bads_device-img,.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{width:100%;float:none}.bads_footer-banner24-ONJQNRF1-inner .bads_device-img{padding-left:0}.bads_footer-banner24-ONJQNRF1 .g-cta-subscribe__title{font-size:20px;line-height:27px;margin-bottom:10px}.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{padding-top:0;padding-bottom:0}.bads_footer-banner24-ONJQNRF1{height:auto}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__actions{margin:0 0 12px;list-style-type:none}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login{line-height:25px;font-size:15px;margin-bottom:10px}.bads_footer-banner24-ONJQNRF1 .bads_device-img{width:280px!important;margin:0 auto}.bads_footer-banner24-ONJQNRF1 .bads_h5{margin:0 0 3px;font-size:14px}}@media only screen and (min-width:480px) and (max-width:1024px){.bads_footer-banner24-ONJQNRF1 .g-cta-subscribe__title{font-size:20px;line-height:30px;margin-bottom:15px}.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{padding:0}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login{font-size:14px}.bads_footer-banner24-ONJQNRF1 .bads_h5{font-size:13px;margin-top:0}}@media only screen and (min-width:1025px) and (max-width:1200px){.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{padding:10px 0}.bads_footer-banner24-ONJQNRF1 .bads_h5{margin:0 0 5px}}@media only screen and (min-width:1401px){.bads_footer-banner24-ONJQNRF1 .bads_device-img>img{float:right}}
	</style>
	<div class="bads_footer-banner24-ONJQNRF1">
	  <div class="bads_footer-banner24-ONJQNRF1-inner bads_clearfix">
		 <div class="bads_subs-btn">
			<p class="g-cta-subscribe__title">Tap into groundbreaking research and clinically relevant insights</p>
			<ul class="g-cta-subscribe__actions">
				<li class="g-cta-subscribe__actions-primary">
				  <a href="/action/clickThrough?id=127716&amp;url=%2Faction%2FstoreProxy%3Faction%3Dsubscribe%26url%3Dhttps%253A%252F%252Fwww.nejm.org%252Fdoi%252Ffull%252F10.1056%252FNEJMoa1917346%26promo%3DONFQNRF1&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa1917346&amp;pubId=41289147&amp;placeholderId=101336&amp;productId=1035" class="ng-btn_primary ng-btn_iconRight"><span class="ng-btn_text">Subscribe </span><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#arrows-longArrowRight"></use></svg></span></a>
				</li>
			</ul>
			<p class="g-cta-subscribe__login">Already a subscriber? <a href="/action/clickThrough?id=127716&amp;url=%2Faction%2FstoreProxy%3Faction%3Dactivate%26url%3Dhttps%253A%252F%252Fwww.nejm.org%252Fdoi%252Ffull%252F10.1056%252FNEJMoa1917346%26promo%3DONFQANR4&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa1917346&amp;pubId=41289147&amp;placeholderId=101336&amp;productId=1035">Activate</a> your online access.</p>
		 </div>

		<div class="bads_device-img">
		   <img src="/sda/127716/footer-devices-2x.png" alt="Devices">
		</div>
	   </div>
	</div>
</aside>
<!--/END: Circulation Footer 3 -->
            
        </div>
    

    

    



        </div>
    

</div></div></div></div>

                    
                        



        
        <footer class="ng-footer footer__top" style="position: relative;"><div data-location="footer" class="ng-footer_columns"><div class="container-fluid"><div class="row"><div class="col-lg-4 col-md-6 col-sm-12 ng-footer_column"><div class="row"><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">ARTICLE CATEGORIES</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item">
        <a href="/browse/nejm-article-category/research" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Research</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/review" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Reviews</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/clinical-cases" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Clinical Cases</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/perspective" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Perspective</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/commentary" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Commentary</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/other" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Other</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/medical-article-index" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Browse all Articles</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/toc/nejm/current" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Current Issue</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/loi/nejm" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Issue Index</span></a></li>
</ul>
</div><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">RESOURCES</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="/author-center/home" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Authors &amp; Reviewers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/author-center/home" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Submit a Manuscript</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/products-and-services" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Subscribers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://tools.ovid.com/ovidtools/nejm.html" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Institutional Administrators</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/media" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Media</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/how-to-advertise" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Advertisers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/information-for-subscription-agents" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Agents</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/permissions" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Permissions &amp; Licensing</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/reprints" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Reprints</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.nejmcareercenter.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">NEJM CareerCenter</span></a>
    </li>
</ul>
</div></div></div><div class="col-lg-4 col-md-6 col-sm-12 ng-footer_column"><div class="row"><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title" aria-label="About us">ABOUT US</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="/about-nejm/about-nejm" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">About NEJM</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.nejmgroup.org/" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">NEJM Group</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/products-and-services" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Products &amp; Services</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/editors-and-publishers" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Editors &amp; Publishers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/advertising-policies" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Advertising Policies</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/contact-nejm" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text" aria-label="Contact us">Contact Us</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/frequently-asked-questions?#Accessibility" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Accessibility</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/frequently-asked-questions" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">FAQs</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/help" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Help</span></a></li>
    <li class="ng-footer_column-list-item"><a href="mailto:sitefeedback@nejm.org" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Site Feedback</span></a></li>
</ul>
</div><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">SUBSCRIPTIONS</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS3" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Subscribe</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=renew&amp;product=nejm&amp;promo=ONFLNRR3&amp;prc=ONFARN52" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Renew</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=activate&amp;promo=ONFLNAA1" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Activate Subscription</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC4" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Create Account</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://myaccount.nejm.org" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Manage Account</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=paybill&amp;product=nejm&amp;promo=BNFLPBA1" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Pay Bill</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.wolterskluwer.com/en/solutions/ovid/nejm-complete-collection" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Institutional Sales</span></a></li>    
    <li class="ng-footer_column-list-item"><a href="https://myaccount.nejm.org/special-content" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Special Content</span></a></li>
</ul>
</div></div></div><div class="col-lg-4 col-md-12 ng-footer_column"><div class="row"><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">STAY CONNECTED</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="https://myaccount.nejm.org/emails?section=NEJM" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Email Alerts</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC3" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Create Account</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/products-and-services" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Apps</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.nejmcareercenter.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">NEJM CareerCenter</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/rss-feed/" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Podcasts</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/rss-feed/" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">RSS Feed</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/institutional-access" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Remote Access</span></a></li>
</ul>
</div><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title" aria-label="Follow us">FOLLOW US</h4>
<ul class="ng-footer_column-list">
<li class="ng-footer_column-list-item"><a href="https://www.facebook.com/TheNewEnglandJournalofMedicine" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-facebook"></use></svg></span></span><span class="ng-footer_column-link-text">Facebook</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://twitter.com/nejm" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-twitter"></use></svg></span></span><span class="ng-footer_column-link-text">X (formerly Twitter)</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.instagram.com/nejm/" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-instagram"></use></svg></span></span><span class="ng-footer_column-link-text">Instagram</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.youtube.com/user/NEJMvideo" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-youtube"></use></svg></span></span><span class="ng-footer_column-link-text">Youtube</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.linkedin.com/company/nejm-group" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-linkedin"></use></svg></span></span><span class="ng-footer_column-link-text">LinkedIn</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://bsky.app/profile/nejm.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-bluesky"></use></svg></span></span><span class="ng-footer_column-link-text">Bluesky</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.tiktok.com/@nejm.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-tiktok"></use></svg></span></span><span class="ng-footer_column-link-text">TikTok</span></a></li>
</ul>
</div></div></div></div></div></div><div data-location="footer" class="ng-footer_journals"><div class="container-fluid"><div class="row"><div class="col-12">



        
        <h4 class="ng-footer_journals-label">JOURNALS</h4>
<ul class="ng-footer_journals-list">
<li class="ng-footer_journals-item"><a href="https://www.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">The New England Journal of Medicine</a></li>
<li class="ng-footer_journals-item"><a href="https://catalyst.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">NEJM Catalyst Innovations in Care Delivery</a></li>
<li class="ng-footer_journals-item"><a href="https://evidence.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">NEJM Evidence</a></li>
<li class="ng-footer_journals-item"><a href="https://ai.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">NEJM AI</a></li>
</ul>
</div></div></div></div><div data-location="legal" class="ng-footer_bottom"><div class="container-fluid"><div class="row"><div class="col-lg-7 col-md-6 ng-footer_bottom-left">



        
        <p>Copyright © 2025 <a href="https://www.massmed.org/" target="_blank" rel="noopener" class="ng-footer_bottom-link"><b>Massachusetts Medical Society</b></a>. All rights reserved, including those for text and data mining, AI training, and similar technologies. Electronic ISSN 1533-4406. Print ISSN 0028-4793.The content of this site is intended for health care professionals.</p>
</div><div class="col-lg-5 col-md-6 ng-footer_bottom-right">



        
        <style>
  #teconsent a {
    color: #666;
    text-decoration: none;
  }
  #teconsent a:hover {
    color: #666;
    text-decoration: underline;
  }
</style>
<ul class="ng-footer_bottom-list">
<li class="ng-footer_bottom-list-item"><a href="https://www.nejmgroup.org/legal/copyright-information.htm" target="_blank" rel="noopener" class="ng-footer_bottom-link">Copyright</a></li>
<li class="ng-footer_bottom-list-item"><a href="https://www.nejmgroup.org/legal/terms-of-use.htm" target="_blank" rel="noopener" class="ng-footer_bottom-link">Terms</a></li>
<li class="ng-footer_bottom-list-item"><a href="https://www.nejmgroup.org/legal/privacy-policy.htm" target="_blank" rel="noopener" class="ng-footer_bottom-link">Privacy Policy</a></li>
<li class="ng-footer_bottom-list-item"><span id="teconsent" consent="undefined" aria-label="Open Cookie Preferences Modal" role="complementary"><a role="link" id="icon-id07238259428841569" tabindex="0" lang="en" aria-haspopup="dialog" aria-label="Cookie Preferences, opens a dedicated popup modal window" class="truste_cursor_pointer">Cookie Preferences</a></span></li>
</ul>
<a href="https://www.nejmgroup.org/" title="NEJM Group" target="_blank" rel="noopener" class="ng-footer_logo-link"><img src="/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/logo_group.svg" alt="NEJM Group logo" class="ng-footer_logo" loading="lazy" width="103" height="40"></a>
</div></div></div></div><div data-show-after="400" class="back-to-top back-to-top--align-right  "><button data-snap="footer__top" class="back-to-top__action position-relative p-0 m-0 border-0 d-flex flex-column align-items-center justify-content-center"><svg viewBox="0 0 36 36" class="position-relative"><path d="M18 2.0845 a 15.9155 15.9155 0 0 1 0 31.831 a 15.9155 15.9155 0 0 1 0 -31.831" class="back-to-top__action__ring-bg"></path><path d="M18 2.0845 a 15.9155 15.9155 0 0 1 0 31.831 a 15.9155 15.9155 0 0 1 0 -31.831" stroke-dasharray="0, 100" class="back-to-top__action__ring"></path></svg><span class="back-to-top__action-icon position-absolute d-flex"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-up"></use></svg></span></span><span class="sr-only">Back to top</span></button></div></footer>

                    
                        



        
        <!-- TrustArc: Banner -->
<div id="consent_blackbar"><style>  #consent_blackbar{    position:relative;    width:100%;    z-index: 999999;  }    #trustarc-banner-overlay {  background-color: rgb(0, 0, 0);   opacity: 0.3;   position: fixed;   z-index: 1000000;   width: 100%;  height: 100%;   top: 0px;   left: 0px;   overflow: hidden;}.truste-title {  /*font-family: "Source Sans Pro", sans-serif;  font-size: 23px;  font-style: normal;  font-stretch: normal;*/  color: #222;  margin-bottom: 20px;  text-align: center;/*  font-weight:bold;*/}.truste-footer {  margin: 0 auto;      }.truste-left {  margin: 0px 0px 15px 15px;/*font-family: "Source Sans Pro", sans-serif;  font-size: 14px;    */}.truste-banner { margin: 0 auto; }.truste-messageColumn {/*font-family: "Source Sans Pro", sans-serif;  font-size: 14px;*/  color: #666666;  margin: 0px;}#truste-consent-button, #truste-consent-required {    background-color: #FF1E00;    color: #F2F1F1;    padding: 5px 10px;    border: 1px solid #FF1E00;    border-radius: 0px;    cursor: pointer;    text-transform:uppercase;/*    font-family: "Source Sans Pro",sans-serif;    font-size: 15px;*/  }      #truste-show-consent {    background-color: #FF1E00;    color: #F2F1F1;    border: 1px solid #FF1E00;    padding: 5px 10px;    border-radius: 0px;    cursor: pointer;    text-transform:uppercase;/*    font-family: "Source Sans Pro",sans-serif;    font-size: 15px;*/  }div.truste-consent-track-class {  position: fixed;  z-index:9999999;   background: #666;   border: 1px solid #333;    /*padding: 10px 60px;*/    bottom:0px;    right:0px;    left:0px;    margin: 10px;}.truste-left {  margin: 0;}div.text-content {  display: flex;  flex-direction: column;  align-self: baseline;}#truste-consent-text {    /*font-family: "Source Sans Pro", sans-serif;    font-size: 16px;*/    color: #fff;    margin: 15px 0px;}.truste-footer {  padding-top: 15px;}#truste-consent-content {  margin: 0 auto;    padding: 0 10px;    max-width: 1366px;}.truste-consent-footer {  display: none;}.flex-container {  display: block;  align-items: center;  justify-content: space-between;}#truste-consent-buttons {  float: right;  margin: 10px 5px 10px 0px;}#truste-show-consent { background: #F30 !important;}#truste-consent-button, #truste-consent-required { background: #F30 !important; } /* MEDIA QUERIES */  @media screen and (max-width: 500px) {  #truste-consent-track {    padding: 5px 20px;  }  }@media screen and (max-width: 375px) {  .truste-buttonsColumn {    float: none;    margin: 0;  }  #truste-consent-button, #truste-consent-required, #truste-show-consent {    width: 100%;    margin-bottom: 5px;  }          #truste-consent-buttons {  float: none;  margin: 10px 0px 10px 0px;	}}</style><div id="truste-consent-track" style="display: block; opacity: 1;">  <div id="trustarc-banner-overlay"></div>  <div class="truste-consent-track-class">    <div id="truste-consent-content" class="truste-banner">        <div class="flex-container">          <div class="text-content">            <div id="truste-consent-text" class="truste-messageColumn">This site uses cookies and related technologies, as described in our privacy policy, for purposes that may include site operation, analytics, enhanced user experience, or advertising. You may choose to consent to our use of these technologies, or manage your own preferences.                       </div>          </div>          <div id="truste-consent-buttons" class="truste-buttonsColumn">            <button id="truste-show-consent" aria-haspopup="dialog">Manage Settings</button>      <button id="truste-consent-button">Accept</button>      <!-- <button id="truste-consent-required">Decline All</button> -->          </div>        </div>                <div style="clear:both;"></div>    </div>  </div></div><!--emptycomment--></div>
<!-- /TrustArc: Banner -->

                    
                        



        
        <link rel="stylesheet" href="https://cssjs.nejm.org/mmsWidgets.css"><script nonce="94d64c3dc210a517-SJC" type="text/javascript" src="https://cssjs.nejm.org/mmsWidgets.js"></script><script nonce="94d64c3dc210a517-SJC" type="text/javascript">var litSSO = {
    "ucid": null,
    "accessToken": null,
    "authState": null
};

var loginUri = '/action/doSsoLogin';
var logoutUri = '/action/doLogout';

displayAuthenticatedMessage();

mmsWidgets.init({
    clientId: 'qsra7g4d6jwdsgn3zbe6udp6r6278mr9',
    origin: 'NEJM',
    xdReceiver: 'http://www.nejm.org/pb-assets/sso/xd.html',
    isFullPageSignIn: isSignInPage(),
    debug: true,

    onReady: function (e) {
        console.log('<<<<<<<<<< client: received onReady event.');
        $("A.litSsoLogin").click(function (e) {
            if (!$(e.currentTarget).hasClass("noMd") || $(e.currentTarget).parents(".header_sm-login").length === 0) {
                mmsWidgets.signIn(e);
                return false;
            }
        });
        $("A.litSsoLogout").click(function (e) {
            mmsWidgets.signOut(e);
            return false;
        });
        $("A.litSsoCreate").click(function (e) {
            mmsWidgets.showRegModal(e);
            return false;
        });
        $("A.litSsoSubscribe").click(function (e) {
            if (!$(e.currentTarget).hasClass("noMd") || $(e.currentTarget).parents(".header_sm-login").length === 0)
                location.assign(e.currentTarget.href);
            return false;
        });
        if (window.doSSOLogin) {
            window.setTimeout(function () {
                mmsWidgets.signIn();
            }, 500);
        }
        ;
    },
    onLoginSuccess: function (e) {
        console.log('<<<<<<<<<< client: received onLoginSuccess event.' + JSON.stringify(e));

        const redirectUrl = getRedirectUri(window.location.search, location.href.replace(window.location.origin, ""));
        document.cookie = "skipSso=; expires=; path=/";
        if (!litSSO.ucid || e.ucid != litSSO.ucid || !litSSO.accessToken || e.accessToken != litSSO.accessToken) {
            location.assign(loginUri + "?ucid=" + e.profile.ucid
                + "&accessToken=" + e.accessToken
                + "&authState=" + e.authState
                + "&email=" + encodeURIComponent(e.profile.email)
                + "&givenNames=" + e.profile.givenName
                + "&surname=" + e.profile.familyName
                + "&redirectUri=" + redirectUrl
                + "&uccLastUpdatedDate=" + encodeURIComponent(e.profile.uccLastUpdatedDate)
                + "&rememberMe=" + e.rememberMe);
        }
    },
    onAuthStateReady: function (e) {
        console.log('<<<<<<<<<< client: received onAuthStateReady event.' + JSON.stringify(e))

        var isMmsSsoAuthenticated = (e.authState && e.authState !== "anonymous" && e.authState !== "lead" && e.ucid && e.accessToken) ? true : false;
        var isLitSsoAuthenticated = (litSSO.ucid && litSSO.accessToken && litSSO.authState) ? true : false;
        console.log('           isMmsSsoAuthenticated=' + isMmsSsoAuthenticated + ', isLitSsoAuthenticated=' + isLitSsoAuthenticated);

        if (isMmsSsoAuthenticated) {
            if (!isLitSsoAuthenticated || litSSO.ucid != e.ucid) {
                if (window.skipSso)
                    document.cookie = "skipSso=" + encodeURIComponent(e.ucid) + "; expires=; path=/";

                if (!window.skipSso && document.cookie.indexOf("skipSso=" + encodeURIComponent(e.ucid)) == -1) {
                    location.assign(loginUri + "?ucid=" + e.profile.ucid
                        + "&accessToken=" + e.accessToken
                        + "&authState=" + e.authState
                        + "&email=" + encodeURIComponent(e.profile.email)
                        + "&givenNames=" + e.profile.givenName
                        + "&surname=" + e.profile.familyName
                        + "&redirectUri=" + location.href.replace(window.location.origin, "")
                        + "&uccLastUpdatedDate=" + encodeURIComponent(e.profile.uccLastUpdatedDate)
                        + "&rememberMe=" + e.rememberMe);
                } else
                    console.log('**** client: Skip SSO ****');
            } else if (e.accessToken !== litSSO.accessToken)
                updateLitSession(e.ucid, e.accessToken);
        } else if (isLitSsoAuthenticated)
            location.assign(logoutUri + "?redirectUri=" + encodeURIComponent(location.href.replace(window.location.origin, "")));

        if (document.getElementById("ssoerr-ucid"))
            document.getElementById("ssoerr-ucid").innerHTML = e.ucid;

    },
    onRegistrationSuccess: function (e) {
        console.log('<<<<<<<<<< client: received onRegistrationSuccess event.' + JSON.stringify(e))
        document.cookie = "skipSso=; expires=; path=/";
        var uccLastUpdatedDate = '1812-01-01 00:00:00.1 +0000';
        location.assign(loginUri + "?ucid=" + e.profile.ucid
            + "&accessToken=" + e.accessToken
            + "&authState=" + e.authState
            + "&email=" + encodeURIComponent(e.profile.email)
            + "&givenNames=" + e.profile.givenName
            + "&surname=" + e.profile.familyName
            + "&redirectUri=" + location.href.replace(window.location.origin, "")
            + "&uccLastUpdatedDate=" + encodeURIComponent(uccLastUpdatedDate)
            + "&rememberMe=" + e.rememberMe);
    },
    onLogoutSuccess: function (e) {
        console.log('<<<<<<<<<< client: received onLogoutSuccess event.' + JSON.stringify(e))

        document.cookie = "skipSso=; expires=; path=/";
        location.assign(logoutUri);
    },
});

function updateLitSession(ucid, accessToken) {
    $.ajax({
        method: "GET",
        url: "/action/doSsoSessionUpdate",
        data: {ucid: ucid, accessToken: accessToken},
        success: function (callData, textStatus) {
            console.log("Session accessToken updated")
            litSSO.accessToken = accessToken
        },
        error: function (jqXHR, textStatus, errorThrown) {
            alert("Your website session has expired and will now be reset.")
            console.log("Session update failed: " + jqXHR.responseText)
            location.assign(logoutUri + "?redirectUri=" + encodeURIComponent(location.href.replace(window.location.origin, "")));
        }
    });
}

function getRedirectUri(location, fallback) {
    const urlParams = new URLSearchParams(location);
    const uriUrlParam = urlParams.get('uri');
    if (uriUrlParam)
        return encodeURIComponent(uriUrlParam);
    else
        return encodeURIComponent(fallback);
}

function isSignInPage() {
    return document.querySelector('meta[name="pbContext"]').content.indexOf("customPage:string:/sign-in") > -1;
}

function displayAuthenticatedMessage() {
    if (isSignInPage()) {
        var div = document.getElementById('authMsg');
        if ("" === "PersonUser") {
            div.innerHTML += "You are already signed in to " + window.location.origin.replace("https://", "").replace("www.", "") + ". If you would like to sign in with a different email address, please use the form below.";
        } else {
            div.innerHTML = '';
        }
    }
}</script>

                    
                
            </div>
        </div><iframe name="trustarc_notice" id="trustarcNoticeFrame" title="Trustarc Cross-Domain Consent Frame" src="https://consent.trustarc.com/get?name=crossdomain.html&amp;domain=nejm.com" style="display: none;"></iframe><script src="https://consent.trustarc.com/asset/notice.js/v/v1.7-1576" async="async" crossorigin="" importance="high" nonce="94d64c3dc210a517-SJC"></script>
        


        
        

            <script src="/products/mms-nextgen/mms/releasedAssets/js/build.lazyload.bundle-c8c4e7d20884f81951fb.js" nonce="94d64c3dc210a517-SJC"></script>

        <script src="/products/mms-nextgen/mms/releasedAssets/js/main.bundle-3819a02ec7bc2aca01ec.js" nonce="94d64c3dc210a517-SJC"></script>
        


<div id="adModal" tabindex="-1" aria-labelledby="exampleModalCenterTitle" class="ng-modal modal" style="display: none;" aria-hidden="true">
    <div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered ad-promoLayer">
        <div class="ng-modal_content modal-content p-0">
            <div class="ng-modal_body modal-body m-0">
                <div class="ng-modal_header modal-header">
                    <button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#close"></use></svg></span></span>
                    </button>
                </div>

            </div>
        </div>
    </div>
</div>
<script type="text/javascript" src="/wro/1125813~product.js" nonce="94d64c3dc210a517-SJC"></script>








<input id="showLayers" type="hidden" value="true">

    <!-- placeholder id=null, description=ad-layer-config -->
    <!-- placeholder id=null, description=ad-lauchLayer-1 -->
    <!-- placeholder id=null, description=ad-layer-promo-1 -->

    <input id="firstAd" type="hidden" value="">
    <input id="secondAd" type="hidden" value="">

    
    
    

    
    
    <input id="IsInstitution" type="hidden" value="false">
    <input id="IsSubscriber" type="hidden" value="true">
    <input id="CustomerId" type="hidden" value="">


<script type="text/javascript" nonce="94d64c3dc210a517-SJC">
  jQuery.extend(jQuery.mmsLayers.config, {
    rules: [{
      "name": "Launch Layer Ad",
      "frequency": 30,
      "showOnPage": 5,
      "enabled": false,
      "cookieName": "MarketingLaunchLayer",
      "styleClass": "launchLayer"
    },
    {
      "name": "Promo Layer Ad",
      "frequency": 14,
      "enabled": true,
      "cookieName": "PromoLayer",
      "styleClass": "promoLayer"
    },
    {
      "name": "Interstitial Ad",
      "frequency": 7,
      "enabled": false,
      "cookieName": "InterstitialAd"
    },
    {
      "name": "Iperceptions - Ion Layer Ad",
      "showOnPage": 1,
      "enabled": false,
      "test": false,
      "cookieName":"Iperceptions"
    }]
 });
</script>

















    <script type="text/javascript" nonce="94d64c3dc210a517-SJC">
        $(document).ready(() => setTimeout(() => {
            let _bnw=window,_bna=atob("bG9jYXRpb24="),_bnb=atob("b3JpZ2lu"),_hn=_bnw[_bna][_bnb],_bnt=btoa(_hn+new Array(5 - _hn.length % 4).join(" "));
            $.get("/resource/lodash?t="+_bnt);
        },4000));
    </script>












    

    
    

    
    
    
    
        
            
                <script type="text/javascript" src="/wro/1125813~article-metrics.js" nonce="94d64c3dc210a517-SJC"></script>
            
            
            
        
    




<div style="display:none;" id="signInEmbedded" class="ucc-fullpage-signin ucc-widgets-nejm-next">
  <div class="capture_header">
    <h1>Sign In</h1>
  </div>    
  <div class="capture_signin">
    {* #signInForm *}
    <div class="ucc-form-inner-wrapper">
      {* signInEmailAddress *}
      {* currentPassword *}
      <div style="padding-top:10px;">
          <div class="capture_form_item capture_form_rememberme">
          <label class="ucc-form-checkbox">                
            <input checked="checked" id="ucc-remember-me-cb-embedded" name="ucc-remember-me-cb-embedded" type="checkbox" value="true">
            <span>Remember Me</span>
          </label>                           
          </div>
          <div class="capture_form_item capture_form_forgotpwd">
            <a role="button" class="ucc-anchor-button" data-capturescreen="forgotPassword">Forgot your password?</a>
          </div>
      </div>
      <div class="capture_form_item">      
        <button id="ucc-sign-in-submit-embedded" class="capture_primary capture-full-width-btn" type="submit">Sign In</button>
      </div>
      <div class="capture_form_item capture_form_footer">
        <div class="ucc-no-acct-msg">Don't have an account?</div>
        <div class="ucc-no-acct-msg-2">
          <a role="button" class="ucc-anchor-button" onclick="mmsWidgets.closeSignIn(event); mmsWidgets.showRegAuto(event);">Create Account</a>
          <span></span><a href="https://store.nejm.org/nejm?promo=ONF4NRS1">Subscribe</a>
        </div>
      </div>
      <div class="capture_form_item capture_form_submit">
        
      </div>      
    </div>
    {* /signInForm *}
  </div>
</div><div style="display:none;" id="forgotPassword" class="ucc-widgets-nejm-next">
  <div class="capture_header">
    <h1>Forgot Password</h1>
  </div>   
  <div class="ucc-form-inner-wrapper">
  <p style="color:black">Enter the email address associated with your account then click Continue. We will email you a link to a page where you can easily create a new password.</p>
  </div> 
  <div class="capture_forgotpassword">
    {* #forgotPasswordForm *}      
      <div class="ucc-form-inner-wrapper">
        {* forgotPasswordEmailAddress *}
        {* captcha *}
        <div class="capture_form_item" style="padding-top: 20px;">        
          <input id="ucc-widget-forgotpwd-submit" value="Continue" type="submit" class="capture_btn capture_primary capture-full-width-btn">
        </div>
      </div>
    {* /forgotPasswordForm *}
  </div>
  </div><div style="display:none;" id="forgotPasswordSuccess" class="ucc-widgets-nejm-next">
  <div class="capture_header">
    <h1>Create New Password</h1>
  </div>    
  <div class="capture_forgotpassword">
      <div class="ucc-form-inner-wrapper">
        <p style="padding-top: 30px; padding-bottom: 30px;">We've sent an email with instructions to create a new password. Your existing password has not been changed.</p>        
        <div class="capture_form_item">      
          <button class="capture_btn capture_primary capture-full-width-btn" onclick="janrain.capture.ui.modal.close()">CLOSE</button>
        </div>
      </div>
  </div>
  </div><div style="display:none;" id="resetPassword" class="ucc-widgets-nejm-next">
      <div class="row">      
        <div class="col-md-8 col-md-offset-2 reset-pwd-info"><p>To reset your password, enter a new password twice and click the 'Reset Password' button.</p></div>
      </div>
      <div class="col-md-4 col-md-offset-4">
        {* #changePasswordFormNoAuth *}
          {* newPassword *}
          {* newPasswordConfirm *}     
          <div class="capture_form_item">
            <input value="RESET PASSWORD" type="submit" class="capture_btn capture_primary capture-full-width-btn">
          </div>
          {* /changePasswordFormNoAuth *}
      </div>
    </div><div style="display:none;" id="resetPasswordSuccess">
        <div class="reset-pwd-info">
          <div class="reset-pwd-success-welcome"></div>
          <p class="reset-pwd-success-msg">Your password has been reset. You will need to <a href="/signin" onclick="mmsWidgets.signIn(event)">sign in</a> again using your new password to access site content and features.</p>
          <p class="reset-pwd-success-nav"></p>
        </div>      
    </div><div style="display:none;" id="resetPasswordRequestCode" class="ucc-widgets-nejm-next">
        {* #resetPasswordForm *}
        <div class="capture_form_error">The link that you followed to reset your password has expired.</div>
          <div class="col-md-8 col-md-offset-2">
            <p class="reset-pwd-info">Enter the email address associated with your account then click Continue. We will email you a link to a page where you can easily create a new password.</p>
          </div>
          <div class="col-md-4 col-md-offset-4">
            {* signInEmailAddress *}
            <div class="capture_form_item">
              <input value="continue" type="submit" class="capture_btn capture_primary capture-full-width-btn">
            </div>
          </div>
        {* /resetPasswordForm *}
    </div><div style="display:none;" id="resetPasswordRequestCodeSuccess">
      <div class="reset-pwd-info">
        <p>If the address matches an existing account, you will receive an email with instructions to reset your password.</p>
        <p class="reset-pwd-success-nav"></p>
      </div>
  </div><script type="text/javascript" src="/wro/1125813~full-text-analytics.js" nonce="94d64c3dc210a517-SJC"></script>


    


            <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'94d64c3dbca9a517',t:'MTc0OTUzMTU1MC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script><iframe height="1" width="1" style="position: absolute; top: 0px; left: 0px; border: none; visibility: hidden;"></iframe><script defer="" src="https://static.cloudflareinsights.com/beacon.min.js/vcd15cbe7772f49c399c6a5babf22c1241717689176015" integrity="sha512-ZpsOmlRQV6y907TI0dKBHq9Md29nnaEIPlkf84rnaERnq6zvWvPUqr2ft8M1aS28oN72PdrCzSjY4U6VaAw1EQ==" data-cf-beacon="{&quot;rayId&quot;:&quot;94d64c3dbca9a517&quot;,&quot;serverTiming&quot;:{&quot;name&quot;:{&quot;cfExtPri&quot;:true,&quot;cfEdge&quot;:true,&quot;cfOrigin&quot;:true,&quot;cfL4&quot;:true,&quot;cfSpeedBrain&quot;:true,&quot;cfCacheStatus&quot;:true}},&quot;version&quot;:&quot;2025.5.0&quot;,&quot;token&quot;:&quot;f55e150c7a5f4a4ab9ef82f4a1c9c43c&quot;}" crossorigin="anonymous"></script>

        
        
    

<div id="addtoany" style="position: static;"><div class="a2a_overlay" id="a2a_overlay"></div><div id="a2a_modal" class="a2a_modal a2a_hide" role="dialog" tabindex="-1" aria-label=""><div class="a2a_modal_body a2a_menu a2a_hide" id="a2a_copy_link"><label for="a2a_copy_link_text" id="a2a_copy_link_icon" class="a2a_svg a2a_s_link a2a_logo_color"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32"><title>Copy link</title><path fill="#FFF" d="M7.591 21.177c0-.36.126-.665.377-.917l2.804-2.804a1.235 1.235 0 0 1 .913-.378c.377 0 .7.144.97.43-.026.028-.11.11-.255.25-.144.14-.24.236-.29.29a2.82 2.82 0 0 0-.2.256 1.056 1.056 0 0 0-.177.344 1.43 1.43 0 0 0-.046.37c0 .36.126.666.377.918a1.25 1.25 0 0 0 .918.377c.126.001.251-.015.373-.047.125-.037.242-.096.345-.175.09-.06.176-.127.256-.2.1-.094.196-.19.29-.29.14-.142.223-.23.25-.254.297.28.445.607.445.984 0 .36-.126.664-.377.916l-2.778 2.79a1.242 1.242 0 0 1-.917.364c-.36 0-.665-.118-.917-.35l-1.982-1.97a1.223 1.223 0 0 1-.378-.9l-.001-.004Zm9.477-9.504c0-.36.126-.665.377-.917l2.777-2.79a1.235 1.235 0 0 1 .913-.378c.35 0 .656.12.917.364l1.984 1.968c.254.252.38.553.38.903 0 .36-.126.665-.38.917l-2.802 2.804a1.238 1.238 0 0 1-.916.364c-.377 0-.7-.14-.97-.418.026-.027.11-.11.255-.25a7.5 7.5 0 0 0 .29-.29c.072-.08.139-.166.2-.255.08-.103.14-.22.176-.344.032-.12.048-.245.047-.37 0-.36-.126-.662-.377-.914a1.247 1.247 0 0 0-.917-.377c-.136 0-.26.015-.37.046-.114.03-.23.09-.346.175a3.868 3.868 0 0 0-.256.2c-.054.05-.15.148-.29.29-.14.146-.222.23-.25.258-.294-.278-.442-.606-.442-.983v-.003ZM5.003 21.177c0 1.078.382 1.99 1.146 2.736l1.982 1.968c.745.75 1.658 1.12 2.736 1.12 1.087 0 2.004-.38 2.75-1.143l2.777-2.79c.75-.747 1.12-1.66 1.12-2.737 0-1.106-.392-2.046-1.183-2.818l1.186-1.185c.774.79 1.708 1.186 2.805 1.186 1.078 0 1.995-.376 2.75-1.13l2.803-2.81c.751-.754 1.128-1.671 1.128-2.748 0-1.08-.382-1.993-1.146-2.738L23.875 6.12C23.13 5.372 22.218 5 21.139 5c-1.087 0-2.004.382-2.75 1.146l-2.777 2.79c-.75.747-1.12 1.66-1.12 2.737 0 1.105.392 2.045 1.183 2.817l-1.186 1.186c-.774-.79-1.708-1.186-2.805-1.186-1.078 0-1.995.377-2.75 1.132L6.13 18.426c-.754.755-1.13 1.672-1.13 2.75l.003.001Z"></path></svg></label><input id="a2a_copy_link_text" type="text" title="Copy link" readonly=""><div id="a2a_copy_link_copied">✓</div></div><div class="a2a_modal_body a2a_menu a2a_thanks a2a_hide" id="a2a_thanks"><div class="a2a_localize" data-a2a-localize="inner,ThanksForSharing">Thanks for sharing!</div></div></div><div class="a2a_menu a2a_full a2a_localize" id="a2apage_full" role="dialog" tabindex="-1" aria-label="Share" data-a2a-localize="title,Share"><div class="a2a_full_header"><div id="a2apage_find_container" class="a2a_menu_find_container"><label for="a2apage_find" id="a2apage_find_icon" class="a2a_svg a2a_s_find"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" aria-hidden="true"><title>Find any service</title><path fill="#CCC" d="M19.7 18.2l-4.5-4.5c.7-1.1 1.2-2.3 1.2-3.6 0-3.5-2.8-6.3-6.3-6.3s-6.3 2.8-6.3 6.3 2.8 6.3 6.3 6.3c1.4 0 2.6-.4 3.6-1.2l4.5 4.5c.6.6 1.3.7 1.7.2.5-.4.4-1.1-.2-1.7zm-9.6-3.6c-2.5 0-4.5-2.1-4.5-4.5 0-2.5 2.1-4.5 4.5-4.5 2.5 0 4.5 2.1 4.5 4.5s-2 4.5-4.5 4.5z"></path></svg></label><input id="a2apage_find" class="a2a_menu_find a2a_localize" type="text" autocomplete="off" title="Find any service" data-a2a-localize="title,FindAnyServiceToAddTo"></div></div><div class="a2a_full_services" id="a2apage_full_services" role="presentation"></div><div class="a2a_full_footer"><a href="https://www.addtoany.com" title="Share Buttons" rel="noopener" target="_blank"><span class="a2a_svg a2a_s__default a2a_s_a2a a2a_logo_color"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32"><g fill="#FFF"><path d="M14 7h4v18h-4z"></path><path d="M7 14h18v4H7z"></path></g></svg></span>AddToAny</a></div></div><div id="a2apage_dropdown" class="a2a_menu a2a_mini a2a_localize a2a_hide" tabindex="-1" aria-label="Share" data-a2a-localize="label,Share"><div class="a2a_mini_services" id="a2apage_mini_services"></div><div id="a2apage_cols_container" class="a2a_cols_container"><div class="a2a_col1" id="a2apage_col1"></div><div id="a2apage_2_col1" class="a2a_hide"></div><div class="a2a_clear"></div></div><div class="a2apage_wide a2a_wide"><a href="#addtoany" id="a2apage_show_more_less" class="a2a_more a2a_localize" title="Show all" data-a2a-localize="title,ShowAll"><span class="a2a_svg a2a_s__default a2a_s_a2a a2a_logo_color"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32"><g fill="#FFF"><path d="M14 7h4v18h-4z"></path><path d="M7 14h18v4H7z"></path></g></svg></span><span class="a2a_localize" data-a2a-localize="inner,More">More…</span></a></div></div><div style="height: 1px; width: 1px; position: absolute; z-index: 100000; top: 0px; visibility: hidden;"><iframe id="a2a_sm_ifr" title="AddToAny Utility Frame" aria-hidden="true" src="https://static.addtoany.com/menu/sm.25.html#type=core&amp;event=load" style="height: 1px; width: 1px; border: 0px; left: 0px; top: 0px; position: absolute; z-index: 100000; display: none;"></iframe></div></div><rnw-mwuvjjjtpejl></rnw-mwuvjjjtpejl><div role="status" aria-live="assertive" aria-relevant="additions" class="ui-helper-hidden-accessible"></div><script type="text/javascript" src="https://api.altmetric.com/v1/internal-556fdf0f/doi/10.1056/nejmoa1917346?callback=_altmetric.embed_callback&amp;domain=www.nejm.org&amp;cache_until=1-10"></script><div id="janrainEngageEmbed" style="display: none;"><div class="janrainContent" style="width: 380px !important; height: 156px !important; padding-left: 5px !important; padding-right: 5px !important; box-sizing: content-box !important; background-color: rgb(255, 255, 255) !important; border: 1px solid rgb(192, 192, 192) !important; border-radius: 10px !important; overflow: hidden !important; position: relative !important;"><div id="janrainView"><div class="janrainHeader" style="background-color: rgb(255, 255, 255) !important; font-size: 14px !important; color: rgb(102, 102, 102) !important; position: relative !important; height: 20px !important; left: -5px !important; padding: 5px 5px 0px !important; white-space: nowrap !important; width: 380px !important; z-index: 100 !important; border-radius: 10px 10px 0px 0px !important; text-align: left !important;"><div style="padding-left: 1px !important; font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important;">Sign in using your account with</div></div><div id="janrainProviderPages" style="padding-top: 5px; left: 5px; position: absolute;"><div class="janrainPage" pageindex="0"><ul class="providers" id="janrainProviders_0" style="float: left !important; list-style-type: none !important; margin: 0px !important; padding: 0px !important;"><li id="janrain-aol" role="button" style="list-style: none !important; height: 30px !important; width: 185px !important; margin-top: 0px !important; margin-right: 5px !important; margin-bottom: 5px !important; position: relative !important; border: 1px solid rgb(204, 204, 204) !important; border-radius: 5px !important; cursor: pointer !important; white-space: nowrap !important; overflow: hidden !important; background-image: -webkit-linear-gradient(bottom, rgb(238, 238, 238), rgb(255, 255, 255)) !important;"><a tabindex="1" href="javascript:void(0);" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; font-size: 12px !important; line-height: 14px !important; margin-left: auto !important; margin-right: auto !important; text-decoration: none !important; display: block !important; padding-left: 5px !important; padding-right: 5px !important; text-align: left !important; width: auto !important;"><span class="janrain-provider-icon-24 janrain-provider-icon-aol" style="margin-top: 3px !important; background-color: transparent !important;"></span><span class="janrain-provider-text-color-aol" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; cursor: pointer !important; margin-left: 7px !important; text-align: left !important; margin-top: 9px !important; vertical-align: top !important; display: inline-block !important;">AOL</span></a></li><li id="janrain-openid" role="button" style="list-style: none !important; height: 30px !important; width: 185px !important; margin-top: 0px !important; margin-right: 5px !important; margin-bottom: 5px !important; position: relative !important; border: 1px solid rgb(204, 204, 204) !important; border-radius: 5px !important; cursor: pointer !important; white-space: nowrap !important; overflow: hidden !important; background-image: -webkit-linear-gradient(bottom, rgb(238, 238, 238), rgb(255, 255, 255)) !important;"><a tabindex="3" href="javascript:void(0);" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; font-size: 12px !important; line-height: 14px !important; margin-left: auto !important; margin-right: auto !important; text-decoration: none !important; display: block !important; padding-left: 5px !important; padding-right: 5px !important; text-align: left !important; width: auto !important;"><span class="janrain-provider-icon-24 janrain-provider-icon-openid" style="margin-top: 3px !important; background-color: transparent !important;"></span><span class="janrain-provider-text-color-openid" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; cursor: pointer !important; margin-left: 7px !important; text-align: left !important; margin-top: 9px !important; vertical-align: top !important; display: inline-block !important;">OpenID</span></a></li></ul><ul class="providers" id="janrainProviders_1" style="float: left !important; list-style-type: none !important; margin: 0px !important; padding: 0px !important;"><li id="janrain-yahoo" role="button" style="list-style: none !important; height: 30px !important; width: 185px !important; margin-top: 0px !important; margin-right: 5px !important; margin-bottom: 5px !important; position: relative !important; border: 1px solid rgb(204, 204, 204) !important; border-radius: 5px !important; cursor: pointer !important; white-space: nowrap !important; overflow: hidden !important; background-image: -webkit-linear-gradient(bottom, rgb(238, 238, 238), rgb(255, 255, 255)) !important;"><a tabindex="2" href="javascript:void(0);" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; font-size: 12px !important; line-height: 14px !important; margin-left: auto !important; margin-right: auto !important; text-decoration: none !important; display: block !important; padding-left: 5px !important; padding-right: 5px !important; text-align: left !important; width: auto !important;"><span class="janrain-provider-icon-24 janrain-provider-icon-yahoo" style="margin-top: 3px !important; background-color: transparent !important;"></span><span class="janrain-provider-text-color-yahoo" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; cursor: pointer !important; margin-left: 7px !important; text-align: left !important; margin-top: 9px !important; vertical-align: top !important; display: inline-block !important;">Yahoo!</span></a></li></ul></div></div><div style="background-color: rgb(255, 255, 255) !important; width: 380px !important; height: 10px !important; position: absolute !important; left: 0px !important; padding-left: 5px !important; padding-right: 5px !important; padding-bottom: 5px !important; bottom: 0px !important; font-size: 10px !important; text-align: left !important; color: rgb(102, 102, 102) !important; font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; border-radius: 0px 0px 10px 10px !important;"><div style="padding-left: 1px !important;"><a href="http://janrain.com/products/engage/social-login?utm_source=mms.rpxnow.com&amp;utm_medium=Partner&amp;utm_campaign=attribution" target="_blank">Social Login by Janrain</a></div></div></div></div></div><iframe name="captureIFrame_x4jydtgd3fmstsvrwnz71tmm5x4uw5aqn021hwl8" data-transactionid="x4jydtgd3fmstsvrwnz71tmm5x4uw5aqn021hwl8" id="captureIFrame_x4jydtgd3fmstsvrwnz71tmm5x4uw5aqn021hwl8" src="about:blank" class="" data-captureiframeloadeventbound="yes" style="display: none;"></iframe><div id="janrainModalOverlay" style="inset: 0px; position: fixed; background-color: rgb(0, 0, 0); opacity: 0.4; display: none; z-index: 1000;"></div><div id="janrainModal" style="width: 380px; height: 131px; position: absolute; z-index: 1000; display: none;"><a href="#" class="janrain_modal_closebutton" style="position: absolute; cursor: pointer; z-index: 1000;">X</a><div style="display: block;" id="signIn" class="ucc-widgets-nejm-next janrain-capture-ui capture-ui-content capture_screen_container" data-capturescreenname="signIn" data-captureventadded="true">
    <div class="capture_header">
      <h1>Sign In</h1>
    </div>    
    <div class="capture_signin">
      <form id="capture_signIn_signInForm" name="signInForm" data-capturefield="signInForm" action="https://mms.us.janraincapture.com/widget/traditional_signin.jsonp" class="capture_form capture_signInForm" method="POST" novalidate="novalidate" data-transactionid="x4jydtgd3fmstsvrwnz71tmm5x4uw5aqn021hwl8" target="captureIFrame_x4jydtgd3fmstsvrwnz71tmm5x4uw5aqn021hwl8" accept-charset="UTF-8" next="{&quot;noop&quot;:&quot;&quot;}"><div id="capture_signIn_signInForm_defaultSavedProfileMessage"></div><div id="capture_signIn_signInForm_errorMessages"></div><input id="capture_signIn_utf8" data-capturefield="undefined" value="✓" type="hidden" class="capture_utf8" name="utf8"><input id="capture_signIn_screen_x4jydtgd3fmstsvrwnz71tmm5x4uw5aqn021hwl8" data-capturefield="undefined" value="signIn" type="hidden" class="capture_screen_x4jydtgd3fmstsvrwnz71tmm5x4uw5aqn021hwl8" name="capture_screen"><input id="capture_signIn_js_version_x4jydtgd3fmstsvrwnz71tmm5x4uw5aqn021hwl8" data-capturefield="undefined" value="d445bf4" type="hidden" class="capture_js_version_x4jydtgd3fmstsvrwnz71tmm5x4uw5aqn021hwl8" name="js_version"><input id="capture_signIn_transactionId_x4jydtgd3fmstsvrwnz71tmm5x4uw5aqn021hwl8" data-capturefield="undefined" value="x4jydtgd3fmstsvrwnz71tmm5x4uw5aqn021hwl8" type="hidden" class="capture_transactionId_x4jydtgd3fmstsvrwnz71tmm5x4uw5aqn021hwl8" name="capture_transactionId"><input id="capture_signIn_form_x4jydtgd3fmstsvrwnz71tmm5x4uw5aqn021hwl8" data-capturefield="undefined" value="signInForm" type="hidden" class="capture_form_x4jydtgd3fmstsvrwnz71tmm5x4uw5aqn021hwl8" name="form"><input id="capture_signIn_flow_x4jydtgd3fmstsvrwnz71tmm5x4uw5aqn021hwl8" data-capturefield="undefined" value="standard" type="hidden" class="capture_flow_x4jydtgd3fmstsvrwnz71tmm5x4uw5aqn021hwl8" name="flow"><input id="capture_signIn_client_id_x4jydtgd3fmstsvrwnz71tmm5x4uw5aqn021hwl8" data-capturefield="undefined" value="qsra7g4d6jwdsgn3zbe6udp6r6278mr9" type="hidden" class="capture_client_id_x4jydtgd3fmstsvrwnz71tmm5x4uw5aqn021hwl8" name="client_id"><input id="capture_signIn_redirect_uri_x4jydtgd3fmstsvrwnz71tmm5x4uw5aqn021hwl8" data-capturefield="undefined" value="https://www.nejm.org" type="hidden" class="capture_redirect_uri_x4jydtgd3fmstsvrwnz71tmm5x4uw5aqn021hwl8" name="redirect_uri"><input id="capture_signIn_response_type_x4jydtgd3fmstsvrwnz71tmm5x4uw5aqn021hwl8" data-capturefield="undefined" value="code" type="hidden" class="capture_response_type_x4jydtgd3fmstsvrwnz71tmm5x4uw5aqn021hwl8" name="response_type"><input id="capture_signIn_flow_version_x4jydtgd3fmstsvrwnz71tmm5x4uw5aqn021hwl8" data-capturefield="undefined" value="20240514181256512029" type="hidden" class="capture_flow_version_x4jydtgd3fmstsvrwnz71tmm5x4uw5aqn021hwl8" name="flow_version"><input id="capture_signIn_settings_version_x4jydtgd3fmstsvrwnz71tmm5x4uw5aqn021hwl8" data-capturefield="undefined" value="" type="hidden" class="capture_settings_version_x4jydtgd3fmstsvrwnz71tmm5x4uw5aqn021hwl8" name="settings_version"><input id="capture_signIn_locale_x4jydtgd3fmstsvrwnz71tmm5x4uw5aqn021hwl8" data-capturefield="undefined" value="en-US" type="hidden" class="capture_locale_x4jydtgd3fmstsvrwnz71tmm5x4uw5aqn021hwl8" name="locale"><input id="capture_signIn_recaptcha_version_x4jydtgd3fmstsvrwnz71tmm5x4uw5aqn021hwl8" data-capturefield="undefined" value="2" type="hidden" class="capture_recaptcha_version_x4jydtgd3fmstsvrwnz71tmm5x4uw5aqn021hwl8" name="recaptchaVersion">
      <div class="ucc-form-inner-wrapper">
        <div id="capture_signIn_form_item_signInEmailAddress" class="capture_form_item capture_email capture_form_item_signInEmailAddress" data-capturefield="undefined"><label for="capture_signIn_signInEmailAddress">Email Address</label><input id="capture_signIn_signInEmailAddress" data-capturefield="signInEmailAddress" value="" type="email" class="capture_signInEmailAddress capture_required capture_text_input" placeholder="Email Address" name="signInEmailAddress"><div class="capture_tip" style="display:none;"></div><div class="capture_tip_validating" data-elementname="signInEmailAddress">Validating</div><div class="capture_tip_error" data-elementname="signInEmailAddress"></div></div>
        <div id="capture_signIn_form_item_currentPassword" class="capture_form_item capture_password capture_form_item_currentPassword" data-capturefield="undefined"><label for="capture_signIn_currentPassword">Password</label><input id="capture_signIn_currentPassword" data-capturefield="currentPassword" value="" type="password" class="capture_currentPassword capture_required capture_text_input" placeholder="Password" name="currentPassword"><div class="capture_tip" style="display:none;"></div><div class="capture_tip_validating" data-elementname="currentPassword">Validating</div><div class="capture_tip_error" data-elementname="currentPassword"></div></div>
        <div style="padding-top:10px;">
            <div class="capture_form_item capture_form_rememberme">
                <label class="ucc-form-checkbox">                
                    <input checked="checked" id="ucc-remember-me-cb" name="ucc-remember-me-cb" type="checkbox" value="true">
                    <span>Remember Me</span>
                </label>          
            </div>
            <div class="capture_form_item capture_form_forgotpwd">
              <a role="button" class="ucc-anchor-button" data-capturescreen="forgotPassword">Forgot your password?</a>
            </div>
        </div>
        <div class="capture_form_item">
          <button id="ucc-sign-in-submit" class="capture_primary capture-full-width-btn" type="submit">Sign In</button>
        </div>
       
        <div class="capture_form_item">
          <div class="ucc-no-acct-msg">Don't have an account?</div>
          <div class="ucc-no-acct-msg-2" id="signInModalCreateAccountLink">
          <a role="button" class="ucc-anchor-button" onclick="mmsWidgets.closeSignIn(event); mmsWidgets.showRegAuto(event);">Create Account</a>
            <span></span><a href="https://store.nejm.org/nejm?promo=ONF4NRS1">Subscribe</a>
          </div>

          <div class="ucc-no-acct-msg-2" id="signInModalCloseLink" style="display:none">
          <a role="button" class="ucc-anchor-button" onclick="mmsWidgets.closeSignIn(event);">Create Account</a>
            <span></span><a href="https://store.nejm.org/nejm?promo=ONF4NRS1">Subscribe</a>
          </div>

        </div>
     
        <div class="capture_form_item capture_form_submit">
          
        </div>      
      </div>
      </form>
    </div>
  </div></div></body></html>